


Guidelines for the **management** of

Absolute cardiovascular disease **risk**



An initiative of the National Vascular Disease Prevention Alliance

About the National Vascular Disease Prevention Alliance

The National Vascular Disease Prevention Alliance (NVDPA) is an alliance of four leading and well-known Australian charities: Diabetes Australia, the National Heart Foundation of Australia, Kidney Health Australia and the National Stroke Foundation.

In 2000, these four charities began to work together to reduce the burden of cardiovascular disease in Australia. Much of the work of the NVDPA to date has been to promote the use of an 'absolute risk' approach to predicting risk of cardiovascular disease.

The NVDPA advocates to government and professional bodies for a health system that supports an absolute risk approach. The NVDPA aims to raise awareness among health professionals to use absolute risk assessment in their everyday practice.

Guidelines for the **management** of **Absolute** cardiovascular disease **risk**

National Vascular Disease Prevention Alliance

Endorsed by



The Royal Australian
College of General
Practitioners

Disclaimer

This document is a general guide to appropriate practice, to be followed subject to the circumstances, clinician's judgement and patient's preferences in each individual case. The guidelines are designed to provide information to assist decision making and are based on the best available evidence at the time of development. The relevance and appropriateness of the information and recommendations in this document depend on individual circumstances. Moreover, the recommendations and guidelines are subject to change over time. While all care has been taken in preparing the content of this material, the National Vascular Disease Prevention Alliance and the funding body expressly disclaims and accepts no responsibility for any undesirable consequences arising from relying on the information or recommendations contained herein.

Funding

The National Stroke Foundation, on behalf of the National Vascular Disease Alliance, gratefully acknowledges the financial assistance provided by the Australian Government Department of Health and Ageing. The Department did not have editorial rights in the development of the guidelines and this publication reflects the views of the authors and not necessarily the views of the Australian Government.

Suggested citation

National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012.

ISBN: 978-0-9872830-1-6

© National Stroke Foundation 2012.

Further information and resources are available from:

www.diabetes.org.au

www.kidney.org.au

www.heartfoundation.com.au

www.strokefoundation.com.au

Publication approval



Australian Government

National Health and Medical Research Council

These guidelines were approved by the Chief Executive Officer of the National Health and Medical Research Council (NHMRC) on 27 April 2012, under Section 14A of the *National Health and Medical Research Council Act 1992*. In approving these guidelines the NHMRC considers that they meet the NHMRC standard for clinical practice guidelines. This approval is valid for a period of 5 years.

NHMRC is satisfied that they are based on the systematic identification and synthesis of the best available scientific evidence and make clear recommendations for health professionals practising in an Australian health care setting. The NHMRC expects that all guidelines will be reviewed no less than once every five years.

This publication reflects the views of the authors and not necessarily the views of the Australian Government.

Contents

Executive summary	06
-------------------	----

Summary of recommendations	10
----------------------------	----

Introduction

Purpose	16
Scope	16
Target audience	17
Development	17
Revision of the guidelines	17
Funding body	17

Chapter 1: **Assessment** and **review** of CVD risk

1.1	Potential benefits of absolute CVD risk assessment	18
1.2	Taking a clinical history	19
1.3	Measuring risk factors	19
1.4	Assessing absolute CVD risk	19
1.5	Assessment of CVD risk in different populations	21
1.5.1	Clinically determined high risk	21
1.5.2	General population	22
1.5.3	Aboriginal and Torres Strait Islander peoples	24
1.5.4	Populations requiring special consideration	25
1.6	Review of CVD risk	28

Chapter 2: **Treatment**

2.1	Lifestyle	29
2.1.1	Nutrition, overweight and obesity	29
2.1.2	Physical activity	34
2.1.3	Smoking	35
2.1.4	Alcohol	37
2.1.5	Multiple lifestyle interventions	39

2.2	Pharmacotherapy	40
2.2.1	Blood pressure-lowering therapy	40
2.2.2	Lipid-lowering therapy	42
2.2.3	Antiplatelet therapy	47
2.2.4	Pharmacological approaches to simultaneously lower blood pressure and lipids	50
2.3	Initiation and maintenance of pharmacotherapy	51
2.3.1	Blood pressure lowering therapy	51
2.3.2	Lipid-lowering therapy	57
2.3.3	Principles of pharmacological therapy	60
2.4	Populations requiring special consideration	60
2.4.1	People with diabetes	60
2.4.2	People with CKD	62

Chapter 3: **Monitoring** of pharmacotherapy

3.1	Maximising the benefits of pharmacotherapy	64
3.2	Patient adherence	65

Appendices

1.	Guidelines development groups and terms of reference	67
2.	Guidelines development process report	72
3.	Economic considerations	90
4.	Assessment and management summary	103
5.	Recommendations for future research	108

Glossary and abbreviations	110
----------------------------	-----

Bibliography	113
--------------	-----

Executive summary

Assessment of cardiovascular disease (CVD) risk on the basis of the combined effect of multiple risk factors (absolute CVD risk) is more accurate than the use of individual risk factors, because the cumulative effects of multiple risk factors may be additive or synergistic.¹⁻³


In Australia, 64% of the adult population have three or more modifiable risk factors.⁴ As CVD is largely preventable, an approach focusing on comprehensive risk assessment will enable effective management of identified modifiable risk factors through lifestyle changes and, where needed, pharmacological therapy.

Absolute CVD risk in the context of these guidelines refers to the likelihood of a person experiencing a cardiovascular event within the next five years. These guidelines incorporate the previous *Guidelines for the Assessment of Absolute Cardiovascular Disease Risk*¹⁰ and provide additional guidance on the management of CVD risk in a primary prevention setting in all adults over 45 years of age (35 years for people of Aboriginal or Torres Strait Islander [A&TSI] descent)


Although the goal for management of absolute CVD risk is to reduce the level of absolute risk (AR) in the person, this is achieved by management of multiple individual risk factors. Individual risk factors such as high blood pressure (BP) and raised lipid levels have been shown to have a continuous association with the risk of CVD events; therefore, moderate reductions in several risk factors may be more effective in reducing overall CVD risk than a major reduction in one factor.⁵ Decisions regarding management of risk are therefore made according to the individual's AR level, while response to treatment is monitored by measurement of individual risk factors.

The algorithms and table on pages 7-9 provide a summary of the recommended assessment pathway, interventions, targets and follow-up.

Risk Assessment and Management Algorithm: Adults aged 45 years and over without known history of CVD



Risk Assessment and Management Algorithm: Aboriginal and Torres Strait Islander adults aged 35 years and over without known history of CVD



EBR: Evidence-based recommendation (Graded A-D), CBR: Consensus-based recommendation, PP: Practice point

Risk Management Summary

CVD risk	Lifestyle	Pharmacotherapy	Targets	Monitoring
High risk Clinically determined or calculated using FRE as >15% absolute risk of CVD events over 5 years	<p>Frequent and sustained specific advice and support regarding diet and physical activity.</p> <p>Appropriate advice, support and pharmacotherapy for smoking cessation.</p> <p>Advice given simultaneously with BP and lipid lowering drug treatment.</p>	<p>Treat simultaneously with lipid lowering and BP lowering unless contraindicated or clinically inappropriate.</p> <p>Aspirin not routinely recommended.</p> <p>Consider withdrawal of therapy for people who make profound lifestyle changes.</p>	<p>BP: $\leq 140/90$ mmHg in general or people with CKD; $\leq 130/80$ mmHg in all people with diabetes; $\leq 130/80$ mmHg if micro or macro albuminuria (UACR >2.5 mg/mmol in men and >3.5 mg/mmol in women).</p> <p>Lipids: TC <4.0 mmol/L; HDL-C ≥ 1.0 mmol/L; LDL-C <2.0 mmol/L; Non HDL-C <2.5 mmol/L; TG <2.0 mmol/L.</p> <p>Lifestyle: Smoking cessation (if smoker); consume diet rich in vegetables and fruit, low in salt and saturated and trans fats; at least 30 mins moderate intensity physical activity on most or preferably every day of the week; limit alcohol intake.</p>	<p>Adjust medication as required.</p> <p>Review of absolute risk according to clinical context.</p>
Moderate risk Calculated using FRE as 10-15% absolute risk of CVD events over 5 years	<p>Appropriate, specific advice and support regarding diet and physical activity.</p> <p>Appropriate advice, support and pharmacotherapy for smoking cessation.</p> <p>Lifestyle advice given in preference to drug therapy.</p>	<p>Not routinely recommended.</p> <p>Consider BP lowering and/or lipid lowering in addition to lifestyle advice if 3-6 months of lifestyle intervention does not reduce risk or:</p> <ul style="list-style-type: none"> BP persistently $\geq 160/100$ mmHg Family history of premature CVD Specific population where the FRE underestimates risk e.g. A&TSI peoples, South Asian, Maori and Pacific Islander, Middle Eastern. <p>Consider withdrawal of therapy for people who make profound lifestyle changes.</p>	<p>TC <4.0 mmol/L; HDL-C ≥ 1.0 mmol/L; LDL-C <2.0 mmol/L; Non HDL-C <2.5 mmol/L; TG <2.0 mmol/L.</p> <p>Lifestyle: Smoking cessation (if smoker); consume diet rich in vegetables and fruit, low in salt and saturated and trans fats; at least 30 mins moderate intensity physical activity on most or preferably every day of the week; limit alcohol intake.</p>	<p>Adjust medication as required.</p> <p>Review absolute risk every 6–12 months.</p>
Low risk Calculated using FRE as <10% absolute risk of CVD events over 5 years	<p>Brief, general lifestyle advice regarding diet and physical activity.</p> <p>Appropriate advice, support and pharmacotherapy for smoking cessation.</p>	<p>Not routinely recommended.</p> <p>Consider BP lowering therapy in addition to specific lifestyle advice if BP persistently $\geq 160/100$ mmHg.</p> <p>Consider withdrawal of therapy for people who make profound lifestyle changes.</p>		<p>Adjust medication as required.</p> <p>Review absolute risk every 2 years.</p> <p>Blood test results within 5 years can be used.</p>

A&TSI: Aboriginal and Torres Strait Islander peoples; BP: blood pressure; CKD: Chronic Kidney Disease; DBP: diastolic blood pressure; FRE: Framingham Risk Equation; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; SBP: systolic blood pressure; TC: total cholesterol; TG: Triglycerides; UACR: urinary albumin:creatinine ratio

Summary of Recommendations

This section lists the recommendations presented in the guidelines together with the relevant section where the supporting evidence is discussed. Each recommendation is given an overall grading based on *National Health and Medical Research Council (NHMRC) Levels of Evidence and Grades for Recommendations for Developers of Guidelines (2009)*.⁶ Where no robust evidence was available but there was sufficient consensus within the Expert Working Group (EWG), consensus-based recommendations (CBR) have been provided. Practice points (PP) were added where necessary, to provide practical guidance to facilitate the implementation of the guidelines. Where recommendations were developed in an AR paradigm, but based on relative risk (single risk factor) evidence, the expert panel carefully examined the literature before

making and grading the recommendations. Consideration included any heterogeneity found between subgroups and the generalisability of the findings. The final grading of these recommendations was downgraded to account for the uncertainty of applying evidence from a relative risk approach to an AR paradigm. Some recommendations have been drawn from the *Guidelines for the Assessment of Absolute Cardiovascular Disease Risk* and have been included to provide context and a complete set of absolute CVD risk recommendations. These recommendations are dated (2009) to indicate that they were developed in a separate process. (See Scope for further details on recommendations from the *Guidelines for the Assessment of Absolute Cardiovascular Disease Risk*).

Grading of evidence-based recommendations (EBR)⁶

Grade of recommendation	Description
A	Body of evidence can be trusted to guide practice
B	Body of evidence can be trusted to guide practice in most situations
C	Body of evidence provides some support for recommendation but care should be taken in its application
D	Body of evidence is weak and recommendation must be applied with caution

Additional guidance

CBR	Consensus-based recommendations: developed by the guidelines expert working group when a systematic review of the evidence found either an absence of direct evidence which answered the clinical question or poor quality evidence, which was deemed not to be strong enough to formulate an evidence-based recommendation.
PP	Practice points: developed by the guidelines expert working group where a systematic review had not been conducted but there was a need to provide practical guidance to support the implementation of the evidence-based and/or consensus-based recommendations.

Evidence-based recommendations

Assessment of CVD risk	Grade
Clinically determined high risk	
EBR 1: Adults with any of the following conditions do not require absolute cardiovascular risk assessment using the Framingham Risk Equation because they are already known to be at clinically determined high risk of CVD: <ul style="list-style-type: none"> i. Diabetes and age >60 years ii. Diabetes with microalbuminuria (>20 mcg/min or UACR >2.5 mg/mmol for males, >3.5 mg/mmol for females) iii. Moderate or severe CKD (persistent proteinuria or eGFR <45 mL/min/1.73 m²) iv. A previous diagnosis of familial hypercholesterolaemia v. SBP ≥180 mmHg or DBP ≥110 mmHg vi. Serum TC >7.5 mmol/L. 	D ¹⁰ (2009)
General population aged 45–74 years	
EBR 2: Absolute CVD risk assessment, using the Framingham Risk Equation to predict risk of a cardiovascular event over the next five years, should be performed for all adults aged 45–74 years who are not known to have CVD or to be at clinically determined high risk.	B ¹⁰ (2009)
Aboriginal and Torres Strait Islander adults aged 35–74 years	
EBR 3: In Aboriginal and Torres Strait Islander adults aged 35–74 years who are not known to have CVD or to be at clinically determined high risk, absolute cardiovascular risk over the next five years should be calculated using the Framingham Risk Equation. Although the Framingham Risk Equation might underestimate risk in this population, available evidence suggests that this approach will provide an estimate of minimum cardiovascular risk.	D ⁶⁵ (2009)
Adults with diabetes	
EBR 4: In adults with diabetes aged 60 years or less who are not known to have CVD or to be at clinically determined high risk, absolute cardiovascular risk over the next five years should be assessed using the Framingham Risk Equation. Although the Framingham Risk Equation might underestimate risk in this population, available evidence suggests that this approach will provide an estimate of minimum cardiovascular risk.	C ¹⁰ (2009)
Adults who are overweight or obese	
EBR 5: In adults who are overweight or obese and who are not known to have CVD or to be at clinically determined high risk, absolute cardiovascular risk over the next five years should be assessed using the Framingham Risk Equation. The results should be interpreted with the awareness that its predictive value has not been specifically assessed in this population.	D ¹⁰ (2009)
Treatment	
Lifestyle modification	
EBR 6: Weight loss should be recommended for people who are overweight or obese.	B ¹²⁴⁻¹²⁷
EBR 7: All adults should be advised to participate in at least 30 minutes of moderate intensity activity on most days or preferably every day of the week.	B ¹³⁵⁻¹³⁹
EBR 8: All smokers should be advised to stop smoking.	A ^{14,148}
Pharmacotherapy	
EBR 9: Aspirin or other antiplatelet therapy is not routinely recommended for primary prevention of CVD.	B ^{234, 237, 238, 242, 243}

Assessment of CVD risk	Grade
For adults at high risk of CVD	
EBR 10: Adults at high absolute risk of CVD should be simultaneously treated with lipid and blood pressure-lowering pharmacotherapy in addition to lifestyle intervention unless contraindicated or clinically inappropriate.	B ^{192, 195, 204, 206, 207}
Blood pressure-lowering therapy	
EBR 11: Treatment should begin with any one of the following agents: <ul style="list-style-type: none"> • ACE inhibitor • Angiotensin receptor blocker • Calcium channel blocker • Low dose thiazide or thiazide-like diuretic. 	A ^{192, 199}
EBR 12: If monotherapy does not sufficiently reduce blood pressure add a second agent from a different pharmacological class.	A ¹⁹²
Lipid-lowering therapy	
EBR 13: Statins should be used as first-line therapy.	A ^{206, 208, 209}
EBR 14: If LDL-C levels are not sufficiently reduced on maximally tolerated dose of statin, one or more of the following may be added: <ul style="list-style-type: none"> • ezetimibe • bile acid binding resin • nicotinic acid. 	C ²²⁴⁻²²⁶ D ^{219, 223} D ^{218, 227}
EBR 15: Where statins cannot be tolerated at all, one or more of the following can be used: <ul style="list-style-type: none"> • ezetimibe • bile acid binding resin • nicotinic acid. 	D ²²⁵ D ²²³ D ²²⁷⁻²²⁹
EBR 16: If triglyceride levels remain elevated, treatment with one of the following may be considered: <ul style="list-style-type: none"> • fenofibrate (especially if HDL is below target) • nicotinic acid • fish oil. 	C ²⁰⁰⁻²²² C ^{218, 227} C ²³⁰⁻²³²
Populations requiring special consideration	
People with diabetes	
EBR 17: Blood pressure-lowering therapy in people with diabetes should preferentially include an ACE inhibitor or angiotensin receptor blocker.	A ^{297, 298, 302, 303}
EBR 18: If monotherapy does not sufficiently reduce blood pressure add one of the following: <ul style="list-style-type: none"> • Calcium channel blocker • Low-dose thiazide or thiazide-like diuretic. 	B ^{299, 300} C ^{273, 299}
People with chronic kidney disease (CKD)	
EBR 19: Blood pressure-lowering therapy in people with CKD should begin with an ACE inhibitor or angiotensin receptor blocker.	A ^{302, 303}

Consensus-based recommendations

Assessment of CVD risk
General population aged over 74 years
CBR 1: In adults aged over 74, who are not known to have CVD or to be at clinically determined high risk, absolute cardiovascular risk over the next five years should be assessed using the Framingham Risk Equation. Calculation should be performed using the age of 74 years. Although the Framingham Risk Equation might underestimate risk in this population, available evidence suggests that this approach will provide an estimate of minimum cardiovascular risk.
Aboriginal and Torres Strait Islander adults aged over 74 years
CBR 2: Aboriginal and Torres Strait Islander adults aged over 74 years should be considered as being at high CVD risk.
Treatment
For adults at moderate risk of CVD
CBR 3: Adults at moderate absolute risk of CVD should have their risk factors initially managed by lifestyle interventions. Pharmacotherapy for blood pressure and/or lipid lowering is not routinely recommended but may be considered if 3–6 months of lifestyle intervention does not reduce the individual's risk factors.
CBR 4: Adults at moderate absolute risk of CVD may be treated with pharmacotherapy for blood pressure and/or lipid lowering in addition to lifestyle intervention if one or more of the following applies: <ul style="list-style-type: none"> • Persistent blood pressure $\geq 160/100$ mmHg • Family history of premature CVD • Aboriginal and Torres Strait Islander peoples • Other populations where Framingham Risk Equation is known to underestimate risk (South Asians, Maori and Pacific Islanders, people from the Middle East).
For adults at low risk of CVD
CBR 5: Pharmacotherapy for blood pressure and lipid lowering is not routinely recommended for adults at low absolute risk of CVD.
CBR 6: Adults at low absolute risk of CVD who have persistent blood pressure $\geq 160/100$ mmHg may be treated with blood pressure-lowering pharmacotherapy in addition to lifestyle intervention.
Maximising the benefits of pharmacotherapy
CBR 7: Pharmacotherapy for blood pressure-lowering should aim towards the following targets while balancing the risks/benefits: <ul style="list-style-type: none"> • $\leq 140/90$ mmHg for adults without CVD (including those with CKD) • $\leq 130/80$ mmHg for adults with micro or macro albuminuria (UACR >2.5 mg/mmol in males and >3.5 mg/mmol in females) • $\leq 130/80$ mmHg for all adults with diabetes.
CBR 8: Pharmacotherapy for lipid lowering should aim towards the following targets while balancing the risks/benefits: <ul style="list-style-type: none"> • TC <4.0 mmol/L • HDL-C ≥ 1.0 mmol/L • LDL-C <2.0 mmol/L • Non HDL-C <2.5 mmol/L • TG <2.0 mmol/L.

Assessment of CVD risk
Conducting a comprehensive risk assessment
<p>PP 1 (2009): In adults without known CVD, a comprehensive assessment of cardiovascular risk includes consideration of the following:</p> <p>Modifiable risk factors</p> <ul style="list-style-type: none"> • Smoking status • Blood pressure • Serum lipids • Waist circumference and Body Mass Index (BMI) • Nutrition • Physical activity level • Alcohol intake. <p>Non-modifiable risk factors</p> <ul style="list-style-type: none"> • Age and sex • Family history of premature CVD • Social history including cultural identity, ethnicity and socioeconomic status. <p>Related conditions</p> <ul style="list-style-type: none"> • Diabetes • Chronic Kidney Disease (albuminuria ± urine protein, eGFR) • Familial hypercholesterolaemia • Evidence of atrial fibrillation (history, examination, electrocardiogram).
Absolute CVD risk categories
<p>PP 2 (2009): The following qualitative risk categories can be used to describe calculated absolute cardiovascular risk:</p> <ul style="list-style-type: none"> • low risk corresponds to <10% probability of CVD within the next five years • moderate risk corresponds to 10–15% probability of CVD within the next five years • high risk corresponds to >15% probability of CVD within the next five years.
All adults aged over 74 years
<p>PP 3: In adults aged over 74 years, the decision to initiate therapy should be based on clinical judgement which takes into account:</p> <ul style="list-style-type: none"> • Likely benefits and risks of treatment • Life expectancy, co-morbidities and quality of life • Personal values.
Adults with depression
<p>PP 4: Adults being assessed for CVD risk should also be assessed for depression (and other psychosocial factors). Cardiovascular risk assessment using the Framingham Risk Equation may underestimate risk in adults with depression.</p>
Socioeconomic status
<p>PP 5 (2009): A comprehensive assessment of cardiovascular risk involves consideration of socioeconomic deprivation, because it is an independent risk factor for CVD. Absolute risk of CVD calculated using the Framingham Risk Equation is likely to underestimate CVD risk in socioeconomically disadvantaged groups.</p>
Atrial fibrillation (AF)
<p>PP 6 (2009): In adults with AF (particularly those aged over 65 years), the increased risk of cardiovascular events and all-cause mortality, in addition to thromboembolic disease including stroke, should be taken into account when assessing cardiovascular risk.</p>

Review of CVD risk
<p>PP 7 (2009): Regular review of absolute cardiovascular risk is recommended at intervals according to the initial assessed risk level:</p> <ul style="list-style-type: none"> • Low – review every 2 years • Moderate – review every 6–12 months • High – review according to clinical context
<p>PP 8: In adults at low absolute risk of CVD, blood test results within five years may be used for review of absolute cardiovascular risk unless there are reasons to the contrary.</p>
Treatment
Lifestyle modification
<p>PP 9: All adults should be supported to follow the current <i>Dietary Guidelines for Australian Adults</i>.</p>
<p>PP 10: All smokers should be offered advice about methods to aid smoking cessation, including counselling services, and if assessed as nicotine dependent, nicotine replacement therapy or other appropriate pharmacotherapy should be used.</p>
<p>PP 11: All adults should be advised to follow the current <i>Australian guidelines to reduce health risks from drinking alcohol (2009)</i>¹⁷¹.</p>
<p>PP 12: Adults at higher absolute risk of CVD should be given more frequent and sustained lifestyle advice, support and follow-up to achieve behavioural change.</p>
Blood pressure-lowering therapy
<p>PP 13: If blood pressure is not responding to pharmacotherapy, reassess for:</p> <ul style="list-style-type: none"> • non-adherence • undiagnosed secondary causes for raised blood pressure • hypertensive effects of other drugs • treatment resistance due to sleep apnoea • undisclosed use of alcohol or recreational drugs • unrecognised high salt intake (particularly in patients taking ACE inhibitors or angiotensin receptor blockers) • 'white coat' raised blood pressure • technical factors affecting measurement • volume overload, especially with CKD.
<p>PP 14: If dual therapy at higher doses does not sufficiently reduce blood pressure, add an additional agent.</p>
<p>PP 15: If combination therapy does not sufficiently reduce blood pressure, consider specialist advice.</p>
<p>PP 16: Treatable secondary causes for raised blood pressure should be considered before commencing blood pressure drug therapy.</p>
<p>PP 17: The following combinations should generally be avoided:</p> <ul style="list-style-type: none"> • potassium-sparing diuretic plus either ACE inhibitor or angiotensin receptor blocker • beta-blocker plus verapamil.
Lipid-lowering therapy
<p>PP 18: Treatable secondary causes of dyslipidaemia should be considered before commencing lipid-lowering pharmacotherapy.</p>
Maximising the benefits of pharmacotherapy
<p>PP 19: Adults who commence pharmacotherapy should have their medication adjusted as required and response assessed regularly (approximately 6-12 weekly) until sufficient improvement has been achieved or maximum tolerated dose has been reached.</p>
<p>PP 20: Reduction or withdrawal of pharmacotherapy may be considered in adults who make sustained lifestyle changes which significantly reduce their risk (e.g. smoking cessation, significant weight loss).</p>

Introduction

Cardiovascular disease (CVD), defined collectively in these guidelines as coronary heart disease (CHD), stroke and other vascular disease including peripheral arterial disease (PAD) and renovascular disease, is a leading cause of death and disability in Australia⁷ and in 2003 accounted for approximately 18% of the total burden of disease in Australia.⁸ In 2008, CVD accounted for over one-third (nearly 50,000) of deaths in Australia.⁹ It has a strong relationship with diabetes and chronic kidney disease (CKD) as these conditions share many risk factors and often co-exist.

In Australia, 90% of the adult population has at least one modifiable risk factor, while 64% have three or more modifiable risk factors.⁴ Although the rate of death due to CVD continues to decline in Australia, the total CVD burden is expected to increase over the next few decades due to the ageing population.⁴ *The Guidelines for the Management of Absolute CVD Risk* have been developed by the National Vascular Disease Prevention Alliance (NVDPA) in response to the burden of CVD in the Australian community. They recommend strategies for management of CVD risk in the primary prevention setting, in addition to providing guidance on assessment of CVD risk in all adults over 45 years of age (35 years for A&TSI peoples).

Purpose

CVD remains the leading cause of mortality in Australia. These guidelines have been developed to consolidate a number of evidence-based guidelines for conditions with similar risk factors and management approaches, and provide clear guidance to prevent first-ever CVD events. They build on the NHMRC approved NVDPA *Guidelines for the Assessment of Absolute Cardiovascular Disease Risk 2009*¹⁰, which introduced the concept of AR in the assessment of CVD risk.

Scope

The *Guidelines for the Management of Absolute Cardiovascular Disease Risk* make recommendations regarding the management of cardiovascular risk in Australian adults aged 45 years and over (35 years for A&TSI peoples) who have no previous history of CVD.

Correlation with the Guidelines for the Assessment of Absolute Cardiovascular Disease Risk (2009)

These guidelines build on the existing *Guidelines for the Assessment of Absolute Cardiovascular Disease Risk*¹⁰ by expanding the age range for absolute CVD risk assessment from 45 to 74 years (35 to 74 for A&TSI peoples) to include all adults aged 75 years and over in addition to providing guidance for the management of risk. All of the recommendations have been replicated in the new guidelines (dated 2009) to ensure completeness and provide context. Some minor wording changes have been made to ensure that the recommendations make sense within the context of the new guidelines e.g. replacement of the term 'high risk' with the term 'clinically determined high risk' to clarify how this risk was determined, and the addition of an upper age limit in some recommendations to clarify the age range.

Correlation with other guidelines

The *Guidelines for the Management of Absolute Cardiovascular Disease Risk* update evidence covered in existing Australian guidelines regarding elevated BP,¹¹ lipids,⁵ and prevention and detection of macrovascular disease in people with type 2 diabetes.¹²

These guidelines do not apply to people with existing CVD, because they are already known to be at high risk of further CVD events. However, they should be considered in parallel with other existing Australian guidelines (some of which are noted within these guidelines and some of which were being updated as this document was being finalised) including:

- Clinical practice guidelines for the management of overweight and obesity in adults. Canberra: NHMRC 2003.
- Dietary Guidelines for Australian Adults. NHMRC 2003.
- Guidelines for preventive activities in general practice (7th edition). The Royal Australian College of General Practitioners 2009.
- National Evidence-based Guideline for Diagnosis, Prevention and Management of Chronic Kidney Disease in Type 2 Diabetes. Diabetes Australia 2009.
- Australian Guidelines to Reduce Health Risks from Drinking Alcohol. NHMRC, Canberra 2009.
- Clinical Guidelines for Stroke Management 2010. National Stroke Foundation, Melbourne 2010.
- Guidelines for the management of acute coronary syndromes. National Heart Foundation 2006. (And addendum 2011 jointly published with Cardiac Society of Australia and New Zealand).
- Prevention of progression of kidney disease. Caring for Australasians with Renal Impairment 2006.
- National Evidence-Based Guideline on Secondary Prevention of Vascular Disease in Type 2 Diabetes. (Currently being drafted - see Appendix 2 Section 6.1 for details of consultation between guideline development groups.)
- Guidelines for the prevention, detection and management of chronic heart failure in Australia. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Updated 2011.
- Nutrient Reference Values for Australia and New Zealand Including Recommended Dietary Intakes. Australian Government (NHMRC approved), Canberra 2006.
- Non-valvular atrial fibrillation and stroke prevention. National Heart Foundation MJA 2001; 174: 234-239.
- Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement. Head et al. J Hypertens. 2012;30(2):253-66.

Correlation with Pharmaceutical Benefits Scheme (PBS)

The timing of releasing a new clinical guideline and review and update of related items in the PBS is not currently aligned in Australia. Therefore in regard to pharmacotherapy recommendations within this guideline doctors should be mindful of current regulations that may apply where the cost of the medicine is subsidised by the Government (Schedule of Pharmaceutical Benefits).

Target audience

The *Guidelines for the Management of Absolute CVD Risk* are intended for use by general practitioners, Aboriginal health workers, other primary care health professionals and physicians. They are intended to provide health system policy makers with the best available evidence as a basis for population health policy.

Development

The *Guidelines for the Management of Absolute CVD Risk* build on the *Guidelines for the Assessment of Absolute CVD Risk 2009*¹⁰ and incorporate information previously provided by specific risk factor guidelines. The guidelines have been developed according to the processes outlined in the document *NHMRC Standards and Procedures for Externally Developed Guidelines (2007)* under the direction of a multidisciplinary EWG (see Appendix 1). Details of the development methodology and consultation process are outlined in Appendix 2.

Revision of the guidelines

To maintain currency these guidelines will be reviewed and updated by 2016/7.

Funding body

The National Stroke Foundation received funding from the Australian Government Department of Health and Ageing (DoHA) to develop guidelines for the management of absolute cardiovascular disease risk on behalf of the NVDPA.

Chapter 1:

Assessment and review of CVD risk

Multiple causal factors contribute to CVD. It has been estimated that 64% of Australians have three or more modifiable risk factors.⁴ Approximately 90% of the risk of myocardial infarction (MI) observed worldwide can be attributed to blood lipid abnormalities, smoking, raised BP, diabetes, abdominal obesity, psychosocial factors, physical inactivity and inadequate intake of fruits and vegetables.¹³ Given that CVD is largely preventable, Australian and overseas primary care guidelines emphasise comprehensive risk assessment to enable effective management of identified modifiable risk factors through lifestyle changes (e.g. weight management, smoking cessation and increased physical activity) and pharmacological therapy (e.g. BP-lowering agents and lipid-modifying agents).^{5, 11, 14-18}

Absolute CVD risk in the context of these guidelines refers to the likelihood of a person experiencing a cardiovascular event within the next five years. The *Guidelines for the Assessment of Absolute Cardiovascular Disease Risk 2009*¹⁰ focused on the assessment of absolute risk in those aged 45–74 years (35–74 years for A&TSI peoples) because many risk factors included in the FRE (e.g. high BP, high total cholesterol [TC]) become more prevalent with increasing age. In addition to providing guidance in the management of CVD risk, these new guidelines build on the assessment guidelines to include a discussion of AR assessment in the population aged greater than 74 years.

This chapter covers methods for assessment and review of CVD risk for adults aged 45 (35 for A&TSI peoples) and over. It incorporates the recommendations from the assessment guidelines and new recommendations for those aged 75 years and over. Evidence relating to the new recommendations is presented in detail in these guidelines. Evidence for the existing recommendations for assessment of CVD risk for people aged 45–74 years (or 35–74 years for A&TSI peoples) is summarised in this document to provide context for the recommendations. Further details on evidence relating to these recommendations can be found in the *Guidelines for the Assessment of Absolute CVD Risk 2009*.¹⁰

1.1 Potential benefits of absolute CVD risk assessment

Individuals tend to develop clusters of risk factors.¹ Assessment of CVD risk on the basis of the combined effect of multiple risk factors is more accurate than the use of individual risk factors, because the cumulative effects of multiple factors may be additive or synergistic.¹⁻³ Individual risk factors such as BP and lipid levels have been shown to have a continuous association with the risk of CVD events, therefore, moderate reductions in several risk factors may be more effective in reducing overall CVD risk than a major reduction in one factor.⁵ This evidence forms the basis of the AR approach, where reduction of any of the key risk factors has an effect on the total risk score, regardless of the starting level of that risk factor. For example, Person A, who presents with a BP of 150/95 mmHg, may have a lower AR score than Person B, who has a BP of 140/90 mmHg but is a smoker and has an elevated lipid level. Person B is more likely to benefit from interventions to reduce risk than Person A because of the potential to reduce the overall absolute CVD risk.

There is emerging evidence that clinical decisions based on absolute CVD risk may lead to improved management of CVD risk. Access to absolute CVD risk assessments has been shown to increase prescribing of lipid-modifying drugs for high-risk people with diabetes¹⁹ and lead to improvement in lipid profiles and significant reductions in the risk of CHD.^{20, 21} As absolute CVD risk assessment provides a more accurate assessment of risk than individual risk factors, it is reasonable to expect that basing management decisions on this assessment will improve outcomes.

Modelling studies provide the most compelling current evidence that absolute CVD risk assessment in general practice is likely to improve CVD outcomes, compared with assessment of single risk factors. When applied to a reference population with known risk factors, a strategy based on targeting those at highest absolute CVD risk is

potentially more than twice as effective in reducing death from CHD than treating people with single risk factors (e.g. high TC level).²²

At the population level, interventions targeting those at highest overall CVD risk are likely to achieve the best balance between preventing death and avoiding unnecessary treatment in those at lower risk.^{23, 24} For example, lipid-lowering treatment in people assessed to be at high risk on consideration of all risk factors present will potentially prevent twice as many deaths from CHD in a given population than treating only those with TC levels above a given arbitrary cut-point.^{22, 23} Therefore, accurate estimation of CVD risk, especially in people without known CVD, could play a complementary role with other strategies (e.g. to reduce salt and tobacco consumption) in delivering effective population preventive health programs. Since the mid-1990s, major guidelines for the prevention of CVD have moved from an approach based on identifying and correcting individual risk factors through the application of several separate guidelines, to a focus on the individual's overall risk through multiple risk factor assessment.

1.2 Taking a clinical history

To ensure a comprehensive risk assessment, a clinical history should be routinely taken and should cover the information given in Practice Point 1. This includes the risk factors to be used for calculation of a risk score and other modifiable and non-modifiable risk factors to be considered in making a clinical judgement about the individual's total CVD risk. Consideration of related conditions that could contribute to CVD risk, such as the presence of AF, should also be made. Readers are referred to an Australian evidence summary²⁵ and international guidelines for a discussion of the general evidence related to AF assessment and management²⁶⁻²⁹ and current Australian guidelines for assessment and management of diabetes,^{12, 30} CKD³¹ and familial hypercholesterolaemia.³²

1.3 Measuring Risk Factors

In order to estimate an individual's absolute risk of CVD, the risk factors in Table 1 should be measured.

1.4 Assessing absolute CVD risk

To calculate an individual's estimated 5-year absolute CVD risk use the Risk Assessment and Management Algorithm (Appendix 4) and the risk charts or online calculator at

Practice point
Conducting a comprehensive risk assessment
<p>PP 1 (2009): In adults without known CVD, a comprehensive assessment of CVD risk includes consideration of the following:</p> <p>Modifiable risk factors</p> <ul style="list-style-type: none">• Smoking status• Blood pressure• Serum lipids• Waist circumference and BMI• Nutrition• Physical activity level• Alcohol intake <p>Non-modifiable risk factors</p> <ul style="list-style-type: none">• Age and sex• Family history of premature CVD• Social history including cultural identity, ethnicity and socioeconomic status <p>Related conditions</p> <ul style="list-style-type: none">• Diabetes• CKD (albuminuria ± urine protein, eGFR)• Familial hypercholesterolaemia• Evidence of AF (history, examination, electrocardiogram)

Table 1: Risk factors that may be considered for absolute CVD risk assessment

Risk factor	Measurement
Blood pressure	Absolute risk calculators have been developed using clinic BP measurements, therefore, if using ambulatory BP readings for risk assessment, clinicians should convert to the clinic equivalent using the appropriate tables (see National Heart Foundation and High Blood Pressure Research Council of Australia consensus statement 2012). For clinic BP measurement, the average of two seated BP measurements over two separate occasions should be used to calculate risk. The most recently recorded pre-treatment value can be adopted for individuals taking antihypertensive medication. Ambulatory BP measurement is a better predictor of outcomes than clinic BP measurements and therefore should be used to monitor BP lowering therapy.
Serum lipids	A fasting lipid profile (TC, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], non high-density lipoprotein cholesterol [non HDL-C], TC:HDL ratio and triglycerides) should be taken. A single TC:HDL ratio is used to calculate CVD risk. When a fasting sample is not possible, a non-fasting TC:HDL ratio may be used for an initial screening assessment of CVD risk, however treatment decisions should be made on the basis of fasting lipid levels.
Plasma glucose	<p>In order to screen for diabetes, an assessment of fasting plasma glucose is recommended. A value of ≤ 5.4 mmol/L indicates a normal level. A result of 5.5–6.0 mmol/L may be normal but some people will show diabetes or impaired glucose tolerance in an oral glucose tolerance test (OGTT). A value of ≥ 6.1 mmol/L but ≤ 6.9 mmol/L is diagnostic of impaired fasting glucose and requires an OGTT to confirm diabetes or impaired glucose tolerance. A value of ≥ 7.0 mmol/L on two separate occasions is diagnostic of diabetes and does not require an OGTT.</p> <p>When a fasting sample is not possible non-fasting glucose can be measured with further testing required if the result is ≥ 5.5 mmol/L. HbA1c can be used to diagnose diabetes with a level of $\geq 6.5\%$ being diagnostic.</p>
Waist circumference and BMI	<p>A BMI <25 kg/m² is desirable. Individuals with a BMI ≥ 25 kg/m² are classified as overweight and those with a BMI ≥ 30 kg/m² are obese and at increased risk of diabetes, CHD and stroke compared with individuals with normal BMI (< 25 kg/m²).³³⁻³⁵</p> <p>Waist circumference, as a measure of central obesity, is a better predictor of CVD risk than BMI.³⁴</p> <p>³⁶ A waist circumference of ≥ 94 cm in men (≥ 90 cm in Asian men) and ≥ 80 cm in women (≥ 80 cm in Asian women) is suggestive of central obesity.³⁷</p>
Left ventricular hypertrophy (LVH) (If assessed)	Echocardiography, if available, should be the test of choice to assess for LVH as it is more sensitive than electrocardiography. In the absence of echocardiography, electrocardiograms can be used.
Renal function	<p>Renal function should be estimated from GFR. An eGFR <60 ml/min/1.73m² is indicative of stage 3 CKD.</p> <p>Proteinuria is defined as urinary albumin:creatinine ratio (UACR) > 35 mg/mmol in females and >25 mg/mmol in males. Persistent proteinuria is defined as 2 positive measurements, 3 months apart. The preferred method for assessment of proteinuria in both diabetic and non-diabetic patients is UACR in a first void spot specimen. Where a first void specimen is not possible or practical, a random spot urine specimen for UACR is acceptable. A positive UACR test should be repeated to confirm persistence of albuminuria. CKD is present if two out of three tests (including the initial test) are positive. If the first positive UACR is a random spot (as it may be for opportunistic testing), then repeat test results should ideally be first morning void specimens.</p>
Smoking status	For the purposes of CVD risk assessment, a non-smoker is defined as someone who has never smoked or has given up smoking and has not smoked for ≥ 12 months.

BMI: body mass index; CHD: coronary heart disease; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; OGTT: oral glucose tolerance test.

www.cvdcheck.org.au which are based on the FRE.

The FRE has been validated to include age, sex, smoking status, diabetes, SBP, TC:HDL ratio and LVH as part of the equation. All other risk factors should be factored into the clinical judgement for decisions regarding the management of individual patients.

Descriptors of risk categories are arbitrary, with definitions of 'moderate' and 'high' risk varying between national and international guidelines. For the Australian context, the *Guidelines for the Assessment of Absolute Cardiovascular Disease Risk (2009)*¹⁰ defined the categories as in Practice point 2.

Diabetes with microalbuminuria

The presence of microalbuminuria approximately doubles CVD risk.³⁸⁻⁴¹ In clinical practice it is both reasonable and expedient to make the assumption that all adults with diabetes and microalbuminuria are at high CVD risk.

Numerical calculation of absolute CVD risk is unlikely to affect clinical management decisions significantly, given that intensive management of risk factors is generally indicated in this group.

Practice point

Assessing absolute CVD risk

PP 2 (2009): The following qualitative risk categories can be used to describe calculated absolute cardiovascular risk:

- **low** risk corresponds to <10% probability of CVD within the next five years
- **moderate** risk corresponds to 10–15% probability of CVD within the next five years
- **high** risk corresponds to >15% probability of CVD within the next five years

1.5 Assessment of CVD risk in different populations

1.5.1 Clinically determined high risk

Based on available published evidence and clinical consensus, certain groups can be assumed to be at high risk of cardiovascular events because of their clinical condition, and a calculation of absolute CVD risk is not considered necessary. This section applies to adults aged 45 and older (35 and older for A&TSI peoples) of any ethnic background who have been clinically determined to be at high risk.

Diabetes and age >60 years

In clinical practice it is both reasonable and expedient to make the assumption that all patients aged over 60 years with diabetes are at high CVD risk, given that numerical calculation of absolute CVD risk is unlikely to affect clinical management decisions significantly because intensive management of risk factors is generally indicated in this group. For instance, blood pressure-lowering drugs are indicated and cholesterol-lowering drugs are likely to be prescribed regardless of numerical risk.

Moderate or severe CKD

Clinical studies indicate that people with moderate or severe CKD (defined as persistent proteinuria or eGFR < 45 mL/min/1.73 m²) have an increased risk of developing CVD. This effect is independent of the presence of diabetes or pre-existing CVD.^{42, 43} The definition of moderate or severe CKD on which this recommendation is based represents a threshold midway between stage 3 and stage 4 CKD as defined by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.⁴⁴ Absolute CVD risk assessment based on the FRE is not suitable in this population because traditional risk factors have been shown to underestimate CVD events in people with CKD.

Familial hypercholesterolaemia

Familial hypercholesterolaemia (FH), a genetic disorder resulting in impaired cellular uptake of plasma LDL-C, is strongly associated with premature CHD. Most international guidelines for CVD risk management recommend that individuals with FH should be considered to be at high risk for CVD and receive treatment to reduce risk.^{14, 45, 46}

Evidence-based recommendation	Grade
Clinically determined high risk	
<p>EBR 1: Adults with any of the following conditions do not require absolute cardiovascular risk assessment using the Framingham Risk Equation because they are already known to be at clinically determined high risk of CVD:</p> <ul style="list-style-type: none"> i. Diabetes and age >60 years ii. Diabetes with microalbuminuria (>20 mcg/min or UACR >2.5 mg/mmol for males, >3.5 mg/mmol for females) iii. Moderate or severe CKD (persistent proteinuria or eGFR < 45 mL/min/1.73m²) iv. A previous diagnosis of familial hypercholesterolaemia v. SBP ≥180 mmHg or DBP ≥110 mmHg vi. Serum total cholesterol >7.5 mmol/L. 	D ¹⁰ (2009)

SBP ≥180 mmHg or DBP ≥110 mmHg

Extreme levels of risk factors are associated with high absolute CVD risk, regardless of other factors. Adults with markedly elevated BP should be assessed as having high risk for CVD.⁴⁷

Serum total cholesterol >7.5 mmol/L

The Framingham Heart Study included few people with TC levels of 7.5 mmol/L or higher. Therefore, the FRE has not been validated in this group. Markedly elevated TC levels are commonly associated with FH, which is known to carry a high risk of CVD. Consistent with other international guidelines, it is reasonable to assume that markedly elevated TC indicates high CVD risk.^{14, 48}

1.5.2 General population

There has been a natural evolution in research evaluating models to assess AR – comparing new and locally produced models with the original FRE or recalibrations of the FRE using local data. This section presents a brief summary of the evidence presented in the *Guidelines for the Assessment of Absolute Cardiovascular Disease Risk*, and a review of the more recent evidence for CVD risk assessment of adults. For details of the evidence relating to risk assessment models for people aged 45–74 years refer to the *Guidelines for the Assessment of Absolute Cardiovascular Disease Risk*.¹⁰

Fourteen high-quality cohort studies that assessed AR in a mixed population (>18 years) with no history of CVD or diabetes^{49–62} were identified in the current literature review in addition to the 10 high-quality studies that were identified

in the literature review of the assessment guidelines. These 14 additional studies reported on the applicability to local populations of recalibrated versions of various risk calculation models including FRE,^{53, 54} SCORE,^{50, 54, 59} UKPDS,⁶² CLEM,⁵⁶ QRISK,⁵⁷ and locally generated models: 3C (France),⁵¹ GP (United Kingdom),⁶⁰ India,⁵² and NIPPON DATA80 (Japan).⁴⁹ A consistent finding from these studies is that regardless of the tool used to measure AR, recalibration using local, country-specific data can produce more accurate risk estimations. However, one study using recalibrated versions of FRE showed that although recalibration of risk calculation models to local data is a practical approach to estimation of CVD risk, the reliability and applicability of the data used for recalibration is of key importance.⁵⁴

In Australia, one new study was located, the purpose of which was to develop a parsimonious model to predict CHD and CVD deaths using individual components of the FRE plus measures of central obesity.⁵⁵ Fifteen-year mortality data were assessed in 8,662 Australian adults in the National Heart Foundation Risk Factor Prevalence Survey of 1989, excluding those with a baseline history of heart disease. Smoking status, HDL-C and the TC:HDL-C ratio together with SBP were found to be significant predictors of CVD deaths. The obesity measures of waist circumference and waist-to-hip ratio were significant univariate predictors but BMI was not. In multivariable analyses, smoking status and waist-to-hip ratio were the only risk factors identified as key independent risk factors for coronary and cardiovascular-related deaths, although TC:HDL-C ratio contributed minimally to the prediction of CHD deaths. However, the FRE was found to have almost identical accuracy of risk prediction as the use of the waist-to-hip ratio plus smoking risk prediction model. These

results suggest that a model for predicting coronary and cardiovascular deaths that incorporates central obesity plus smoking would have similar efficacy as the FRE.

One study found that the locally calibrated version of the SCORE risk prediction tool was more accurate than the standard tool in populations aged 36–64 years.⁵⁰ Another study in people aged 30–74 years validated a sex-specific multivariable risk factor algorithm that can predict risk based on traditional risk factors such as age, TC, HDL-C, SBP, treatment for hypertension, smoking and diabetes status.⁵³ A comparison of the FRE and CLEM models in a population aged 30–67 years demonstrated reasonable discriminating ability for both models to predict risk in this age group.⁵⁶

Another recent study constructed a prediction algorithm for 30-year risk of cardiovascular events (e.g., coronary death, MI and stroke) using observational follow-up data from 4,506 participants from the Framingham Offspring cohort aged 20–59 years and free of CVD and cancer at baseline.⁶¹ After adjusting for competing risks of death, the 30-year event rates were 7.6% for women and 18.3% for men. Standard risk factors (male sex, SBP, antihypertensive treatment, TC and HDL-C, smoking and diabetes mellitus) measured at baseline, were significantly related to the incidence of CVD and remained significant when updated regularly. BMI was also associated positively with 30-year risk of CVD, but only in models that did not update risk factors.

Collectively, these results indicate that risk prediction models can be used to reasonably predict CVD risk in adult populations. The FRE, when compared to other absolute CVD risk assessment methods, has shown equivalent or higher predictive ability in non-diabetic cohorts. It remains the most thoroughly tested method of assessing absolute CVD risk in adults without a previous history of diabetes or CVD. The FRE has been found to overestimate or underestimate risk in some populations. There is no current support for the use of ancillary cardiac imaging such as coronary CT angiography to refine FRE based risk assessment and decisions to initiate therapy.

Many of the risk factors included in the FRE become more prevalent with increasing age. An analysis of the risk factors associated with chronic disease found that in Australia, the proportion of people with five or more risk factors for chronic disease (including CVD) was highest in the 45–64 and 65–84 year old age groups.⁶³

The lower and upper age limits presented by the *Guidelines for the Assessment of Absolute CVD Risk* were selected for several reasons. Firstly, the lower age limit of 45 years was consistent with Australian policy initiatives, such as

the ‘45-year-old health check’ (Medicare Benefits Scheme item number 717). This program has now been updated to encourage preventative health checks for people between the ages of 45 and 49 years who are at risk of developing chronic disease (Medicare Benefits Scheme items 701, 703, 705 and 707). The lower age limit of 45 years is also aligned with existing clinical recommendations in Australia, such as the Royal Australian College of General Practitioners (RACGP) *Guidelines for Preventative Activities in General Practice*,⁶⁴ which recommends assessment of lipid levels from 45 years. The upper age limit of 74 years was proposed because this was the upper age for the original Framingham Heart Study cohort.⁶⁵

The literature review found little strong evidence supporting CVD risk estimation in people aged 30 years or less and only limited evidence for those 30–45 years. Hence the original baseline age of 45 years (35 years for A&TSI peoples) was deemed appropriate. For people aged under 45 years clinicians should examine those with isolated, elevated single risk factors or a strong family history of CVD to rule out secondary causes and to determine if they fall into the clinically determined high risk category.

Aged over 74 years

The upper age limit of 74 years was proposed by the expert panel for the use of the FRE for routine assessment of absolute CVD risk because this was the upper age for the original Framingham Heart Study cohort. In the absence of robust data for risk estimation in this population, the FRE can provide an estimate of risk for this age group, which can be used to guide management decisions. Although age is a significant risk factor for CVD, age in itself is not a reason to initiate pharmacotherapy. Age alone should not be a contraindication to drug therapy, but consideration should be given to quality of life, co-morbidities and life expectancy. These issues should be discussed with the patient before making treatment decisions. Although older people gain a similar relative benefit from reduction of the levels of individual risk factors such as BP and lipids, they are more likely to benefit in absolute terms because of their much higher pre-treatment cardiovascular risk. Therefore, when assessing CVD risk in people aged 74 and older, FRE may be used as a guide to determine the level of risk by assuming an age of 74 years. While acknowledging that FRE may underestimate risk in that individual, the resulting score may be used to inform management decisions by discriminating between adults at moderate risk and those at high risk.

Evidence-based recommendation	Grade
General population aged 45–74 years	
EBR 2: Absolute CVD risk assessment, using the Framingham Risk Equation to predict risk of a cardiovascular event over the next five years, should be performed for all adults aged 45–74 years who are not known to have CVD or to be at clinically determined high risk.	B ¹⁰ (2009)

Consensus-based recommendation
General population aged over 74 years
CBR 1: In adults aged over 74, who are not known to have CVD or to be at clinically determined high risk, absolute cardiovascular risk over the next five years should be assessed using the Framingham Risk Equation. Calculation should be performed using the age of 74 years. Although the Framingham Risk Equation might underestimate risk in this population, available evidence suggests that this approach will provide an estimate of minimum cardiovascular risk.

Practice point
All adults aged over 74 years
PP 3: In adults aged over 74 years, the decision to initiate therapy should be based on clinical judgement which takes into account: <ul style="list-style-type: none"> • Likely benefits and risks of treatment • Life expectancy, co-morbidities and quality of life • Personal values

1.5.3 Aboriginal and Torres Strait Islander peoples

Aboriginal and Torres Strait Islander peoples have a high prevalence of risk factors for heart, stroke and vascular disease. The presence of these risk factors may contribute to the overall risk differently from the patterns observed in reference populations that are reported in the published evidence. People of Aboriginal and Torres Strait Islander background may experience more rapid disease

progression than the reference population. They also have exceedingly high age-standardised mortality that has not shown the downward trend seen in the rest of the Australian community over the past 40 years. A literature search failed to locate any new data on this cohort. Therefore, the recommendations below are based on one published study⁶⁶ from the *Guidelines for the Assessment of Absolute CVD Risk*¹⁰ and on expert opinion.

Evidence-based recommendation	Grade
Aboriginal and Torres Strait Islander adults aged 35–74 years	
EBR 3: In Aboriginal and Torres Strait Islander adults aged 35–74 years who are not known to have CVD or to be at clinically determined high risk, absolute cardiovascular risk over the next five years should be calculated using the Framingham Risk Equation. Although the Framingham Risk Equation might underestimate risk in this population, available evidence suggests that this approach will provide an estimate of minimum cardiovascular risk.	D ⁶⁶ (2009)

Consensus-based recommendation

Aboriginal and Torres Strait Islander adults aged over 74 years

CBR 2: Aboriginal and Torres Strait Islander adults aged over 74 years should be considered as being at high CVD risk.

1.5.4 Populations requiring special consideration

Adults with diabetes

In adults with diabetes without known CVD, most risk equations developed in the general population underestimate risk. However, there is little evidence that risk scores developed in diabetic populations provide better estimates. Two high-quality studies were identified that each compared two methods of absolute CVD risk assessment. The FRE was compared with the UKPDS risk score in people participating in a small (n=428) UK general practice-based follow-up study conducted among men and women with diabetes aged 30–64 years.⁶⁷ For the entire cohort, no statistically significant difference in predictive ability was found between the two methods. However, the area under the curve (AUC) for 10-year risk was numerically higher for the FRE than the UKPDS risk score for both men and women when data were analysed separately. The clinical implications of this finding are unclear.

A US study of 1,237 men and women with diabetes aged 45–64 years compared the predictive ability of traditional risk factors (e.g. age, race, TC, HDL-C, SBP) with the predictive ability of a combination of traditional and non-traditional factors (e.g. BMI, waist-to-hip ratio, serum lipoprotein(a), serum albumin, serum creatinine, white blood cell count, fibrinogen, factor VIII, physical activity, dietary lipid, left ventricular hypertrophy, carotid intima-media thickness).

The score based on a combination of traditional and non-traditional factors was a better predictor of 10-year absolute CVD risk than traditional factors alone, in both men and women.⁶⁸

Other recent cohort studies have reported that the FRE underestimated risk in people with diabetes,^{69, 70} consistent with the findings of the systematic review. Based on these findings, some investigators argue for the development of diabetes-specific CVD risk calculators.⁶⁹ However, others have concluded that the development of separate risk prediction models for people with diabetes does not improve predictive ability and that the presence of diabetes alone should not be assumed to indicate a common level of high risk.⁷¹ Some investigators have proposed the use of the FRE with the addition of a constant calibration factor for diabetes.⁷⁰

A more recent systematic review compared the FRE with observed events in people with type 1 diabetes, and found that, in general, the equation was a poor predictor of cardiovascular events.⁷² However, the authors noted that diabetes-specific risk scores need to be validated in other populations before they are widely adopted. In another recent study, the FRE, SCORE and UKPDS tools were compared in adults with and without diabetes.⁷³ The FRE appeared to either underestimate or overestimate events, while the SCORE and UKPDS risk models, with the addition of non-traditional risk factors, proved more accurate for the assessment of AR.

Overall, current evidence supports the use of the FRE for calculation of CVD risk in the general population of adults with diabetes, despite evidence to show that it underestimates risk in this population.^{70, 74} In people with diabetes aged over 60 years, a high risk of CVD events (>15% probability of a CVD event within five years) is likely, therefore numerical calculation of absolute CVD risk is not necessary in this group.

Evidence-based recommendation	Grade
Populations requiring special consideration: adults with diabetes	
EBR 4: In adults with diabetes aged 60 years or less who are not known to have CVD or to be at clinically determined high risk, absolute cardiovascular risk over the next five years should be assessed using the Framingham Risk Equation. Although the Framingham Risk Equation might underestimate risk in this population, available evidence suggests that this approach will provide an estimate of minimum cardiovascular risk.	C ¹⁰ (2009)

Adults who are overweight or obese

No studies were identified that specifically evaluated the predictive ability of absolute CVD risk assessment in adults who are overweight or obese and without known CVD. Two meta-analyses from large observational studies have found a strong relationship between overweight and obesity and CVD mortality.^{75, 76} Australian data are limited. Investigators in a multivariate analysis concluded that obesity (in this study, best measured by waist-to-hip ratio) is a dominant and independent predictive variable for CVD events and deaths in Australian men and women.⁷⁷ In line with previous meta-analyses, a recent meta-analysis found the association of measures of obesity are generally accounted for by changes in BP, diabetes and lipid measures.⁷⁸

The most widely recognised indicator of overweight and obesity is BMI, measured as weight divided by height squared (kg/m^2). Recently, several authors have proposed that CVD risk correlates better with other metrics that quantify abdominal (visceral) obesity, such as waist circumference or waist-to-hip ratio.^{79, 80} NHMRC clinical practice guidelines for the management of overweight and obesity in adults recommend that waist circumference should be measured in combination with either BMI or weight, for those patients who wish to be measured.⁸¹ Definitions and targets based on data from European populations may not be appropriate for all ethno-cultural groups.

The FRE does not include measures of obesity. Hence, in the absence of evidence for the predictive ability of an absolute CVD risk assessment method in adults who are overweight or obese, it is reasonable to use the FRE in this group. Further details of assessment of those who are

overweight or obese can be found in the *Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults*.⁸¹

Adults with depression

Clinical depression, social isolation and lack of quality social support have been shown to predict incident CHD and worsen its prognosis, independent of conventional risk factors such as smoking, raised lipids and elevated BP.⁸²⁻⁸⁷ Therefore, adults being assessed for CVD risk should also be assessed for depression and other psychosocial factors. This section reviews the evidence to support the assessment of depression in adults at risk of CVD.

Multiple cohort studies have found a similar strength of association between depression, social isolation or lack of quality social support and CHD compared with traditional risk factors.^{84, 88} With minor depression, the risk of CHD increased one-to two-fold. However, with major depression there was a three-to five-fold increase in CHD risk.⁸⁴ These results concur with the results of another meta-analysis involving 11 cohort studies in initially healthy subjects that found an overall increase in risk by 64% (RR 1.64, 95% CI 1.29–2.08, $p < 0.001$).⁸⁵ Another recent review of the relationship between depression and anxiety with chronic diseases found consistent evidence that depression is a risk factor for heart disease, stroke and diabetes.⁸³ However, there is no evidence that treatment of depression reduces the risk of CVD events. Two systematic reviews, both in patients with established CHD, failed to demonstrate a link between cardiovascular outcomes and the treatment of depression.^{89, 90} Both reviews concluded, however, that the lack of evidence should not detract from the need to address depression as a clinical issue in its own right.

Evidence-based recommendation	Grade
Populations requiring special consideration: adults who are overweight or obese	
EBR 5: In adults who are overweight or obese and who are not known to have CVD or to be at clinically determined high risk, absolute cardiovascular risk over the next five years should be assessed using the Framingham Risk Equation. The results should be interpreted with the awareness that its predictive value has not been specifically assessed in this population.	D ¹⁰ (2009)

Practice point
Populations requiring special consideration: adults with depression
PP 4: Adults being assessed for CVD risk should also be assessed for depression (and other psychosocial factors). Cardiovascular risk assessment using the Framingham Risk Equation may underestimate risk in adults with depression.

Socioeconomic status

Measures of socioeconomic status are not included in the FRE, but are included in some more recent absolute CVD risk assessment methods. Socioeconomic deprivation should be considered in addition to calculated risk, because it is an independent risk factor for CVD.

Few data are available to quantify the effect of socioeconomic status on absolute CVD risk. Data from a study conducted in Scotland indicate that the FRE underestimated absolute CVD risk in socioeconomically deprived groups.^{91, 92} No Australian studies have directly addressed this issue.

Socioeconomic deprivation has been associated with adverse cardiovascular outcomes in Australian adults (where socioeconomic disadvantage is measured according to the Index of Relative Socioeconomic Disadvantage, which takes into account social and economic characteristics of the geographical area such as low income, low educational attainment, high levels of public sector housing, high unemployment and jobs in relatively unskilled occupations).^{4, 9} There is emerging evidence that the incorporation of social deprivation scores into absolute CVD risk assessment tools improves their predictive value.^{92, 93} However, this approach has been tested only in specific populations and has not been validated in the Australian population. In the absence of a numerical formula for incorporating

social deprivation into risk assessments for Australian adults, it is recommended that a subjective assessment of the effect of social status should be taken into account when assessing CVD risk.

Atrial fibrillation

Atrial fibrillation (AF) is an important marker (regardless of causality), not only of thromboembolic disease and stroke, but also of incident all-cause mortality, cardiovascular death, heart failure and possibly coronary events.^{94, 95} AF is associated with an odds ratio for death of 1.5 for men and 1.9 in women, which does not vary by age, but most of the excess of mortality attributed to AF occurs early after the diagnosis.⁹⁴

The prothrombotic state imposed by AF predisposes individuals to stroke and thromboembolism, with an approximately five-fold greater risk than that of people without AF.⁹⁶ Furthermore, the risk of stroke increases with increasing age, previous transient ischaemic attack (TIA) or stroke, raised BP, diabetes, impaired left ventricular function and a large left atrium.

The presence of AF should prompt a thorough investigation for other CVD risk factors.²⁵⁻²⁹ Readers are referred to an Australian evidence summary²⁵ and international guidelines for a discussion of the general evidence related to AF management.²⁶⁻²⁹

Practice point

Populations requiring special consideration: socioeconomic status

PP 5 (2009): A comprehensive assessment of cardiovascular risk involves consideration of socioeconomic deprivation, because it is an independent risk factor for CVD. Absolute risk of CVD calculated using the Framingham Risk Equation is likely to underestimate CVD risk in socioeconomically disadvantaged groups.

Practice point

Populations requiring special consideration: atrial fibrillation

PP 6 (2009): In adults with AF (particularly those aged over 65 years), the increased risk of cardiovascular events and all cause mortality, in addition to thromboembolic disease including stroke, should be taken into account when assessing cardiovascular risk.

Adults already receiving pharmacotherapy for single risk factors

Use of on-therapy measures for BP and cholesterol will inaccurately estimate AR for people already receiving lipid or blood pressure-lowering therapy. Therefore, it is recommended that the most recently recorded pre-treatment measure be used to estimate absolute CVD risk. Where this is not possible, clinicians should make decisions on intensification or withdrawal of pharmacotherapy or lifestyle interventions based on discussions with the patient and consideration of their individual context.

1.6 Review of CVD risk

Intervals for review of absolute CVD risk were determined after consideration of the recommendations of established preventive guidelines for general practice and of the likelihood that an individual's risk status will change over time. Reassessment of absolute CVD risk status should be undertaken when there is a reasonable expectation that it will affect clinical management decisions. In those at low risk, absolute CVD risk should be assessed approximately every two years or if individual risk factor status deteriorates. Another set of blood tests may not be necessary for assessment of people at low risk, i.e. assessment may be conducted with previous cholesterol or blood glucose

levels if they have been taken within five years.⁹⁷ The decision to conduct a blood test should be made by the clinician after taking into consideration the individual person's context, e.g. specific populations known to be at increased risk, or recent changes such as significant weight gain, uptake of smoking, or onset of menopause.

In a person assessed to be at moderate absolute CVD risk (10–15% probability of a cardiovascular event within five years), closer monitoring of risk is needed because risk level may become high in response to worsening status of one or more risk factors. In a person assessed to be at high absolute CVD risk (>15% probability of a cardiovascular event within five years), risk status is unlikely to be revised downward in the short term, although occasionally it may be reduced following reversal of modifiable risk factors (e.g. permanent smoking cessation). Reassessment of risk status will depend on the individual's clinical profile and the purpose of risk assessment (e.g. to encourage continued adherence to a treatment plan or to inform the decision to commence additional treatment).

The following intervals are intended only as a guide. Appropriate intervals at which an individual's absolute CVD risk should be reviewed will depend on clinical judgement.

Practice point

Review of CVD risk

PP 7 (2009): Regular review of absolute cardiovascular risk is recommended at intervals according to the initial assessed risk level:

- **Low** – review every 2 years
- **Moderate** – review every 6–12 months
- **High** – review according to clinical context

PP 8: In adults at low absolute risk of CVD, blood test results within five years may be used for review of absolute cardiovascular risk unless there are reasons to the contrary.

Chapter 2:

Treatment

2.1 Lifestyle

This section covers treatment, including targets, for the management of CVD risk, and applies to all adults aged over 45 years (35 years for A&TSI peoples), irrespective of CVD risk level.

Lifestyle changes in nutrition, physical activity and smoking status typically show excellent cost-effectiveness in lowering the burden of disease, especially with respect to obesity, future diabetes and heart disease.⁹⁸ However, there is an inherent difficulty in undertaking randomised controlled trials of lifestyle factors. For example, the diet of any individual is related to other lifestyle factors (e.g. smoking, exercise, etc.), and although randomised controlled trials are able to eliminate such bias, they are more difficult to conduct for lifestyle factors than those for pharmacotherapy. For that reason, data pertaining to lifestyle interventions is primarily from cohort and observational studies.

2.1.1 Nutrition, overweight and obesity

A number of behavioural characteristics, including nutrition, overweight and obesity, play an important role in the development of CVD. In Australia, the prevalence of overweight and obesity has been steadily increasing over the past 20–30 years. Data from 2004–05 indicate that about 2.5 million Australian adults were obese (19% of males and 17% of females aged 18 years and over), and a further 4.9 million adults were estimated to be overweight.⁹ This section reviews the relationship between nutrition, overweight, obesity and CVD.

Dietary advice

Dietary advice appears to be effective in bringing about modest beneficial changes in diet and CVD risk factors. In a recent review of 38 trials with a minimum follow-up period of three months, dietary advice (e.g. advice to decrease consumption of fat, saturated fatty acids, cholesterol, salt and/or increase consumption of fruit, vegetables, polyunsaturated fatty acids, monounsaturated fatty acids, fish, fibre and potassium) reduced total serum cholesterol by 0.16 mmol/L (95% CI 0.06–0.25) and LDL-C by 0.18 mmol/L (95% CI 0.1–0.27).⁹⁹ Mean HDL-C levels and triglyceride levels were unchanged, however BP was reduced, SBP by 2.07 mmHg (95% CI 0.95–3.19) and DBP by 1.15 mmHg (95% CI 0.48–1.85). *Dietary Guidelines for Australian Adults* have been developed by the NHMRC¹⁰⁰ and are currently being updated. Although the dietary guidelines have been developed for general health measures and not specifically for CVD prevention, the recommendations are consistent with the aim of CVD prevention. Referral for nutritional review and dietary counselling should be considered, depending on need. A brief guide to dietary advice is presented, along with other lifestyle advice, in Table 4.

Altering dietary fat: saturated fat

There is a strong, consistent and graded relationship between saturated fat intake, blood cholesterol and the occurrence of CVD. A review of 27 trials involving 18,196 participants examined the effect of a reduction or modification of dietary fats for at least six months on reducing serum cholesterol levels and on all-cause and cardiovascular mortality and morbidity.¹⁰¹ The review included trials of high (n=7), moderate (n=6) and low risk (n=14) participants. There was a trend towards protection from cardiovascular mortality (rate ratio 0.91, 95% CI 0.77–1.07), and significant protection from cardiovascular events (rate ratio 0.84, 95% CI 0.72–0.99). This effect was non-significant if studies at high risk of bias were removed.

However, there was stronger evidence of protection against cardiovascular events when trials with at least two years of follow-up were assessed (rate ratio 0.76, 95% CI 0.65–0.90).

Altering dietary fat: n-3 fatty acids

While the evidence for the benefits of fish oil is stronger in secondary prevention, the benefits also appear to translate to the primary prevention setting. Several large systematic reviews have reported lower rates of fatal coronary events and sudden death among people who regularly consume fish than among non-consumers.^{102–104} In a meta-analysis of observational studies including 222,364 individuals and an average follow-up period of 11.8 years, individuals with a higher intake of fish had lower CHD-related mortality compared with those who never consumed fish or ate fish less than once per month.¹⁰³ The relative risks for CHD were 0.89 (95% CI 0.79–1.01) for fish intake 1–3 times per month, 0.85 (95% CI 0.76–0.96) for once per week, 0.77 (95% CI 0.66–0.89) for 2–4 times per week, and 0.62 (95% CI 0.46–0.82) for five or more times per week. Furthermore, each 20 g/d increase in fish intake was related to a 7% lower risk of CHD mortality (*p* for trend = 0.03).

However, conflicting results were reported in a 2006 meta-analysis of 48 randomised controlled trials and 26 cohort studies.¹⁰⁵ In that analysis, the observational studies alone suggested that omega 3 fats reduced total mortality. The pooled results from the 48 randomised controlled trials showed no benefit of omega 3 fats on mortality or cardiovascular events in patients with existing CHD. Further high-quality trials are needed to confirm suggestions of a protective effect of n-3 fatty acids on cardiovascular health to prevent CVD.

Salt intake

There is now abundant evidence from epidemiological studies and clinical trials that increased levels of salt intake increases BP and therefore, the risk of stroke and CHD. A meta-analysis of 28 trials showed that BP could be significantly reduced in people with raised or normal BP levels, by a modest reduction of dietary salt over four or more weeks.¹⁰⁶

A Cochrane review of salt restriction for the prevention of CHD cited too few cardiovascular events to make a clear conclusion.¹⁰⁷ However, it did report that SBP and DBP were reduced in those given low sodium advice as compared with controls (SBP by 1.1 mmHg, 95% CI 1.8–0.4, DBP by 0.6 mmHg, 95% CI 1.5 to -0.3). Furthermore, people on anti-hypertensive medications were able to

stop their medication more often on a reduced sodium diet as compared with controls, while maintaining similar BP control. Over 70% of the salt consumed comes from processed foods and is not related to the discretionary use of salt, therefore a reduction in the amount of salt in the diet would require reduction in the amount of salt used in food production.

Vegetables and fruit

Four systematic reviews examined the benefits of vegetable and fruit intake for the reduction of CVD risk.^{108, 111} There is evidence from these reviews to support the notion that vegetable and fruit consumption is inversely associated with the risk of CVD. In one review of eight cohort studies, the pooled relative risk of stroke was 0.89 (95% CI 0.83–0.97) for individuals with 3–5 servings per day, and 0.74 (95% CI 0.69–0.79) for those with more than five servings per day, compared with those who had less than three servings of vegetables and fruit per day.¹¹¹ Another report found that the risk of CHD decreased by 4% (RR 0.96, 95% CI 0.93–0.99, *p*=0.0027) for each additional portion of vegetables and fruit intake per day.¹⁰⁹

Dairy products

A detailed meta-analysis of the evidence on milk and dairy consumption and the incidence of vascular diseases and diabetes was recently published.¹¹² The results provide evidence of an overall survival advantage from the consumption of milk and dairy foods. However, it should be noted that the meta-analysis did not differentiate between full fat and reduced fat products. The relative risk of stroke and/or heart disease in subjects with high milk or dairy consumption was 0.84 (95% CI 0.76–0.93) and 0.79 (95% CI 0.75–0.82) respectively, relative to the risk in those with low consumption.

Wholegrain cereals

Despite the evidence from observational studies that whole grains can have a beneficial effect on risk factors for CHD,^{113–118} a meta-analysis of 10 randomised controlled trials found no effect of wholegrain diets on CHD mortality or CHD events or morbidity.¹¹⁹ In eight of the included studies, the wholegrain component was oats. Pooled analysis of those studies demonstrated lower TC (-0.20 mmol/L, 95% CI -0.31 to -0.10, *p*=0.0001) and LDL-C (0.18 mmol/L, 95% CI -0.28 to -0.09, *p*<0.0001) with oatmeal foods. However, many of the trials were short-term, poor quality and had insufficient power.

Low glycaemic index diets

The glycaemic index (GI) is a physiological measure of the ability of a carbohydrate to affect blood glucose. Interest is growing in the low GI index for the clinical management of people at risk of or with established CHD. To date, however, the evidence from randomised controlled trials showing that low GI diets reduce CHD and CHD risk factors is weak. In a meta-analysis of 15 trials there was no evidence that low GI diets have an effect on LDL-C or HDL-C, triglycerides, fasting glucose or fasting insulin levels.¹²⁰

Mediterranean diets

The Mediterranean diet is characterised by the traditional cooking style of countries bordering the Mediterranean Sea. The principle of the Mediterranean diet includes high levels of olive oil, legumes, unrefined cereals, fruits, vegetables, moderate consumption of dairy products (mostly as cheese and yogurt), moderate to high consumption of fish, low consumption of meat and meat products, and moderate wine consumption.

A systematic review of 12 observational studies with a total of 1,574,299 subjects followed from 3 to 18 years, demonstrated that adherence to a Mediterranean diet is associated with a significant improvement in health status, as seen by a significant reduction in overall mortality (RR 0.91, 95% CI 0.89–0.94), and mortality from CVD (RR 0.91, 95% CI 0.87–0.95).¹²¹

Other interventions

Several other interventions, including soya protein,¹²² phytosterols¹²³ and selenium supplements,¹²⁴ have been investigated for their potential benefits on CVD risk factors. In general, soya protein,¹²² phytosterols and soluble fibre¹²³ may have modest hypocholesterolaemic effects, while there is insufficient evidence to determine the effect of selenium supplements on the prevention of CVD.¹²⁴ More evidence is required before clear recommendations can be made regarding these interventions.

Table 2: Effect of lifestyle and dietary factors on CVD outcomes: summary of key evidence

Reference	Study details	Intervention	Results
Brunner et al (2007) ⁹⁹	Good quality SR (n=38 RCTs); 17,871 healthy adults. Median follow-up 10 months.	Dietary advice vs no advice or minimal advice	↓TC 0.16 mmol/L, ↓ LDL-C 0.18 mmol/L, ↓SBP 2.07 mmHg / DBP 1.15 mmHg after 3-24 months. Mean HDL-C levels and triglyceride levels unchanged.
Dickinson et al (2006) ¹²⁵	Good quality SR (n=105 RCTs); 6,805 adults with BP ≥140/85 mmHg. At least 8 weeks follow-up.	Lifestyle interventions vs control	Improved diet ↓SBP 5.0 mmHg; ↑ aerobic exercise ↓SBP 4.6 mmHg; ↓ alcohol ↓SBP 3.8 mmHg; sodium restriction ↓SBP 3.6 mmHg; and fish oil supplements ↓ 2.3 mmHg.
Dauchet et al (2005) ¹⁰⁸	Good quality SR (n=7 prospective cohort studies); 232,049 participants; 90,513 men, 141,536 women.	Vegetables and Fruit	↓ risk of stroke (RR 0.89, 95% CI 0.85-0.93) for each additional portion per day of fruit. ↓ risk of stroke (RR 0.95, 95% CI 0.92-0.97) for additional fruit and vegetables per day. Linear relationship between fruit or fruit and vegetables and stroke.
Dauchet et al (2006) ¹⁰⁹	Good quality SR (n=9 prospective cohort studies); 221,080; 91,379 men, 129,701 women.	Vegetables and Fruit	For each additional portion per day of vegetable and fruit ↓ risk CHD (RR 0.96, 95% CI 0.93-0.99). For each additional portion per day of fruit intake ↓ risk of CHD (0.93, 95% CI 0.89-0.96).

Reference	Study details	Intervention	Results
Elwood et al (2008) ¹¹²	Fair quality SR (n=15 cohort studies).	Dairy	High vs low milk or dairy consumption ↓ stroke and/or CHD (RR 0.84, 95% CI 0.76-0.93 and RR 0.79, 95% CI 0.75-0.82 respectively). Limited data on full vs fat reduced products although the risk of IHD was halved in one large cohort of women with reduced fat products.
Flores-Mateo et al (2006) ¹²⁴	Moderate quality SR (n=31 studies). 14 cohort and 11 CCTs that measured selenium concentrations and six RCTs of selenium supplements.	Selenium supplements	In the 6 RCTs, there was no difference in CHD (RR 0.89, 95% CI 0.68-1.17).
Harland et al (2008) ¹²²	Good quality SR (n=30 RCTs); 2,913 adults with normal or mildly elevated cholesterolaemia.	Soya protein	The inclusion of modest amounts of soya protein (~25 g) into the diet of adults with normal-mild raised lipids resulted in small, but significant reductions in LDL-C, TC and triglycerides.
He et al (2004) ¹⁰³	Good quality SR (n=11 cohort studies); 222,364 participants. Mean follow-up 11.8 years.	Fish Intake	Compared with those who never ate fish or ate fish <once a month, individuals with a higher intake of fish had lower CHD mortality. Each 20-g/d increase in fish intake was related to a 7% lower risk of CHD mortality.
He et al (2006) ¹¹¹	Good quality SR (n=8 cohort studies); 257,551 individuals. Average follow-up 13 years.	Vegetables and Fruit	Compared with individuals who had <3 servings/day of vegetables and fruit: >5 servings/day ↓ stroke (RR 0.74, 95% CI 0.69-0.79); 3-5 servings per day ↓ stroke (RR 0.89, 95% CI 0.83-0.97)
He et al (2007) ¹¹⁰	Good quality SR (n=12 cohort studies); 278,459 individuals (9,143 CHD events). Median follow-up 11 years.	Vegetables and Fruit	Compared with individuals who had <3 servings/day of vegetables and fruit: >5 servings/day ↓ CHD (RR 0.83, 95% CI 0.77-0.89); 3-5 servings per day did not change CHD (RR 0.93, 95% CI 0.86-1.00; p=0.06)
Hooper et al (2001) ¹⁰¹	Good quality SR (n=27 RCTs); 18,196 healthy adults. Follow-up periods were grouped into <2 years and >2 years.	Reduction or modification of dietary fats	↓ CVD events (RR 0.84, 95% CI 0.72-0.99). No difference in all-cause mortality (RR 0.98, 95% CI 0.86-1.12) or CV mortality (RR 0.91, 95% CI 0.77-1.07). Analysis of CVD events became non-significant on sensitivity analysis. Stronger results found for trials >2 yrs.
Hooper et al (2004) ¹⁰⁷	Good quality SR (n=11 RCTs); 3,514 healthy adults reducing sodium intake over at least a six month period.	Salt reduction diet	Dietary salt reduction may lower BP by small amounts (e.g. ~1 mmHg SBP, <1 mmHg DBP after one year). However reductions may be higher in people with higher BP.
Hooper et al (2006) ¹⁰⁵	Good quality SR (n=48 RCTs and 41 cohort studies); 36,913 participants in the RCTs. Mixed primary and secondary prevention.	Omega-3 fatty acids	No difference for all-cause mortality or CVD events.
Kelly et al (2004) ¹²⁰	Good quality SR (n=21 RCTs); 713 adults with existing CHD or who had at least one risk factor for CHD.	Low GI diet	Compared to high GI diets, there is no evidence that low GI diets have any effect on CHD outcomes, and only borderline reduction in LDL-C (-0.16 mmol/L, 95% CI -0.32-0.00, p=0.05).

Reference	Study details	Intervention	Results
Kelly et al (2007) ¹¹⁹	Good quality SR (n=10 RCTs); 738 adults with existing CHD or who had at least one risk factor for CHD. Minimum 4 weeks diet.	Wholegrain cereal diet	There is no evidence that wholegrain diets have an effect on CHD outcomes. In eight studies wholegrain (oats) ↓ TC (-0.20 mmol/L, p=0.0001) and ↓ LDL-C (0.18 mmol/L, p<0.0001).
Sofi et al (2008) ¹²¹	Good quality SR (n=12 prospective cohort studies); 1,574,299 subjects with 3-18 years follow up.	Mediterranean diet	Greater adherence to a Mediterranean diet is associated with a ↓ in overall mortality (RR 0.91, 95% CI 0.89-0.94) and a ↓ in CVD mortality (RR 0.91, 95% CI 0.87-0.95).
Wang et al (2006) ¹⁰⁴	Good quality SR (n=33 trials). 1,199,246 participants. Primary prevention (1 RCT; 25 prospective cohort studies; 7 CCTs). Secondary prevention (14 RCTs; 1 prospective cohort study). All studies followed patients for >1 yr.	Fish oils / n-3 fatty acids	Increased consumption of n-3 fatty acids from fish or fish-oil supplements, but not of alpha-linolenic acid, ↓ all-cause mortality, cardiac and sudden death, and possibly stroke. The evidence for the benefits of fish oil is stronger in secondary than in primary-prevention settings.

BP: blood pressure; CCT: clinical controlled trial; CHD: coronary heart disease; CI: confidence interval; CVD: cardiovascular disease; DBP: diastolic blood pressure; GI: glycaemic index; HDL: high density lipoprotein; HR: hazard ratio; IHD: ischaemic heart disease; LDL: low density lipoprotein; RCTs: randomised controlled trials; RR: relative risk; SBP: systolic blood pressure; SR: systematic review; TC: total cholesterol.

Practice point

Nutrition, overweight and obesity

PP 9: All adults should be supported to follow the current *Dietary Guidelines for Australian Adults*.

Weight loss

There is evidence to support the promotion of weight loss interventions in people who are overweight or obese. Such interventions can favourably influence CVD risk factors such as BP and blood lipid levels. There is limited evidence that directly links weight loss with a reduction in cardiovascular events.

Four systematic reviews covering a range of weight loss interventions including, pharmacologic, diet, exercise, behaviour therapy and surgery were identified.¹²⁶⁻¹²⁹ The most recent assessed the effects of weight loss interventions versus placebo or no intervention across nine trials involving almost 2,000 participants.¹²⁹ At 12 months, weight loss interventions resulted in significantly greater weight loss compared with controls (-3.0 kg, 95% CI -5.1 to -0.9, p=0.005). Weight loss interventions were also

associated with significant reductions in TC (-0.36mmol/L; 95% CI -0.75 to 0.04, p=0.008), and favourable (although not statistically significant) changes in LDL-C, HDL-C and triglycerides. This study also identified some evidence to indicate that weight loss could have an independent effect on cardiovascular events, showing a hazard ratio for recurrence of hypertension or cardiovascular events of 0.65 (95% CI 0.50–0.85) for weight loss compared with controls.¹³⁰

These observations are supported by the results of other reviews where weight loss resulted in improvements in BP,^{126-128, 131, 132} lipid profiles¹²⁶⁻¹²⁸ and glucose.¹²⁸ In general, the combination of physical activity and dietary advice provided the greatest benefit,¹²⁸ while low carbohydrate and high protein diets were more effective than low fat diets in reducing weight and CVD risk factors at 12 months in one review.¹²⁷

Evidence-based recommendation	Grade
Nutrition, overweight and obesity	
EBR 6: Weight loss should be recommended for people who are overweight or obese.	B ¹²⁴⁻¹²⁷

In another review of 84 studies, a weight loss of 10 kg was associated with a fall in TC of 0.25 mmol/L and a fall in DBP of 3.6 mmHg, while a weight loss of 10% was associated with a fall in SBP of 6.1 mmHg.¹²⁶ Low fat diets were associated with the prevention of type 2 diabetes and improved control of elevated BP. These diets were associated with a weight loss after 12 months of 5.31 kg (95% CI -5.86 to -4.77 kg). Furthermore, intentional weight loss in women with obesity-related illnesses was associated with a reduced risk of death, CVD death, cancer and diabetes-related death – a result that was irrespective of the amount of weight lost. Men with general illness who lost weight intentionally appeared to have a reduced risk of diabetes related death, but there was no demonstrable effect on CVD mortality, and cancer mortality appeared increased.

In one study, participants randomised to the weight loss group demonstrated a BP reduction of 4.0/1.1 mmHg compared with a 0.8/0.8 mmHg change in the control group ($p < 0.001$).¹³⁰ The net effect of those reductions resulted in the discontinuation of antihypertensive medications in 93% of the weight loss group.

2.1.2 Physical activity

Physical activity is defined as any bodily movement produced by skeletal muscles that requires energy expenditure.¹³³ Physical inactivity, including sitting time and leisure activity, is a growing public health problem and is associated with an increased risk of ill health and death, particularly relating to CVD.^{134, 135} Regular physical activity reduces CVD risk in its own right, reduces CVD risk factors such as obesity and elevated blood pressure, improves the levels of HDL-C and helps protect against type 2 diabetes.⁹

This section summarises the evidence for physical activity from systematic reviews and individual trials considered for the primary prevention of cardiovascular events.

Physical activity as an independent risk factor

Several meta-analyses provide evidence for a significant effect of physical activity on CVD risk, after controlling for other key risk factors.¹³⁶⁻¹⁴⁰ In general, these studies confirm an inverse relationship between physical activity and the risk of a cardiovascular event or all-cause mortality. Effect sizes for specific activities range from 30% to 40% relative risk reductions for CVD^{137, 138} and 19% to 33% risk reductions for all-cause mortality.^{136, 139}

One meta-analysis combined the results of 22 observational studies, involving 977,925 participants, and used a dose-response meta-regression model to estimate the relationship between non-vigorous physical activity and mortality.¹⁴⁰ The results demonstrated a dose response-relationship for exercise duration: 2.5 hours/week (equivalent to 30 minutes daily of moderate intensity activity on five days a week) compared with no activity, was associated with a reduction in mortality risk of 19% (95% CI 15–24), while 7 hours/week of moderate activity compared with no activity reduced the mortality risk by 24% (95% CI 19–29). Furthermore, the largest benefit was found when moving from no activity to low levels of activity. The presence of a dose-response curve for exercise duration is consistent with results from other studies.^{136, 141}

The evidence also suggests a dose-response relationship for exercise intensity. For example, one well conducted meta-analysis evaluated the results from 38 studies with 3–4 different intensities of regular physical activity.¹³⁷ For studies with three activity categories (mildly, moderately and highly active), highly active men had a 22% lower risk of all-cause mortality (RR 0.78; 95% CI 0.72–0.84) compared with mildly active men (RR 0.81; 95% CI 0.75–0.87). Similarly, for women, the relative risk was 0.69 (95% CI 0.53–0.90) for those who were highly active, compared with 0.76 (95% CI 0.66–0.89) in the moderately active group. Similar results were observed when moderately active persons were compared with mildly active individuals (RR of 0.81 for men and 0.76 for women).

These results suggest that physical activity should include occupational and/or leisure time activity and incorporate

Evidence-based recommendation	Grade
Physical Activity	
EBR 7: All adults should be advised to participate in at least 30 minutes of moderate intensity activity on most days or preferably every day of the week.	B ¹³⁶⁻¹⁴⁰

accumulated bouts of moderate intensity activities such as brisk walking, cycling, taking public transport and household physical activity. Adults who are moderately active and are able to increase their activity should be encouraged to do so. This may involve changes to intensity, duration or frequency of activity. Any increase in activity should be done gradually irrespective of the level of fitness.

Effects of physical activity on other CVD risk factors

Several randomised controlled trials¹⁴²⁻¹⁴⁵ and meta-analyses¹⁴⁶⁻¹⁴⁸ provide evidence for a significant effect of physical activity on CVD risk factors. All forms of exercise appear to be effective, with a positive influence on CVD risk factors: lowering LDL-C and triglycerides,¹⁴⁶ increasing HDL-C¹⁴⁶ and insulin sensitivity,¹⁴⁸ reducing body fat^{144, 147} and lowering BP.^{142, 144, 146}

2.1.3 Smoking

There is overwhelming evidence that smoking has a strong, dose-dependent association with cardiovascular events, including CHD, stroke, peripheral arterial disease and cardiovascular death.¹⁴⁹⁻¹⁵⁷ Men who smoke are three times more likely to die aged 45–64 years, and twice as likely to die aged 65–84 years than non-smokers.¹⁵⁰ The Nurse's Health Study showed that female smokers had nearly 1.9 times the risk of total mortality from smoking than non-smokers.¹⁵⁴ Passive smoking also increases the burden of CVD.¹⁵⁸ Smoking cessation reduces these risks substantially, although the decrease is dependent on the duration of cessation.^{157, 159} This section summarises the published evidence for smoking cessation for the primary prevention of cardiovascular events.

During the period of the literature search, one high-quality randomised controlled trial of smoking cessation¹⁴⁹ and one secondary analysis of a longitudinal study were located.¹⁶⁰ The randomised controlled trial assessed the effects of a smoking cessation program on long-term mortality among 5,887 middle-aged volunteers with asymptomatic airway

obstruction. Intervention included a 10-week smoking cessation program, strong physician support and 12 group sessions using behaviour modification and nicotine gum, plus either ipratropium or a placebo inhaler. At five years, 21.7% of the intervention participants had stopped smoking compared with 5.4% of usual care participants. After up to 14.5 years of follow-up, all-cause mortality was significantly lower in the special intervention group than in the usual care group (8.83 per 1000 person-years vs. 10.38 per 1,000 person-years; $p = 0.03$). The hazard ratio for mortality in the usual care group compared with the special intervention group was 1.18 (95% CI 1.02–1.37).

Longitudinal data also support smoking cessation as an important primary prevention strategy. In England and Wales between 1981 and 2000, smoking prevalence in adults aged 25–84 years decreased from 43% to 28% in men and from 35% to 24% in women. Using that information and a validated mortality model to estimate the deaths prevented or postponed by changes in population smoking prevalence, the authors estimated that 29,460 deaths were prevented or postponed by the reduction in smoking prevalence.¹⁶⁰

The number of studies identified during the literature search was small. However, the recommendations presented here also take into account the results of literature prior to 2002. Specifically, one randomised controlled trial found that advice to change diet and smoking habits reduced the relative risk of CHD mortality after 23 years in men with high triglyceride concentrations (HR 0.56. 95% CI 0.34–0.93, $p = 0.027$).¹⁵¹ Men with normal triglyceride concentrations did not appear to achieve the same long-term benefit.

Five observational studies of over 293,000 patients support these results.^{150, 153-155, 157} In one study, cause-specific mortality was monitored for 50 years in 34,439 male British doctors. For those born between 1900 and 1909, the probabilities of dying in middle age (35–69) were 42% vs 24% (a two-fold death rate ratio) for smokers and non-smokers, respectively, but were 43% vs 15% (a three-fold death rate ratio) for those born in the 1920s. Cessation at age 60, 50, 40 or 30 years provided an approximate 3, 6, 9 or 10 additional years, respectively, of life expectancy.¹⁵⁰

Table 3: Effect of physical activity on CVD outcomes: summary of key evidence

Reference	Study details	Intervention	Results
Hamer et al (2008) ¹³⁶	Good quality SR (n=18 prospective cohort studies). 459,833 participants free from CVD at baseline.	Walking	For highest vs lowest walking category: ↓CVD events (HR 0.69, 95% CI 0.61-0.77) ↓all-cause mortality (HR 0.68, 95% CI 0.59-0.78). Walking pace was a stronger independent predictor of overall risk compared with walking volume (48% vs 26% risk reductions, respectively).
Lollgen et al (2009) ¹³⁷	Good quality SR (n=38 prospective cohort studies) Primary prevention. Study duration > four years. >271,000 participants.	Physical activity	All-cause mortality. Highly vs mildly active: Men (RR = 0.78, 95% CI 0.72-0.84); Women (RR 0.69, 95% CI 0.53-0.90). There is a dose-response curve from sedentary subjects to those with mild and moderate exercise. This association was similar for sex and age.
Nocon et al (2008) ¹³⁸	Fair quality SR (n=33 cohort studies). 883,372 participants. Follow-up from 4 to >20 years.	Physical activity	↓CV mortality by 35% and ↓all-cause mortality by 33% in both men and women.
Orozco et al (2008) ¹⁴⁷	Good quality SR (n=8 RCTs; 10 interventions) 5,095 participants at risk of diabetes. Study duration ranged from one to six years.	Exercise or exercise and diet	Exercise and diet interventions had a modest effect on blood lipids, and improved SBP and DBP by 4 mmHg, (95% CI -5 to -2) and 2 mmHg, (95% CI -3 to -1), respectively. Exercise alone or diet alone did not demonstrate these effects.
Shaw et al (2008) ¹²⁸	Good quality SR (43 RCTs). 3,476 participants who are obese or overweight. Trials at least 3 months length. Unclear those with existing CVD.	Exercise + diet vs diet or no treatment	Exercise + diet resulted in a greater weight reduction than diet alone (WMD - 1.0 kg; 95% CI -1.3 to -0.7). ↑ exercise intensity increased the magnitude of weight loss (WMD -1.5 kg; 95% CI -2.3 to -0.7). Exercise alone ↓DBP (WMD -2 mmHg; 95% CI -4 to -1), ↓triglycerides (WMD - 0.2 mmol/L; 95% CI -0.3 to -0.1) and ↓fasting glucose (WMD - 0.2 mmol/L; 95% CI -0.3 to -0.1).
Shiroma et al (2010) ¹³⁹	Fair quality review based on previous robust SR (n=54 prospective cohort studies). >957,000 people.	Physical activity	Compared with no activity, physical activity provides a significant and consistent benefit in the order of 30-40% risk reduction for CHD and CVD. Consistent benefit for sex, age and ethnicity. Higher intensity had greater effects than moderate intensity.
Thomas et al (2006) ¹⁴⁸	Good quality SR (n=14 RCTs) 377 participants with type 2 diabetes mellitus. Trials ranged from 8 weeks to 12 months duration.	Aerobic, fitness or PRT exercise vs no exercise	Exercise significantly improves glycaemic control and reduces visceral adipose tissue and plasma triglycerides, but not plasma cholesterol, in people with type 2 diabetes even without weight loss.
Woodcock et al (2010) ¹⁴⁰	Good quality SR (n=22 prospective cohort studies). 977,925 people (334,738 men and 643,187 women). Included studies with >10,000 general/healthy people.	Light or moderate physical activity	2.5 h/week moderate intensity activity ↓risk of mortality by 19% (95% CI 15-24), while 7 hr/ week of moderate activity ↓mortality risk by 24% (95% CI 19-29). Smaller effects found in trials of walking alone.

CI: confidence interval, CHD: coronary heart disease; CV: cardiovascular; CVD: cardiovascular disease; DBP: diastolic blood pressure; PRT: progressive resistive training; RCT: randomised controlled trial; SBP: systolic blood pressure; WMD: weighted mean difference.

Evidence-based recommendation	Grade
Smoking	
EBR 8: All smokers should be advised to stop smoking.	A ^{14, 149}

Practice point
Smoking
PP 10: All smokers should be offered advice about methods to aid smoking cessation, including counselling services, and if assessed as nicotine dependent, nicotine replacement therapy or other appropriate pharmacotherapy should be used.

Another two case controlled studies involving 1,274 subjects and 3,372 controls indicated that smoking is associated with an increased risk of MI¹⁵⁶ and CHD-related mortality,¹⁵² and a dose-response relationship exists between the total tar consumption per day and risk. The odds ratio for subjects smoking medium and high-tar-yield compared with low-tar-yield cigarettes was 1.86 (95% CI 1.21–2.87) and 2.21 (85% CI 1.47–3.34), respectively.¹⁵⁶ The INTERHEART study demonstrated the dose-response relationship between number of cigarettes smoked and MI.¹³ People who smoked over 40 cigarettes per day were found to have an almost 10-fold relative risk of MI compared with non-smokers (OR 9.16, 99%CI 6.18–13.58).

Several Cochrane reviews have been undertaken related to different therapies for smoking cessation. Nicotine replacement therapy can increase smoking cessation by 50–70%.¹⁶¹ Some antidepressants, for example bupropion and nortriptyline, but not selective serotonin reuptake inhibitors, aid long-term smoking cessation.¹⁶² Varenicline, a nicotine receptor partial agonist, leads to a two-fold success rate compared with non drug quit attempts and appears to be more beneficial than bupropion.¹⁶³ Tailored behavioural strategies via group or individual approach have demonstrated modest effects for smoking cessation.¹⁶⁴ ¹⁶⁵ Strategies and support provided from a range of health professionals including physicians, community pharmacists or nurses are effective.^{166–168} Telephone counselling improved smoking cessation rates particularly when three or more call-backs were made.¹⁶⁹ Other approaches using the

internet may also be useful where tailored information is provided.¹⁷⁰

Overall, the evidence shows a dose dependent relationship between smoking and CVD events. A range of behavioural and support interventions have been shown to improve smoking cessation. Although there are several high-level reviews for interventions for smoking cessation, the literature was not systematically searched and hence the guidance is included as a practice point.

2.1.4 Alcohol

Alcohol has a complex role in Australian society. Most Australians drink alcohol, generally for enjoyment, relaxation and sociability, and do so at levels that cause few adverse effects. However, a substantial proportion of people drink at levels that increase their risk of alcohol-related harm.¹⁷¹ As such, alcohol is known to have both beneficial and harmful effects on the risk of cardiovascular events and the psychological consequences of the disease.¹⁷² *The 2007 National Drug Strategy Household Survey* indicated that approximately 10% of Australian adults have never had a full serve of alcohol and about 17% have not consumed alcohol in the past year.¹⁷³ On the other hand, the number of Australians who drink daily and weekly was approximately 8% and 14%, respectively. This section summarises the evidence for alcohol consumption from systematic reviews and individual trials considered for the primary prevention of cardiovascular events.

Several systematic reviews of observational studies have consistently reported lower CVD mortality and CVD events with light to modest alcohol consumption.¹⁷⁴⁻¹⁷⁸ The most recent meta-analysis involving 84 observational studies (>2 million participants) found reduced relative risks for alcohol drinkers relative to non-drinkers for CVD mortality (21 studies; RR 0.75, 95% CI 0.70–0.80), incident CHD (29 studies; RR 0.71, 95% CI 0.66 to 0.77), CHD mortality (31 studies; RR 0.75, 95% CI 0.68–0.81), incident stroke (17 studies; RR 0.98, 95% CI 0.91–1.06) and stroke mortality (10 studies; RR 1.06, 95% CI 0.91–1.23).¹⁷⁵ Dose-response analysis revealed that the lowest risk of CHD mortality occurred with 1–2 drinks a day, but for stroke mortality it occurred with ≤ 1 drink per day. Secondary analysis of all-cause mortality demonstrated lower risk for drinkers compared with non-drinkers (RR 0.87, 95% CI 0.83–0.92). Modest alcohol intake was found to lower stroke incidence and mortality, but, unlike the risk for CHD, the risk of all stroke subtypes increased significantly with heavier drinking.^{175, 179} It is also noted that the association of alcohol consumption differs by stroke subtype; there is a lower risk of ischaemic stroke but increased risk of haemorrhagic stroke.¹⁷⁵ This is likely due to the fact that studies analysing the effect of alcohol on BP reported linear BP elevations at levels above 20 g/day for women and 30 g/day for men.¹⁷⁴

A recent meta-analysis of 44 intervention studies (mix of random and non random studies) found alcohol significantly increased levels of HDL-C (pooled mean difference 0.094 mmol/L, 95% CI 0.064–0.123), apolipoprotein A1 (0.101 g/L, 95% CI 0.073–0.129) and adiponectin (0.56 mg/L, 95% CI 0.39–0.72). Alcohol decreased fibrinogen levels (–0.20 g/L, 95% CI –0.29 to –0.11), but did not affect triglyceride levels. Different study designs and beverage types demonstrated consistent findings.¹⁷⁵ These biomarker studies provide indirect pathophysiological support for a protective effect of moderate alcohol use on CHD.

It is important to note that studies reported here focus on the link between alcohol intake and CVD only and do not consider other known detrimental effects of high alcohol consumption, including the risk of alcohol abuse. The results of the most recent meta-analysis generally reinforce the current national alcohol guidelines which recommend consuming light to moderate amounts of alcohol to prevent alcohol-related harm.¹⁷¹

People with atrial fibrillation

Among 34,715 healthy middle-aged women (>45 years and free of AF at baseline) participating in the Women’s Health Study, consumption of up to two alcoholic beverages per day was not associated with an increased risk of incident AF. Heavier consumption of two or more drinks per day, however, was associated with a small but statistically significant increased risk of AF (hazard ratio 1.60, 95% CI 1.13–2.25).¹⁸⁰

People with raised blood pressure

A cohort of the Physicians’ Health Study assessed total and CVD mortality among 14,125 men with raised BP who had reported to be either non-drinkers or rare drinkers, or light to moderate drinkers.¹⁸¹ During 75,710 person-years of follow-up, there were 1,018 deaths, including 579 from CVD. Compared with individuals who rarely or never drank alcoholic beverages, those who reported monthly, weekly and daily alcohol consumption, respectively, had multivariate adjusted relative risks for CVD mortality of 0.83 (95% CI 0.62–1.13), 0.61 (95% CI 0.49–0.77) and 0.56 (95% CI 0.44–0.71) ($p<0.001$ for linear trend). In the same groups, relative risks for total mortality were 0.86 (95% CI 0.67–1.10), 0.72 (95% CI 0.60–0.86) and 0.73 (95% CI 0.61–0.87), respectively ($p<0.001$ for linear trend). These results, which require confirmation in other large-scale studies, suggest that light to moderate alcohol consumption is associated with a reduction in risk of total and CVD-related mortality in hypertensive men.

People with diabetes

Two systematic reviews assessing the effect of alcohol use on the incidence and complications of diabetes mellitus in adults were identified. In the first, the risks of fatal and total CHD were significantly lower in all three categories of alcohol consumers (<6, 6 to <18 and ≥ 18 g/day) than in non-consumers; relative risks ranged from 0.34 to 0.75.¹⁸² Similar results were reported in the second review: compared with no alcohol use, moderate consumption (1–3 drinks/day) was associated with a 33–56% lower incidence of diabetes and a 34–55% lower incidence of diabetes-related CHD.¹⁸³ It is clear from these reviews and those noted above there is no difference in effect between those with or without diabetes.

Practice point

Alcohol

PP 11: All adults should be advised to follow the current *Australian guidelines to reduce health risks from drinking alcohol* (2009).

2.1.5 Multiple lifestyle interventions

One Cochrane review¹⁸⁴ and three trials¹⁸⁵⁻¹⁸⁷ using lifestyle change interventions to improve cardiovascular outcomes were located. In the Cochrane review, 55 trials using education or counselling with or without pharmacotherapy to reduce CVD risk factors were assessed.¹⁸⁸ The trials were all more than six months in duration using counselling or education to modify more than one CVD risk factor in adults from general populations, occupational groups or specific risk factors (i.e. diabetes, hypertension, hyperlipidaemia, obesity) and all involved people aged 40 years or older with no evidence of CVD at baseline (trials with more than 25% participants with prior CVD were excluded). The interventions had some effect on risk factors, demonstrating reductions in SBP (53 trials; WMD -2.71 mmHg, 95% CI -3.49 to -1.93), DPB (53 trials; WMD -2.13 mmHg, 95% CI -2.67 to -1.58) and blood cholesterol (50 trials; WMD -0.24 mmol/L, 95% CI -0.32 to -0.16). In general, lifestyle intervention was ineffective for improving cardiovascular outcomes, including total mortality and CHD mortality (OR 1.00, 95% CI 0.96-1.05 and OR 0.99, 95% CI 0.92-1.07 respectively).

However, the interventions showed benefits in total mortality and combined fatal and non-fatal cardiovascular events in people with hypertension (16 trials) and diabetes (5 trials) (OR 0.78, 95% CI 0.68–0.89) and (OR 0.71, 95% CI 0.61–0.83), respectively.

In several randomised controlled trials, intensive interventions to address lifestyle factors were used,^{143, 145, 185, 186, 189-191} while in another, motivational interviewing based on an AR profile was investigated.¹⁸⁷ The group-based interventions resulted in modest improvements in body weight, waist circumference and BP, while motivational interviewing, used in the latter study demonstrated a small difference compared with controls in terms of 10-year Framingham risk profile. In that study, the effects on individual risk factors (e.g., BP, cholesterol and smoking) were generally modest where they occurred at all.

Collectively, this evidence indicates that for the general population, lifestyle interventions can modestly reduce the levels of individual CVD risk factors, but have not been consistently found to affect CVD outcomes. The reduction in number of CVD events by multiple lifestyle interventions appears to be related to the initial level of AR.

Practice point

General Lifestyle

PP 12: Adults at higher absolute risk of CVD should be given more frequent and sustained lifestyle advice, support and follow-up to achieve behavioural change.

Table 4: General lifestyle advice

Lifestyle factor	Advice
Diet	Consume a varied diet rich in vegetables, fruits, wholegrain cereals, lean meat, poultry, fish, eggs, nuts and seeds, legumes and beans, and low-fat dairy products
Fats	Limit foods containing saturated and trans fats
Salt	Limit salt to <6g/day (approximately 2300 mg sodium)
Alcohol	Limit alcohol intake to ≤2 standard drinks per day
Physical activity	At least 30 minutes physical activity on most or preferably every day of the week
Weight	Limit energy intake to maintain a healthy weight. Ideal weight should be BMI <25 kg/m ² and waist circumference <94 cm in men (<90 cm in Asian men) or <80 cm in women (including Asian women)
Smoking	Stop smoking using counselling, and if required nicotine replacement therapy or other medication

2.2 Pharmacotherapy

2.2.1 Blood pressure-lowering therapy

Blood pressure-lowering reduces CVD risk

BP lowering using pharmacotherapy results in reduction in both total mortality and mortality from CHD and stroke.^{192, 193} However, questions remain about which drugs to use, at what dose and whether BP should be reduced to a limited extent only – a treat to target approach – or reduced as far as possible. This section summarises the evidence for lowering BP from systematic reviews and individual trials considered for the primary prevention of cardiovascular events.

Two large systematic reviews of BP-lowering drugs versus placebo in people without a history of CVD demonstrate that pharmacological lowering of BP reduces the incidence of CHD events and strokes in the order of 20–25% and 30–45%, respectively. The first review analysed the results from 147 randomised trials of BP-lowering drugs in preventing CHD and stroke events.¹⁹² The preventive effect of BP-lowering therapies in people without a history of CVD, and those with and without high blood pressure was similar. For people without a history of CVD, active treatment resulted in a 10 mmHg reduction in SBP or 5 mmHg reduction in DBP, and led to a relative risk of CHD events of 0.79 (95% CI 0.72–0.86) and for stroke of 0.54 (95% CI 0.45–0.65).

In the second review, a quantitative assessment of elevated BP trials was performed to investigate to what extent lowering of SBP and DBP contributed to prevention of CVD.¹⁹³ A total of 12,903 young (30–49 years of age) people, 14,324 old (60–79 years of age) and 1,209 very old (≥ 80 years of age) people were assessed. In the young, old and very old, the median follow-up period was 5.0, 3.9 and 3.8 years, respectively, and active treatment reduced SBP and DBP by a similar amount in each cohort. However, with increasing age, the ratio of DBP to SBP lowering significantly decreased from 0.55 (95% CI 0.46–0.64) in the young to 0.39 (95% CI 0.29–0.49) and 0.32 (95% CI 0.01–0.63) in the old and very old, respectively ($p=0.004$). Despite this, active treatment reduced all cardiovascular events and the risk of stroke and CHD events to a similar extent in all three age strata. In addition, active treatment reduced total mortality by 17% (95% CI 6–26; $p=0.003$) and cardiovascular mortality by 21% (95% CI 7–33; $p=0.004$) in old people. This was not the case in the young and very old groups ($p\geq 0.28$), although this result was expected given the relatively short period of follow-up in young people and long period in the very elderly.

The HYVET trial examined the effects of a diuretic on people aged 80 or over with raised BP. This randomised trial found that treatment with a diuretic reduced the relative risk of fatal and non-fatal stroke, but not significantly (hazard ratio 0.70, 95% CI 0.49–1.01, $p=0.06$). The same study demonstrated significant reductions in all cause mortality (hazard ratio 0.79, 95% CI 0.65–0.95, $p=0.02$) and CVD events (hazard ratio 0.79, 95% CI 0.69–0.90, $p=0.0004$).¹⁹⁴

Collectively, these data demonstrate that active treatment with BP-lowering therapies improves cardiovascular outcomes.

People with diabetes

In people with type 2 diabetes, BP-lowering therapy reduces CVD risk to an equal or greater extent than for the population without diabetes.^{192, 195}

People with CKD

There is a growing body of evidence to suggest that people with CKD receive the same or similar benefits from BP-lowering therapy as those in the general population. Other evidence shows benefits of BP lowering in this population for cardiovascular events but not mortality.¹⁹⁶ Much less evidence is available for people on maintenance dialysis; however, the available evidence suggests that treatment using agents that lower BP reduces cardiovascular morbidity and mortality.¹⁹⁷ Treatment for BP lowering in people on dialysis is highly complex and specialist advice and management is usually required. While more studies are required, the possible risks and benefits of BP lowering should be considered for all people receiving dialysis.

Other considerations

The benefits of BP lowering using an AR approach have not been assessed. Meta-analysis clearly demonstrates reductions of CVD risk from lowering BP, which is consistent across all subgroups.

It is also noted that BP lowering reduces important non-CVD related conditions such as heart failure, glaucoma and diabetic and non-diabetic nephropathy.^{47, 192}

Table 5: Effect of blood pressure-lowering on CVD outcomes: summary of key evidence

Reference	Study details	Intervention	Results
BP Lowering Treatment Trialists' Collaboration; Turnbull et al (2008) ¹⁹⁸	Good quality SR (n=31 RCTs); 190,606 participants. Compared age groups <65 and above 65. Mixed primary and secondary prevention.	Comparison of BP-lowering regimens against placebo or less intensive control	No difference in reductions in major CV events between age groups for any comparison. For each ↓5mmHg SBP, risk of CVD events ↓11.9% (5.3-18%) for those aged <65 and ↓9.1% (3.6-14.3%) for those aged ≥65.
Law et al (2009) ¹⁹²	Good quality SR (n=147 RCTs); 464,000 participants. 26 RCTs specifically with no history of CVD.	All BP lowering medications vs placebo or other class of drug	For a reduction of 10mmHg SBP or 5mmHg DBP: ↓CHD events (RR 0.79, 95% CI 0.72-0.86), ↓stroke (RR 0.54, 95% CI 0.45-0.65). Preventative effect similar in people with and without history of CVD. Effect is similar for all classes of blood pressure-lowering drugs (although CCBs slightly more effective for stroke prevention and BBs slightly less effective). CCBs ↓heart failure by 19% whereas for other classes ↓24%. Consistent RR for CHD (0.84) and stroke (0.70) irrespective of initial BP.
Wang et al (2005) ¹⁹³	Good quality SR (n=10 RCTs). 12,903 young (30-49 yrs old) from 3 trials; 14,324 old (60-79 yrs) and 1209 very old (≥80 yrs old) from 8 trials. Limited to trials with available individual data. Combined primary and secondary trials.	All BP lowering medications vs placebo or no treatment	↓BP in young (8.3/4.6 mmHg), old (10.7/4.2 mmHg) and very old (9.4/3.2 mmHg). ↓17% all-cause mortality (p=0.003) and ↓21% CVD mortality (p=0.004) in those 60-79 but not in the younger or older groups. No difference in CVD events for different ages but ↑absolute benefit with increasing age. Effects related to ↓SBP rather than DBP.
Wright et al (2009) ¹⁹⁹	Good quality SR (n=24 RCTs; 28 arms). 58,040 people, 42,196 (72.7%) were primary prevention. Included trials had >70% of people with BP >140/90 mmHg at baseline and were for >1year duration.	All BP lowering medications vs placebo or other class of drug	Low-dose thiazides in ↓mortality (RR 0.89, 95% CI 0.83-0.96) and ↓CV events (RR 0.70, 95% CI 0.64-0.76). BBs ↓CV events (RR 0.89 95% CI 0.8-0.98) but not CHD or mortality. ACEi ↓mortality (RR 0.83, 95%CI 0.72-0.95) and CV events (RR 0.76, 95% CI 0.67-0.85). CCBs ↓CV events (RR 0.71, 95% CI 0.57 to 0.87) but not CHD or mortality. Moderate to high BP in primary prevention ARR 3.7-5.1 (NNT for 5 years 20-27); Mild BP in primary prevention ARR 0.75-0.82 (NNT 120); secondary prevention ARR 5.5 (NNT 18).

ACEi: ACE inhibitor; ARR: absolute risk reduction; BB: beta blocker; BP: blood pressure; CCB: calcium channel blocker; CI: confidence interval; CHD: coronary heart disease; CV: cardiovascular; CVD: cardiovascular disease; DBP: diastolic blood pressure; MI: myocardial infarction; NNT: number needed to treat; RCTs: randomised controlled trials; RR: relative risk; SBP: systolic blood pressure.

2.2.2 Lipid-lowering therapy

Lipid-lowering reduces CVD risk

High plasma cholesterol is a well-known, modifiable risk factor for CVD. A 10% increase in TC is associated with a 27% increase in the incidence of CHD,²⁰⁰ and the relationship persists, irrespective of smoking status, the presence or absence of elevated BP, or a history with or without vascular disease.^{19, 201-203} Lipid lowering therefore plays an important role in the prevention of cardiovascular events.

Most of the cholesterol in blood plasma is carried by LDL-C and the strong relationship between TC and CVD suggests that LDL-C is a powerful risk factor.²⁰⁴ Moreover, the results of epidemiological studies, as well as trials with clinical endpoints, confirm that a reduction in LDL-C must be of primary concern in the prevention of CVD.²⁰⁵ This section summarises the evidence for lowering blood lipids from systematic reviews and meta-analyses considered for the primary prevention of cardiovascular events.

The preponderance of evidence suggests that, compared with placebo, statins reduce the risk of death or cardiovascular events in populations without a history of CVD, irrespective of age and gender and across a wide range of cholesterol levels (see Table 6).²⁰⁶⁻²¹² One meta-analysis of 14 trials found all-cause mortality was reduced by statins (RR 0.83, 95% CI 0.73–0.95) as were combined fatal and non-fatal CVD events (RR 0.70, 95% CI 0.61–0.79). Combined fatal and non-fatal stroke events were reduced (RR 0.78, 95% CI 0.65–0.94) as were combined fatal and non-fatal CHD events (RR 0.72, 95% CI 0.65–0.79). There was no clear evidence of any significant harm caused by statins or effects on patient quality of life.²⁰⁸

Another meta-analysis of 26 trials (mixed primary and secondary prevention) focusing on the comparison of high and low doses of statins, reported a strong benefit of statin use, with a reduction in major vascular events in people without previous CVD (RR 0.75, 95% CI 0.69–0.82 per 1 mmol/L reduction in LDL-C) and a 0.4% lower risk difference per year in those taking statins.²⁰⁹ This result is similar to the approximately 20% reductions found in those with existing CVD (across all subgroups). The data confirmed an approximate linear relationship between LDL-C reduction and relative risk reduction of CVD events, independent of presenting levels, and that more intensive treatment can further lower the risks.

Similar benefits were observed in another meta-analysis of 10 trials, 94% of whom were in people without established

CVD but with CVD risk factors.²⁰⁶ During a mean follow-up of 4.1 years, statin therapy significantly reduced the risk of all-cause mortality (OR 0.88, 95% CI 0.81–0.96), major coronary events (OR 0.70, 95% CI 0.61 to 0.81) and major stroke events (OR 0.81, 95% CI 0.71–0.93). There was no increased risk of cancer and the effects were similar in various clinical subgroups.

In contrast, two smaller meta-analyses showed trends towards decreased all-cause mortality that just failed to reach statistical significance. These include a recent meta-analysis of 11 trials specifically excluding those with pre-existing CVD (RR 0.93, 95% CI 0.86–1.00).²⁰⁷ No individual or composite CVD endpoints were considered as part of this review although there was a 1 mmol/L mean difference in LDL-C levels overall between the intervention and control groups after an average of 3.7 years of statin treatment (2.4 mmol/L on statin therapy vs. 3.5 mmol/L in control group; compared with 3.6 mmol/L at baseline). Finally, a slightly older meta-analysis based on only two trials found that statins were associated with a statistically significant reduction in the risk of non-fatal MI (RR 0.60, 95% CI 0.37 to 0.97) and of CHD death plus non-fatal MI (RR 0.66, 95% CI 0.46–0.96), but not all-cause mortality (RR 0.73, 95% CI 0.53–1.01) or CVD mortality (RR 0.67, 95% 0.40–1.10).²¹¹

Three recent stroke specific primary prevention meta-analyses of those at high risk of CVD (all of which involved trials that included people with other CVD events at baseline) also confirm the risk reduction offered by statin therapy is in the order of 20% due primarily to the reduction in ischaemic stroke and other CVD events without any significant decrease or increase in haemorrhagic stroke.²¹³⁻²¹⁵

Although similar overall, variations in results from the five most recent meta-analyses highlight the differences in the inclusion criteria (particularly the percentage of participants found to have existing CVD), review dates, outcomes chosen (individual versus composite endpoints), early termination of some included trials, and data analysis and reporting.

Collectively, the evidence confirms that there is a continuous, graded, strong relationship between serum cholesterol and risk for major cardiovascular events.²⁰⁸

²⁰⁹ Statin trials consistently found significant reductions in TC (net difference -0.89 mmol/L, 95% CI -1.20 to -0.57 mmol/L) and LDL-C (net difference -0.92 mmol/L, 95% CI -1.10 to -0.74 mmol/L).²⁰⁸ The effect of statin therapy appears to be related primarily to LDL-C reductions, which is confirmed in the recent meta-analysis of 26 trials that found a 25% relative reduction in CVD events for those

without CVD at baseline for each 1.0 mmol/L decrease in LDL-C.²⁰⁹

The benefit of statin therapy is greatest for individuals at higher levels of risk.²⁰⁸ Of all the methods to modify lipids, the weight of evidence suggests that statins are the most effective agents and should be the first-line agent to reduce lipids.^{208, 209, 216-219}

Other than statins, lipid-lowering pharmacotherapy includes fibrates, bile acid binding resins, niacin (nicotinic acid) and selective cholesterol absorption inhibitors (e.g. ezetimibe).

Fibrates effectively lower triglycerides and increase HDL-C. However, they lower TC and LDL-C much less than statins.^{216, 219} A meta-analysis of 10 long-term, placebo controlled trials (two trials were exclusively primary prevention and two further trials were mixed) found on average fibrates reduced TC by 8% and plasma triglyceride levels by 30% and increased HDL-C levels by 9%. LDL-C was also reduced by 7% although most individual trials reported no statistically significant changes in LDL-C levels.²²⁰ There were no significant differences in the efficacy of the various fibrates in reducing triglyceride or increasing HDL-C levels. The use of fibrates significantly reduced the occurrence of non-fatal MI (OR 0.78, 95% CI 0.71–0.86) but had no significant effect on CVD or all-cause mortality, fatal MI or stroke – all of which have been found in other meta-analyses to be significantly reduced by statins.

Another recent meta-analysis of 18 trials (four primary prevention trials, three mixed primary and secondary trials, and 11 secondary prevention trials) found overall benefit of fibrates for the prevention of major CVD events (RR 0.90, 95% CI 0.82–1.00; $p=0.048$) primarily due to reduction in coronary disease (RR 0.87, 95% CI 0.81–0.93; $p<0.0001$) with no effect on stroke (RR 1.03, 95% CI 0.91–1.16), CVD mortality (RR 0.97, 95% CI 0.88–1.07) or all-cause mortality (RR 1.00, 95% CI 0.93–1.08).²²¹ Fibrates significantly reduced the risk of retinopathy (RR 0.63, 95% CI 0.49–0.81) and progression of albuminuria (RR 0.86, 95% CI 0.75–0.98). There was no significant increase in the risk of serious adverse events (RR 1.21, 95% CI 0.91–1.61; $p=0.19$). The only data reported for the four primary prevention trials found a significant reduction in coronary events (RR 0.75, 95% CI 0.58–0.97). One further meta-analysis specific to those with diabetes also found a significant reduction in non-fatal coronary events (RR 0.84, 95% CI 0.74–0.96) but no effect on stroke or mortality outcomes.²²² The number needed to treat (NNT) to prevent one CHD event over 10 years was 26 for those without pre-existing CHD. In general, fibrates are easy to use. However, particular care should be taken when co-administering statins with gemfibrozil due to the possible increased risk of myopathy.

One trial of the bile acid resin cholestyramine monotherapy reported from the mid 1980s found a significant 19% reduction in risk of CHD death and/or nonfatal myocardial infarction, but an increase in side effects (mainly gastrointestinal irritation).²²³

Ezetimibe is a relatively new agent that inhibits cholesterol absorption from the small intestine. Two meta-analyses (both with mixed primary and secondary prevention trials) were consistent in their findings that a combination of ezetimibe plus statin significantly reduced LDL-C and TC compared with statin alone.²²⁴ Patients on ezetimibe/statin relative to those on placebo/statin were more likely to reach the LDL-C treatment goal (RR 3.4, 95% CI 2.0–5.6; $p<0.0001$).²²⁴ Monotherapy with ezetimibe, for patients where a statin was not considered appropriate, also significantly reduced LDL-C levels compared with placebo ($p<0.00001$) but the reductions were smaller than that demonstrated for statins.²²⁵

During the finalisation of this Guideline, the landmark SHARP trial reported that in a population of 9,270 with CKD (15% with history of vascular disease i.e. angina, stroke or peripheral vascular disease), a combination of ezetimibe 10 mg plus simvastatin 20 mg daily reduced LDL-C by an average of 0.85 mmol/L (SE 0.02; approximately 66% compliance, median follow-up of 4.9 years).²²⁶ There was a 17% reduction in major atherosclerotic events (non-fatal MI or coronary death, non-haemorrhagic stroke or any arterial revascularisation procedure) with combined therapy compared with placebo (RR 0.83, 95% CI 0.74–0.94) with no evidence of adverse effects.

Nicotinic acid, or niacin, has been found to reduce cholesterol. One meta-analysis of 30 trials (in mixed primary and secondary populations) found niacin significantly reduced TC (10%), increased net HDL-C (16%), reduced LDL-C (12%) and reduced triglycerides (20%).²²⁷ Similar results were found in another meta-analysis which included seven trials of niacin (all secondary prevention) which found a 17% reduction in non HDL-C and a 17% reduction in CHD risk, over 6.2 years although there was significant heterogeneity among the mostly small trials and most used combination therapy (mainly with statins).²¹⁸ Only one main outcome trial in those with existing MI reported significant reduction in events by 14% with no change in mortality although the eight-year follow up of this trial found significantly reduced mortality with niacin monotherapy.²²⁸

²²⁹ No outcome trials for niacin were found in those without existing CVD.

Omega 3 fatty acid (fish based rather than plant based) has been found to significantly reduce levels of triglycerides and increase levels of HDL-C but has not been found

to reduce TC or LDL-C.^{230, 231} While observational data suggest a reduction in CVD events with n-3 fatty acids (refer to section 2.1.1) only one major outcomes trial has been published. The JELIS trial involved 18,645 Japanese people with TC >6.5mmol/L (26% of participants had a prior history of MI, angina or revascularisation therapy). Fish oil supplementation (1,800 mg/day) was given in addition to regular statin therapy. After a mean follow-up of 4.6 years there was a significant reduction in major coronary events (OR 0.81, 95% CI 0.69–0.95), but this benefit was not statistically significant in the primary prevention subgroup (OR 0.82, 95% CI 0.63–1.06).²³²

An important result of the studies reported here is that the benefits of lipid-lowering therapy depend on initial levels of risk: the absolute reductions in risk were highest in people at the highest baseline risk irrespective of initial lipid levels. The decision to treat people at moderate levels of risk with lipid-lowering pharmacotherapy is more complex and can be determined by responsiveness to lifestyle interventions, taking into consideration other risk factors not included in the FRE.

Other considerations

In clinical practice, it is important to consider and exclude treatable causes for dyslipidaemia before starting treatment, since often the treatment of underlying disease improves dyslipidaemia and no other lipid-lowering therapy is necessary. Causes of dyslipidaemia may include diet and alcohol influences, hypothyroidism, diabetes, liver disease, nephrotic syndrome and steroid treatment.

A family history of premature CVD and/or central adiposity should also be considered as both these factors increase overall risk, independently of traditional risk factors.^{233, 234}

A family history of premature CVD refers to an event that occurs in relatives including parents, grandparents, uncles and/or aunts before the age of 55 years.

Table 6: Effect of lipid-lowering on CVD outcomes: summary of key evidence

Reference	Study details	Intervention	Results
Allerman et al (2006) ²²²	Good quality SR (8 RCTs). 12,249 participants with type 2 diabetes +/- CVD (78% were primary prevention)	Fibrates vs placebo	↓CHD events (RR 0.84, 95% CI 0.74–0.96). No effect on death due to CHD, MI or stroke. No difference between primary and secondary prevention trials.
Amarenco et al (2009) ²¹³	Good quality SR (n=26 RCTs). 165,792 participants. Mix of primary and secondary prevention.	Statins vs placebo	Each 1.0 mmol/L decrease in LDL-C equates to a reduction in relative risk for stroke of 21.1% (95% CI 6.3–33.5, p=0.009).
Ara et al (2008) ²²⁵	Good quality SR (n=13 RCTs). No clinical outcome studies of >12 weeks found so included studies using surrogate outcomes.	Ezetimibe alone or + statin vs statin alone, placebo or other	Ezetimibe monotherapy significantly ↓ LDL-C levels compared with placebo (p<0.00001). Ezetimibe and statin significant ↓LDL-C and TC compared with statin alone (p<0.00001).
Brugts et al (2009) ²⁰⁶	Good quality SR (n=10 RCTs). 70,388 participants. Inclusion of trials if >80% without CVD or reported primary prevention data separately. Mean follow-up at least 1 yr.	Statins vs placebo control or usual care	↓all-cause mortality (OR 0.88, 95% CI 0.81–0.96), ↓major coronary events (OR 0.70, 95% CI 0.61–0.81), ↓major strokes (OR 0.81, 95% CI 0.71–0.93).
Cholesterol Treatment Trialists' Collaboration; Baigent et al (2010) ²⁰⁹	Moderate quality SR (n=21 RCTs of statins vs control). 129,526 subjects; 54% (70,025) without prior CVD.	Statins vs placebo	25% ↓in major vascular events in those without CVD at baseline per 1.0 mmol/L reduction in LDL cholesterol (1.4% vs 1.8% per year; RR 0.75, 95% CI 0.69–0.82).

Reference	Study details	Intervention	Results
Corvol et al (2003) ²¹⁶	Moderate quality SR (n=38 RCTs). 10 primary, 28 secondary prevention studies. 83,161 subjects, mean follow-up of 4.7 years	All lipid-lowering therapies	Lipid-lowering therapies ↓overall stroke by approx. 17%, with the most convincing effects from statins (RRR 26%). ↓22% of MI. NNT overall stroke =735, MI=93. No difference between primary and secondary trials.
Delahoy et al (2009) ²¹²	Good quality SR (n=25 RCTs; 8 identified as primary prevention and 2 mixed primary/secondary prevention). Total 155,613 subjects. Mean follow-up of at least 1 year.	Statins vs placebo	Meta regression analysis for every 25 mg/dL (0.65-mmol/L) reduction in LDL-C: ↓vascular mortality (RR 0.89, 95% CI 0.87-0.92); ↓major CV events (RR 0.86, 95% CI 0.84-0.88); ↓major coronary events (RR 0.84, 95% CI 0.82-0.86); and ↓stroke (RR 0.90, 95% CI 0.86-0.94). No difference between primary and secondary trials reported (no data given)
Henyan et al (2007) ²¹⁴	Good quality SR (n=37 RCTs). Mixture of primary and secondary CVD prevention (focus on prevention of stroke). 100,560 participants, mostly white males with a history of hyperlipidaemia.	Statins vs placebo	↓CV events (RR 0.83, 95% CI 0.76-0.91), ↓ischaemic stroke (RR 0.79, 95% CI 0.63-0.99), no effect on haemorrhagic stroke (RR 1.11, 95% CI 0.77-1.60)
Jun et al (2010) ²²¹	Good quality SR (n=18 RCTs) Primary (n=4), secondary (n=11) studies and 3 were mixed. 45,058 participants mean age 46–68 years, mean follow-up 2.7–8.8 yrs.	Fibrates vs placebo	Primary prevention only: coronary events (RR 0.75, 95% CI 0.58–0.97). Combined data: major CVD events (RR 0.90, 95% CI 0.82–1.00; p=0.048), ↓CHD (RR 0.87, 95% CI 0.81–0.93), stroke (RR 1.03, 95% CI 0.91–1.16), CVD mortality (RR 0.97, 95% CI 0.88–1.07) or all-cause mortality (RR 1.00, 95% CI 0.93–1.08).
Mikhailidis et al (2007) ²²⁴	Good quality SR (n=5 RCTs). 5,039 adults with hypercholesterolaemia who have failed to reach goals on statin alone. Minimum treatment duration of 6 weeks. 3/5 trials included those with CHD.	Ezetimibe + statin vs placebo + statin +/- a fibrate	Ezetimibe co-administered with ongoing statin therapy provides significant additional lipid-lowering in patients not at LDL-C target on statin therapy alone, allowing more patients to reach their LDL-C target (RR 3.4, 95% CI 2.0-5.6; p<0.0001). Consistent results in those with and without CHD.
Navaneethan et al (2009) ²³⁵	Good quality SR (n=26 RCT and quasi RCTs). 25,017 CKD patients not requiring dialysis but +/- CVD.	Statins vs placebo	↓all-cause mortality (RR 0.81, 95% CI 0.74-0.89) and CV mortality (RR 0.80, 95% CI 0.70-0.90). Statins decreased 24-hour urinary protein excretion but didn't seem to change renal function (creatinine clearance). No difference in adverse effects.
O'Regan et al (2008) ²¹⁵	Good quality SR (n=42 RCTs; 14 RCTs with no prior stroke or <10% CHD); 24 RCTs with either all stroke or CHD. Others mixed populations. 121,000 participants.	Statins vs placebo or usual care	↓all-cause mortality (RR 0.88, 95% CI 0.83–0.93), ↓combined stroke (RR 0.84, 95% CI 0.79–0.91) –due to ↓in ischaemic stroke without difference in haemorrhagic stroke or fatal stroke. ↓CVD mortality (RR 0.81, 95% CI 0.74-0.90)
Ray et al (2010) ²⁰⁷	Good quality SR (n=11 RCTs) 65,229 participants without CVD. Mean follow-up ranged from 2.2–4.9 years	Statins vs placebo	Non-significant ↓all-cause mortality (RR 0.91; 95% CI 0.83–1.01).

Reference	Study details	Intervention	Results
Robinson et al (2009) ²¹⁸	Moderate quality SR (n=23 RCTs); 132,021 participants. Mixed primary and secondary prevention. 14 statin trials, 7 fibrate trials, 6 niacin trials, and 1 trial each of bile acid sequestrant, diet, and ileal bypass surgery.	All lipid-lowering therapies	The relationship between non-HDL-C lowering and CHD risk reduction is similar for statins and fibrates (only one fibrate trial). Most lipid-modifying drugs used as monotherapy appear to have an approx. 1:1 relationship between percent non-HDL-C lowering and CHD reduction.
Saha et al (2007) ²²⁰	Good quality SR (n=10 RCTs) 36,489 participants. 2 trials completely primary prevention, and 2 others partly. Mean duration of follow-up ≥ 1 year	Fibrates vs placebo	No significant benefit on mortality, fatal MI, or stroke. \downarrow non-fatal MI (OR 0.78, 95% CI 0.71–0.86) in patients with non-LDL dyslipidaemia to a comparable extent with that seen with statins in patients with high LDL-C levels.
Studer et al (2005) ²¹⁹	Good quality SR (n=97 RCTs) Follow-up of at least 6 months. For primary prevention only (<10% CHD at baseline): 9 statin RCTs; 3 fibrate RCTs; 1 resin RCT; no niacin RCT; 1 small RCT of n-3 fatty acid; 5 diet RCTs.	All lipid-lowering therapies	Statin: \downarrow all cause mortality (RR 0.86, 95% CI 0.76–0.99) Fibrates: \uparrow all cause mortality (RR 1.25, 95% CI 1.05–1.48) Resins: no difference in all cause mortality n-3 fatty acids: no difference in all cause mortality Diet: no difference in all cause mortality
Taylor et al (2011) ²⁰⁸	Good quality SR (n=14 RCTs). 34,272 participants. Trials of minimum duration of one year, >6 months follow-up, <10% pre-existing CVD.	Statins vs placebo	\downarrow all-cause mortality (RR 0.83, 95% CI 0.73–0.95), \downarrow CVD events (RR 0.70, 95% CI 0.61–0.79), \downarrow combined fatal and non-fatal stroke (RR 0.78, 95% CI 0.65–0.94), \downarrow combined fatal and non-fatal CHD events (RR 0.72, 95% CI 0.65–0.79). No difference in harms.
Thavendiranathan et al (2006) ²¹⁰	Good quality SR (n=7 RCTs). 42,848 participants; 90% had no history of CVD (inclusion of >80% without CVD); Mean follow-up 4.3 years.	Statins vs placebo, active control, or usual care	\downarrow major coronary (RR 0.71; 95% CI 0.60–0.83) and cerebrovascular events (RR 0.86; 95% CI 0.75–0.97), but not CHD disease mortality (RR 0.77; 95% CI 0.56–1.08) or overall mortality (RR 0.92; 95% CI 0.84–1.01).
Ward et al (2007) ²¹¹	Good quality SR (n=31 RCTs) Adults with, or at risk of, CHD (2 RCTs specifically without CVD, multiple trials with or without CVD)	Statins vs placebo	Overall: \downarrow all-cause mortality (RR 0.84; 95% CI 0.78–0.90), \downarrow CHD mortality (RR 0.77; 95% CI 0.72–0.83) and \downarrow fatal MI (RR 0.55; 95% CI 0.45–0.67). Two exclusively primary prevention studies: \downarrow non-fatal MI (RR 0.60, 95% CI 0.37–0.97) and \downarrow CHD death plus non-fatal MI (RR 0.66, 95% CI 0.46–0.96), but not all-cause mortality (RR 0.73, 95% CI 0.53–1.01) or CVD mortality (RR 0.67, 95% CI 0.40–1.10).
Zhou et al (2006) ²³⁶	Good quality SR (n=8 RCTs; 4 pravastatin trials (25,572 participants), 2 simvastatin trials (24,980 participants), and 2 atorvastatin trials (13,143 participants). % of those with existing CVD not specified. Minimum follow-up of 1 year.	Statins vs placebo	Pravastatin, simvastatin, and atorvastatin, when used at their standard dosages, show no statistically significant difference in their effect on long-term cardiovascular prevention.

CHD: coronary heart disease; CI: confidence interval; LDL-C: low density lipoprotein cholesterol; MI: myocardial infarction; NA: not available; OR: odds ratio; RCTs: randomised control trials; RR: relative risk; RRR: relative risk reduction; SR: systematic review; TC: total cholesterol.

2.2.3 Antiplatelet therapy

Aspirin is of limited benefit when risks/benefits are considered

For people with established CVD the benefit to risk profile of long-term aspirin for reducing the risk of MI, stroke and vascular death is well established.^{237–240} However, the role of aspirin in primary prevention is less clear. This section summarises the evidence for antiplatelet agents from systematic reviews and individual trials considered for the primary prevention of cardiovascular events and does not consider other reported effects for aspirin such as cancer.²⁴¹

Evidence from three meta-analyses^{239, 242, 243} indicates that aspirin does not affect all-cause or CVD-related mortality, but does have a small benefit for the reduction of non-fatal vascular events (e.g., MI or stroke) – a benefit driven largely by a reduction in non-fatal MI among men. In the most recent meta-analysis by the Antiplatelet Trialists' Collaboration, based on six primary prevention trials, aspirin (at doses of 75–100 g/day) reduced the relative risk of serious vascular events by approximately 12% (ARR 0.51% aspirin vs. 0.57% control per year, $p=0.0001$); a result driven largely by a 23% relative reduction in non-fatal MI (0.18% vs. 0.23% per year, $p<0.0001$).²³⁹ All-cause mortality and stroke incidence were not shown to be affected, and the reduction in non-fatal MI was statistically significant in men, but not in women. Conversely, for ischaemic stroke, the proportional risk reduction was greater in women than in men, although that result was not statistically significant. Aspirin increased the relative risk for gastrointestinal and extracranial bleeds by 54% (AR 0.10% vs 0.07% per year, $p<0.0001$).

These results concur with another good-quality meta-analysis where a review of the same six primary prevention trials involving 51,342 women and 44,114 men, showed that low-dose aspirin (50–500 mg daily) was associated with a 12% and 14% reduction in the relative risk of cardiovascular events (non-fatal MI, non-fatal stroke and cardiovascular mortality) in men and women, respectively, but with an approximate 70% increase in the risk of major bleeding events.²⁴² For women, there was a significant reduction in the likelihood of stroke (mainly ischaemic stroke) whereas in men, no significant effect was observed on all strokes; however, a significant 32% reduction in the relative risk of MI was observed.

Based on the absolute benefits and risks observed in this analysis²⁴² (absolute benefit: 0.30% and 0.37%; AR 0.25% and 0.33%, for women and men, respectively), aspirin therapy for an average of 6.4 years prevents approximately three cardiovascular events per 1,000 women and results in 2.5 major bleeding events. In 1,000 men treated for the

same period, aspirin prevents four cardiovascular events and results in three major bleeding events.²⁴² There was no evidence that higher doses of aspirin are more effective in reducing the risk of cardiovascular events. It is questionable whether the additional resources required to treat such a large number of people to prevent a small number of events is justified. In addition, any effect of aspirin on cardiovascular events needs to be balanced against the potential for harm.

In one subsequent study, the benefits of once-daily aspirin (100 mg) or placebo in 3,350 patients without clinical CVD, identified with a low ankle brachial index (ABI, ≤ 0.95) were assessed.²⁴⁴ After a mean follow-up of 8.2 ± 1.6 years, no statistically significant difference was found between groups for the primary endpoint of a composite of fatal or non-fatal coronary events or stroke or revascularisation (13.7 events per 1,000 person-years in the aspirin group vs 13.3 in the placebo group; hazard ratio, 1.03; 95% CI 0.84–1.27). Furthermore, the combined secondary endpoint (composite of the primary endpoint or angina, intermittent claudication or TIA) also failed to show statistical significance (22.8 events per 1,000 person-years in the aspirin group vs 22.9 in the placebo group; hazard ratio, 1.00; 95% CI 0.85–1.17). Major haemorrhage requiring admission to hospital occurred in 34 participants in the aspirin group and 20 in the placebo group (hazard ratio, 1.71; 95% CI 0.99–2.97). Although the study was underpowered to identify a potentially small beneficial effect of aspirin, given the large NNT to benefit as identified in the analysis above, questions remain of the usefulness of routine aspirin for preventing CVD.

Studies modelling the potential benefits and harms of aspirin on 5- and 10-year risk of CVD are conflicting. In the Antiplatelet Trialists' Collaboration review, the proportional reduction did not differ significantly between individuals with predicted 5-year risk of CHD less than 2.5%, 2.5–5%, 5–10%, or 10% or more; although statistical analysis in the highest risk group was limited by small participant numbers. In that meta-analysis, the majority of people were not taking statin therapy. When the risk was assumed to be halved by other drugs first (e.g. statin and BP lowering), then the further absolute benefit of adding aspirin was found to be only half as large as was suggested by the trials, but the main bleeding hazards would remain. In that case, the benefits and hazards of adding long-term aspirin in people without pre-existing disease were found to be approximately equivalent.²³⁹

Other modelling based on older meta-analysis data, found that a risk of CHD of $\geq 15\%$ over 10 years was the point where benefit was greater than harm for people without existing CVD.²⁴⁵ Recently, another study modelling by risk category and age group found benefits were greater than harms in those with cardiovascular risk $>15\%$ up to the age

of 80 years; however, for men 70–79 years, consideration of lipid and blood pressure-lowering therapies was suggested first before reassessment of whether aspirin added additional net benefit.²⁴⁶ It is important to consider that there is significant overlap between the major risk factors for CVD events which might be prevented with aspirin and risk factors for bleeding with treatment. Given the various assumptions in all models and small absolute benefits but increased risk of harm with aspirin, a conservative approach to the use of aspirin is suggested for prevention of CVD.

Table 7: Effect of aspirin on CVD outcomes: summary of key evidence

Reference	Study details	Intervention	Results
Antithrombotic Trialists' (ATT) Collaboration; Baigent et al (2009) ²³⁹	Good quality SR (n=22 RCTs). Included six primary prevention trials, 95,456 participants.	Aspirin vs placebo	12% ↓CV events (0.51% aspirin vs. 0.57% control per year, p=0.0001), ↓non-fatal MI (0.18% vs. 0.23% per year, p<0.0001), no effect on vascular mortality (0.19% vs 0.19% per year, p=0.7). Risk of CV events in those with diabetes (RR 0.88, 95% CI 0.67–1.15). ↑major GI and extracranial bleeds (0.10% vs. 0.07% per year, p<0.0001). No difference in those at low, moderate and high risk.
Berger et al (2006) ²⁴²	Good quality SR (n=6 RCTs –same as above). 51,342 women and 44,114 men.	Aspirin vs placebo	CV events (OR 0.88, 95% CI, 0.79 to 0.99). No effect on MI or CV mortality. In men, 32% ↓MI (OR 0.68, 95% CI 0.54–0.86). In women, 24% ↓ischaemic stroke (OR 0.76,; 95% CI 0.63–0.93). Aspirin ↑risk of bleeding in both men and women.
Calvin et al (2009) ²⁴³	Good quality SR (n=8 RCTs). 89,392 participants without CVD; 11,634 with diabetes.	Aspirin vs placebo	Overall mortality (OR 0.93, 95% CI 0.85–1.03), MI (OR 0.79, 95% CI 0.66–0.95), and ischaemic stroke (OR 0.73, 95% CI 0.43–1.22). For those with diabetes: MI (RR 0.86, 95% CI 0.67–1.11), ischaemic stroke (RR 0.62, 95% CI 0.31–1.24).
De Berardis et al (2009) ²⁴⁷	Good quality SR (n=6 RCTs). 10,117 diabetic participants without CVD.	Aspirin vs placebo	Major CV events (RR 0.90, 95% CI 0.81-1.00), CV mortality (RR 0.94, 95% CI 0.72-1.23), all-cause mortality (RR 0.93, 95% CI 0.82-1.05), MI (RR 0.86, 95% CI 0.61–1.21), stroke (RR 0.83, 95% CI 0.60–1.14). ↓risk of MI in men (RR 0.57, 95% CI 0.34- 0.94). No effect for ↓stroke for men or women.
Pignone et al (2010) ²⁴⁹	Moderate quality SR (n=9 RCTs). 11,787 diabetic participants without CVD.	Aspirin vs placebo	CHD events (RR 0.91, 95% CI 0.79 –1.05), Strokes (RR 0.85, 95% CI 0.66 –1.11).
Zhang et al (2010) ²⁴⁸	Moderate quality SR (n=7 RCTs). 11,618 diabetic participants without CVD.	Aspirin vs placebo	Major CV events (RR 0.92, 95% CI 0.83–1.02), all-cause mortality (RR 0.95, 95% CI 0.85–1.06), CV mortality (RR 0.95, 95% CI 0.71–1.27), stroke (RR 0.83, 95% CI 0.63–1.10), MI (RR 0.85, 95% CI 0.65–1.11). Trend to ↑major bleeding risk (RR 2.46, 95% CI 0.70–8.61).

CI: confidence interval; CV: cardiovascular; CVD: cardiovascular disease; GI: gastrointestinal; MI: myocardial infarction; OR: odds ratio; RCTs: randomised controlled trials; RR: relative risk; SR: systematic review.

People with diabetes

Four systematic reviews^{239, 243, 247, 248} and one clinical guideline²⁴⁹ were identified with data on aspirin for primary prevention of CVD among diabetic individuals. These reviews consistently report that aspirin therapy is associated with a statistically non-significant 8–12% reduction in risk of major cardiovascular events in people with diabetes. When individual endpoints are considered in people with diabetes, sex-specific trends have also been reported: that is, reduced risk of MI in men and reduced risk of stroke in women.^{247, 248} As the effects in people with diabetes are smaller than those for the general population, a conservative approach to use of aspirin therapy is suggested for prevention of CVD.

People with atrial fibrillation

The increased risk of stroke in people with non-valvular AF is well recognised and scoring systems (e.g. CHADS2*) are recommended to determine risk levels and need for pharmacotherapy. Three robust systematic reviews^{250–252} and three notable randomised controlled trials^{253–255} have investigated the benefits of antiplatelet or anticoagulant therapy in primary prevention populations. Two separate reviews report consistent reductions in the combination of stroke, MI or vascular death (OR 0.71, 95% CI 0.51–0.97) with aspirin (75–125 mg daily or 125 mg every second day),²⁵⁰ and clear benefits of warfarin for preventing stroke (OR 0.39, 95% CI 0.26–0.59), all cause mortality (OR 0.69, 95% CI 0.50–0.94) and the combined endpoint of all stroke, MI or vascular death (OR 0.56, 95% CI 0.42–0.76).²⁵¹ A third systematic review assessed the relative effect of long-term oral anticoagulant treatment compared with antiplatelet therapy on major vascular events in eight trials involving 9,598 individuals.²⁵² Overall, warfarin and related oral anticoagulants reduced stroke, disabling stroke and other major vascular events by about one-third and are clearly recommended compared with antiplatelet therapy.

However, anticoagulation therapy may be unsuitable for a small percentage of individuals with AF. In a trial, 7,554 patients with AF in whom warfarin therapy was unsuitable were assigned clopidogrel (75 mg/day) plus aspirin (75–100 mg/day) or aspirin alone.²⁵⁴ The primary outcome was the composite of stroke, MI, non-central nervous

system systemic embolism or death from vascular causes. At a median of 3.6 years of follow-up, the incidence of major vascular events was 6.8% and 7.6% per year for clopidogrel plus aspirin and aspirin alone, respectively (RR 0.89, 95% CI 0.81 - 0.98; $p=0.01$). The difference was primarily due to a reduction in the rate of stroke with clopidogrel. However, the benefits were offset by an increased incidence of major bleeding (2.0% per year for people receiving dual antiplatelet therapy and 1.3% per year for individuals receiving aspirin alone, RR 1.57, 95% CI 1.29–1.92; $p<0.001$). It is unclear from this study what percentage were individuals without established CVD. Another recent trial randomised 5,599 patients with AF, in whom warfarin therapy was deemed unsuitable, to receive apixaban, a novel factor Xa inhibitor (at a dose of 5 mg twice daily) or aspirin (81–324 mg/day). The trial was terminated early for safety concerns with apixaban found to significantly reduce the risk of stroke or systemic embolism (HR 0.45, 95% CI 0.32–0.62; $P<0.001$) and non-significantly reduce mortality per year (HR 0.79, 95% CI 0.62–1.02; $P=0.07$).²⁵⁶ No difference in adverse events was found.

Readers are referred to an Australian evidence summary²⁵ and international guidelines for a discussion of the general evidence related to AF management.^{26–29}

Dual antiplatelet therapy is not appropriate for primary prevention

Only one high-quality randomised controlled trial has examined the efficacy and safety of dual antiplatelet therapy with clopidogrel and aspirin vs aspirin alone in a primary prevention population. In the *Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilization, Management, and Avoidance (CHARISMA)* trial, approximately 2,289 of the 15,603 participants were free of existing CVD at baseline.²⁵⁴ Individuals were randomly assigned to receive clopidogrel (75 mg/day) plus low-dose aspirin (75–162 mg/day) or placebo plus low-dose aspirin and followed for a median of 28 months. The primary efficacy endpoint was a composite of MI, stroke or death from cardiovascular causes. In the primary prevention cohort, the rate of cardiovascular death for single vs dual-antiplatelet therapy was 1.8% and 3.0%, respectively ($p=0.07$).²⁵⁴ Furthermore, multivariate analysis of the primary prevention group showed a trend towards excess cardiovascular death (HR 1.72, 95% CI 0.99–2.97; $p=0.054$) with dual-antiplatelet therapy. Results from the CHARISMA trial suggest that a dual antiplatelet strategy with clopidogrel and aspirin should not be used for primary prevention.

*CHADS2 score is a clinical prediction rule for estimating the risk of stroke in patients with non-rheumatic AF. The score is calculated by the presence of Congestive heart failure (1 point); Hypertension: BP consistently above 140/90 mmHg (or treated hypertension on medication) (1 point); Age ≥ 75 years (1 point); Diabetes mellitus (1 point); or Prior Stroke or TIA (2 points).

Evidence-based recommendation	Grade
Pharmacotherapy	
EBR 9: Aspirin or other antiplatelet therapy is not routinely recommended for primary prevention of CVD.	B ^{234, 237, 238, 242, 243}
For adults at high risk of CVD	
EBR 10: Adults at high absolute risk of CVD should be simultaneously treated with lipid and blood pressure-lowering pharmacotherapy in addition to lifestyle advice unless contraindicated or clinically inappropriate.	B ^{192, 195, 204, 206, 207}

Consensus-based recommendations
For adults at moderate risk of CVD
CBR 3: Adults at moderate absolute risk of CVD should have their risk factors initially managed by lifestyle interventions. Pharmacotherapy for blood pressure and/or lipid lowering is not routinely recommended but may be considered if 3–6 months of lifestyle intervention does not reduce the individual's risk factors.
CBR 4: Adults at moderate absolute risk of CVD may be treated with pharmacotherapy for blood pressure and/or lipid lowering in addition to lifestyle intervention if one or more of the following applies: <ul style="list-style-type: none"> • Persistent blood pressure $\geq 160/100$ mmHg • Family history of premature CVD • Aboriginal and Torres Strait Islander peoples • Other populations where FRE is known to underestimate risk (South Asians, Maori and Pacific Islanders, people from the Middle East).
For adults at low risk of CVD
CBR 5: Pharmacotherapy for blood pressure and lipid lowering is not routinely recommended for adults at low absolute risk of CVD.
CBR 6: Adults at low absolute risk of CVD who have persistent blood pressure $\geq 160/100$ mmHg may be treated with blood pressure-lowering pharmacotherapy in addition to lifestyle intervention.

2.2.4 Pharmacological approaches to simultaneously lower blood pressure and lipids

There is robust evidence to support the efficacy of using medication to reduce both BP and cholesterol to reduce CVD risk. Several studies have evaluated the co-administration of amlodipine and atorvastatin, and found the same or improved effectiveness from simultaneously administering both drugs, compared with a single drug regimen.²⁵⁷⁻²⁵⁹ In the AVALON trial,²⁵⁷ co-administration of amlodipine and atorvastatin was compared with single drug therapy, and placebo in 847 patients. At week 8, 45% of the people receiving amlodipine 5 mg once

daily and atorvastatin 10 mg once daily reached both their BP and LDL-C targets, compared with 8.3% with amlodipine ($p < 0.001$), 28.6% with atorvastatin ($p < 0.001$) and 3.5% with placebo. At 28 weeks, 67.1% of people co-administered amlodipine and atorvastatin (mean doses, 7.6 mg and 28.4 mg, respectively) achieved both targets. Furthermore, the Framingham study estimated 10-year risk of CHD in that group declined from baseline levels of 15.1% to 6.9% at week 28.

Similar results were observed in the ASCOT-LLA²⁵⁹ and the RESPOND study.²⁵⁸ In the ASCOTT-LLA study, people with baseline hypertension and TC ≥ 6.5 mmol/L, received atorvastatin (10 mg once daily) in addition to their

antihypertensive routine for a mean duration of 3.3 years. This combined treatment led to a 36% reduction in the relative risk of non-fatal MI and fatal CHD, compared with the group receiving placebo plus antihypertensive therapy. In the RESPOND study, the use of amlodipine and atorvastatin together did not differ from the efficacy achieved with each medication alone. However, the estimated 10-year Framingham risk with combination therapy declined from baseline values of 15.8–18.0% to 7.3–10.7%.

Comparative and non-comparative studies investigating the efficacy of single pill combination therapy with amlodipine and atorvastatin in people with elevated BP and lipids at baseline have, in general, demonstrated similar results. The proportion of people achieving both improved BP and LDL-C levels in those trials ranged from 48.3% to 57.7%²⁶⁰⁻²⁶³ and 10-year Framingham risk scores were reduced by up to 52%.²⁶³

2.3 Initiation and maintenance of pharmacotherapy

2.3.1 Blood pressure-lowering therapy

Blood pressure-lowering therapy should be determined by individual needs and aimed towards optimal blood pressure levels

The relationship between BP and CVD risk is continuous, and guidelines have recommended reduced BP targets over recent years as evidence of benefit and safety have accumulated.^{14, 47, 264-268} While there has been general consensus that the most important clinical implication is to achieve the correct total dosage to achieve appropriate BP control,^{192, 269} new data from several systematic reviews has reopened the issue as to whether lowering BP as far as possible – a ‘lower the pressure the better’ approach – is of any greater value than lowering it to below standard BP targets (i.e. 140/90 mmHg).²⁶⁹⁻²⁷¹

The Blood Pressure-lowering Treatment Trialists’ Collaboration found that BP lowering reduced major cardiovascular events.²⁷² The magnitude of this effect could be attributed to the degree of BP lowering. More recently, a Cochrane review was conducted to determine if lower BP targets ($\leq 135/85$ mmHg) are associated with a reduction in mortality and morbidity as compared with standard BP targets ($\leq 140-160/90-100$ mmHg).²⁷⁰ No trials comparing

different SBP targets were found; however, seven trials comparing different DBPs were identified involving 22,089 adults. Despite a -4/-3 mmHg greater achieved reduction in SBP/DBP ($p < 0.001$), attempting to achieve ‘lower targets’ instead of ‘standard targets’ had no significant effect on total mortality (RR 0.92, 95% CI 0.86–1.15), MI (RR 0.90, 95% CI 0.74–1.09), stroke (RR 0.99, 95% CI 0.79–1.25), congestive heart failure (RR 0.88, 95% CI 0.59–1.32), major cardiovascular events (RR 0.94, 95% CI 0.83–1.07) or end-stage renal disease (RR 1.01, 95% CI 0.81–1.27).

These results coincide with other systematic reviews that have confirmed a proportional relationship between BP levels and cardiovascular events.^{269, 271} A meta-analysis of 30 trials and more than 149,000 people demonstrated that the relationship between the odds ratio for fatal and non-fatal cardiovascular outcomes and the corresponding within-trial differences in SBP is curvilinear,²⁶⁹ and when these outcomes were combined, there was no further benefit if the within-trial differences in SBP exceeded ~15 mmHg. In another systematic review, the incidence of major cardiovascular events in BP-lowering trials was calculated after classifying each trial into four categories according to people’s baseline cardiovascular risk: low risk, elderly, diabetic and high risk. Of note, low rates of major cardiovascular events (3–6% in five years) were only achieved in trials enrolling low risk people.²⁷¹ In contrast, the incidence of major cardiovascular events in trials enrolling elderly hypertensive people, hypertensive people with diabetes or people with previous CVD or events was rarely reduced to below 12–14% in five years. People enrolled in these trials remained at high risk despite aggressive BP reduction and extensive use of concomitant medications, suggesting that pre-existing high risk sets a ceiling effect to the benefits of treatment.

Current evidence indicates that more intensive BP lowering produces greater reductions in cardiovascular events and all-cause mortality. Although treatment targets are generally recognised and can be used to monitor treatment effects, the extra effort required to achieve lower levels of BP should be assessed against the benefits and risks to the individual patient.

People with diabetes

BP lowering reduces cardiovascular events and all-cause mortality in people with type 2 diabetes to a similar or even greater extent than for the general population.¹⁹⁵ However, the target levels for BP therapy have been based on little direct evidence.

Two major recent randomised controlled trials are of particular interest in informing target BP levels for those with diabetes. The ADVANCE trial randomised 11,140 participants with type 2 diabetes to either perindopril-indapamide versus placebo (double-blind comparison) and intensive glucose control with a gliclazide MR-based regimen (target A1C $\leq 6.5\%$) versus standard glucose control (open comparison).²⁷³ During an average follow-up period of 4.3 years, the risks of major macrovascular and microvascular events were considered jointly and separately, in addition to renal events and death. Those treated to lower SBP (achieved mean updated SBP during the study 134.7 mmHg) were found to have reduced all-cause and CVD mortality (OR 0.86, 95% CI 0.75–0.98; and OR 0.81, 95% CI 0.68–0.98, respectively) but surprisingly had no effect on stroke (OR 0.99, 95% CI 0.81–1.19). Compared with neither intervention, combination treatment with BP lowering and intensive glucose control reduced the risk of all-cause mortality by 18% (95% CI 1–32%, $p=0.04$), reduced new or worsening nephropathy by 33% (95% CI 12–50%, $p=0.005$), reduced new onset of macroalbuminuria by 54% (95% CI 35–68%, $p<0.0001$) and reduced new onset of microalbuminuria by 26% (95% CI 17–34%).

The ACCORD investigators tested the effect of a target SBP <120 mmHg on a composite outcome of non-fatal MI, non-fatal stroke or death from cardiovascular causes.²⁷⁴ In that trial, 4,733 participants were randomly assigned to lower their BP by receiving either intensive therapy (SBP target <120 mmHg) or standard therapy (SBP target <140 mmHg). The mean follow-up period was 4.7 years and 34% of participants had existing CVD. After one year, the mean SBP was 119.3 mmHg and 133.5 mmHg in the intensive therapy and standard therapy groups, respectively and this difference was maintained throughout the study. The annual rate of the primary outcome was similar between groups: 1.87% in the intensive-therapy group and 2.09% in the standard-therapy group (HR 0.88, 95% CI 0.73–1.06; $p=0.20$). However, the incidence of serious adverse events, including deterioration in renal function, was significantly higher in participants randomised to the intensive-therapy group (3.3% vs 1.3%, $p<0.001$). Of interest, however, was the annual incidence of stroke, a pre-specified secondary outcome: 0.32% and 0.53% in the intensive therapy and

standard therapy groups, respectively (HR 0.59, 95% CI 0.39–0.89; $p=0.01$).

During finalisation of these guidelines, two meta-analyses were published that updated previous meta-analyses with important trials such as those discussed above.^{275, 276} One meta-analysis included 13 trials (mixed primary and secondary prevention) and found that intensive BP control (achieving SBP ≤ 135 mmHg) was associated with a reduction in all-cause mortality (OR 0.90, 95% CI 0.83–0.98 and a reduction in stroke (OR 0.83, 95% CI 0.83–0.98), but with an increase in serious adverse effects (OR 1.2, 95% CI 1.08–1.32). There were similar outcomes for other macrovascular and microvascular (cardiac, renal and retinal) events compared with standard BP control (SBP ≤ 140 mmHg).²⁷⁵ More intensive BP control (SBP ≤ 130 mmHg) was associated with further reduction in stroke only and there was a 40% increase in serious adverse events compared to standard BP control (95% CI 1.19–1.64; $P=0.01$), but significant heterogeneity was noted.

The other meta-analysis included 31 trials (mixed primary and secondary prevention) and reported intensive therapy (mean SBP 129 mmHg vs SBP 139 mmHg) significantly reduced the risk of stroke (RR 0.61, 95% CI 0.48–0.79; based on five trials) but not MI (OR 0.87, 95% CI 0.74–1.02; based on six trials).²⁷⁶ The effects were found to occur with reductions in SBP or DBP with meta-regression analysis noting the risk of stroke decreased by 13% (95% CI 5–20%) for each 5 mmHg reduction in SBP and by 11.5% (95% CI 5–17%) for each 2 mmHg reduction in DBP.

In general, people with diabetes appear to benefit from modestly more aggressive thresholds for treatment than the general population with targets towards SBP 130 mmHg and DBP 80 mmHg. However, based on the ACCORD and ADVANCE study results and the newer meta-analyses, this target is currently being reconsidered by a number of organisations world-wide and the SBP may be adjusted upwards. Until such deliberations are complete, the general international BP target for people with diabetes remains $\leq 130/80$ mmHg.

People with CKD

Recent evidence considered during the finalisation of these guidelines suggests that treating people with CKD to lower BP targets than the general population does not improve clinical outcomes.²⁷⁷ New targets are currently being considered internationally and may be adjusted upwards. The EWG, after detailed consultation locally and internationally, has adjusted the recommended targets for Australia based on the recent evidence. Target BP for

people with CKD is now $\leq 140/90$ mmHg and for people with micro or macroalbuminuria (UACR >2.5 mg/mmol in men and >3.5 mg/mmol in women) the target is now $130/80$ mmHg. Available evidence suggests that treatment using agents that lower BP reduces CVD morbidity and mortality for people on maintenance dialysis;¹⁹⁷ however, specialist advice and management of BP is usually required for people on dialysis.

Initiation of blood pressure-lowering treatment

There is now a large body of evidence on BP-lowering therapies, both those comparing active treatment versus placebo and those comparing different treatment regimens. Results from nine systematic reviews of BP-lowering drugs in the prevention of cardiovascular events^{192, 198, 199, 269, 272,}

²⁷⁸⁻²⁸¹ confirm that:

- a) The main benefits of BP-lowering therapies are due to the reduction of BP and are largely independent of the drugs employed;
- b) Thiazide diuretics, calcium channel blockers (CCB), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs) have similar BP-lowering outcomes and significantly reduce cardiovascular morbidity and mortality;
- c) There is no interaction between age and effect of treatment on cardiovascular events for any BP-lowering treatment compared with control.^{194, 198}

Apart from beta-blockers, in primary prevention, no one class of agent appears to offer a major advantage over another. However, there are exceptions in certain situations. In terms of medication adherence and/or persistence, two systematic reviews assessed the results of trials involving ARBs, ACE inhibitors, CCBs, beta-blockers and diuretics.^{278,}

²⁸² In one meta-analysis of eight trials, ARBs provided a non-significant BP reduction compared with ACE inhibitors (net difference $1.8/1.0$ mmHg).²⁷⁸ However, compliance at 12 months with ARBs was consistently higher (42–64%) than that observed for other therapeutic classes. This is similar to the other systematic review of 17 trials, which found adherence lowest for diuretics and beta-blockers, and highest in ARBs and then ACE inhibitors.²⁸²

With regard to individual endpoints (e.g. stroke, MI, heart failure) the literature does suggest differences between various BP-lowering therapies. Beta-blockers have been found to be less effective in reducing the risk of stroke,^{192,}
²⁷² while CCBs may have a slightly superior effect on stroke prevention.^{192, 269, 272, 283} In contrast, the benefit of CCBs does not appear to extend equally to the prevention of

heart failure.^{283, 284} In one large meta-analysis, therapies other than CCBs (with the exception of non-cardioselective beta-blockers) reduced the incidence of heart failure by 24% (19–28%). CCBs reduced the incidence of heart failure by 19% (6–31%).¹⁹²

The first class of drugs to use for management of elevated BP has always been a matter of debate. Low-dose thiazide diuretics have been recommended based on results obtained in a systematic review of 24 trials and more than 58,000 participants.¹⁹⁹ In that review, the reduction in morbidity and mortality was similar between low-dose thiazides, ACE inhibitors and CCBs; however, the authors note that the data for thiazide diuretics is more robust than that available for the latter therapeutic classes. In contrast, first-line therapy with high-dose thiazide diuretics or beta-blockers is inferior to first-line therapy with low-dose thiazides¹⁹⁹ and, in some reports, the use of high-dose (four times standard) thiazides has increased the risk of sudden cardiac death.¹⁹²

The extent of BP reductions is similar at standard doses for the five therapeutic categories of blood pressure-lowering agents: average reduction was 9.1 mmHg systolic and 5 mmHg diastolic.^{192, 195} However, in practice, more than one drug is often required to lower BP to optimal levels and, in these situations, the effect of combinations of two or more drugs on BP is additive. Furthermore, the adverse effect profiles of drugs can be minimised by using half-standard or standard doses, rather than titrating any given drug to higher doses. The exceptions are ACE inhibitors and ARBs, where the adverse effects are either present or absent.¹⁴ In a large meta-analysis, one drug at standard dose reduced the incidence of CHD by about 24% and stroke by 35% in 60–69 year olds with a DBP of 90 mmHg.¹⁹² Three drugs at half standard doses approximately doubled this effect, reducing CHD by 45% and stroke by 60%. At higher BPs (e.g. $180/105$ mmHg) and lower BPs (e.g. $120/75$ mmHg), the effect of one drug at standard dose is about 7% and 9% greater and smaller, respectively. Three drugs at half standard dose is about 12% and 14% greater and smaller.

In summary, thiazide diuretics, CCBs, ACE inhibitors and ARBs are all suitable for initiation of BP-lowering therapy. In addition, they can all be used for maintenance of BP-lowering therapy, either as monotherapy or in combination. Beta-blockers appear to offer less clinical efficacy in terms of CVD prevention.

Table 8: Blood pressure-lowering targets: summary of key evidence

Reference	Study details	Intervention	Results
Arguedas et al (2009) ²⁷⁰	Good quality SR (n=7 RCTs). 22,089 subjects comparing different DBP targets.	All BP-lowering medications with lower or vs standard BP targets.	No difference between standard targets ($\leq 140/90$) and lower targets ($\leq 135/85$). Mortality (RR 0.92, 95% CI 0.86-1.15), MI (RR 0.90, 95% CI 0.74-1.09), stroke (RR 0.99, 95% CI 0.79-1.25), CHF (RR 0.88, 95% CI 0.59-1.32), major CV events (RR 0.94, 95% CI 0.83-1.07), or end-stage renal disease (RR 1.01, 95% CI 0.81-1.27). No difference for diabetes and CKD.
Bangalore et al (2011) ²⁷⁵	Good quality SR (n=13 RCTs) 37,736 participants with type 2 diabetes or pre diabetes.	All BP-lowering medications vs placebo or less intensive control.	Intensive BP control had 10% ↓all-cause mortality, 17% ↓stroke, and a 20% ↑in serious adverse effects with similar outcomes for other macrovascular and microvascular events. For targets <130 mm Hg SBP, 40% ↑in serious adverse events (heterogeneity noted) without other benefits. Meta-regression analysis found only ↓stroke with ↓BP.
BP Lowering Treatment Trialists' Collaboration; Turnbull et al (2003) ²⁷²	Good quality SR (n=29 RCTs). 162,341 participants. Most trials selected people on basis of existing CVD or risk factors.	All BP-lowering medications vs placebo or less intensive control.	Regimens targeting lower BP goals ↓stroke and CV events without any convincing evidence of j-curve relationship.
Law et al (2009) ¹⁹²	Good quality SR (n=147 RCTs; 464,000 participants). 26 RCTs specifically with no history of CVD.	All BP lowering medications vs placebo or other class of drug.	For a reduction of 10mmHg SBP or 5mmHg DBP: ↓CHD events (RR 0.79, 95% CI 0.72-0.86), ↓stroke (RR 0.54, 95% CI 0.45-0.65). No significant trend in proportional disease reduction with lower pre-treatment blood pressure, indicating a constant proportional effect (although too few data <110/70 mmHg).
Reboldi et al (2011) ²⁷⁶	Good quality SR (n=31 RCTs). 73,913 participants with diabetes.	All BP-lowering medications with lower or vs standard BP targets.	Overall, treatment ↓stroke by 9% (P=0.0059), and MI by 11% (P=0.0015). Allocation to more-tight, compared with less tight, BP control ↓stroke by 31% (RR 0.61, 95% CI 0.48-0.79) but not risk of MI (OR 0.87, 95% CI 0.74-1.02). Meta-regression found clear link between ↓BP and stroke but not MI.
Upadhyay et al (2011) ²⁷⁷	Good quality SR (n=3 RCTs). 2,272 adults with non-dialysis-dependent CKD but excluded type 1 diabetes and had few with type 2 diabetes.	All BP-lowering medications with lower or vs standard BP targets.	Included trials failed to demonstrate improved outcomes for lower BP targets. Lower-quality evidence suggests that a low target may be beneficial in subgroups with proteinuria greater than 300 to 1000 mg/d. Participants with lower targets required more BP medications and had a slightly higher rate of adverse events.

BP: blood pressure; CI: confidence interval; CHF: chronic heart failure; CKDL: chronic kidney disease; CV: cardiovascular; CVD: cardiovascular disease; DBP: diastolic blood pressure; MI: myocardial infarction; RCTs: randomised controlled trials; RR: relative risk; SBP: systolic blood pressure; SR: systematic review.

Table 9: Blood pressure-lowering therapy: summary of key evidence

Reference	Study details	Intervention	Results
BP Lowering Treatment Trialists' Collaboration; Turnbull et al (2008) ¹⁹⁸	Good quality SR (n=31 RCTs); 190,606 participants. Compared age groups <65 and above 65. Mixed primary and secondary prevention.	All BP-lowering medications vs placebo or less intensive control.	No difference in reductions in major CV events between age groups for any comparison. No difference between the effects of any class of drug on risk of CV events.
Bramlage et al (2009) ²⁷⁸	Fair quality SR (n=8 cohort studies) Mixed primary and secondary prevention	All BP lowering medications.	Persistence was higher with ARBs than any other therapeutic class.
Kronish et al (2011) ²⁸²	Good quality SR (n=17 cohort studies). Mixed primary and secondary prevention.	All BP lowering medications.	ARBs had the highest adherence followed by ACEi, CCBs, diuretics and BBs. After consideration of publication bias there was no difference between ARBs and ACEi (HR 1.10, 95% CI 0.94-1.30) or diuretics and BBs (HR 1.13, 95% CI 0.89-1.44). The pooled mean adherence ranged from 28% for BBs to 65% for ARBs.
Law et al (2009) ¹⁹²	Good quality SR (n=147 RCTs; 464,000 participants). 26 RCTs specifically with no history of CVD.	All BP lowering medications vs placebo or no treatment.	Effect is similar for all classes of blood pressure-lowering drugs for CHD although CCBs were slightly more effective for stroke prevention and BBs slightly less effective. CCBs ↓HF by 19% whereas for other classes ↓24%. One drug at standard dose reduces CHD and stroke by approximately 24% and 35%, respectively in 60–69 year olds with SBP of 90 mmHg. Three drugs modelled at half standard doses approximately double this effect.
Musini et al (2009) ²⁸⁰	Good quality SR (n=9 RCTs). 460 patients with primary hypertension defined as BP >140/90 mmHg at baseline.	Loop diuretics vs placebo.	The BP-lowering effects of loop diuretics is modest (approx. 8/4 mmHg) and whether the effects are greater or lower than other classes of BP-lowering agents is difficult to say.
Webb et al (2010) ²⁸¹	Good quality SR (n=389 RCTs). Mixed primary and secondary prevention.	All BP lowering medications vs placebo or no treatment.	Compared with other drug classes, CCBs and non-loop diuretic drugs reduced interindividual variation in SBP whereas ACEi, ARBs, and BBs increased it. CCB was most effective vs placebo. Interindividual variation in SBP accounted for the effects on risk of stroke independently of differences in mean SBP.
Wright et al (2009) ¹⁹⁹	Good quality SR (n=24 RCTs; 28 arms). 58,040 people, 42,196 (72.7%) were primary prevention. Included trials had >70% of people with BP >140/90 mmHg at baseline and were for >1 year duration.	All BP lowering medications vs placebo or other class of drug.	Low-dose thiazides ↓mortality (RR 0.89, 95% CI 0.83-0.96) and ↓CV events (RR 0.70, 95% CI 0.64-0.76). BBs ↓CV events (RR 0.89, 95% CI 0.8-0.98) but not CHD or mortality. ACEi ↓mortality (RR 0.83, 95% CI 0.72-0.95) and CV events (RR 0.76, 95% CI 0.67-0.85). CCBs ↓CV events (RR 0.71, 95% CI 0.57 to 0.87) but not CHD or mortality. Overall there are more trials of low-dose thiazides but CCBs and ACEi have similar effect and BBs are less effective.

ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BB: beta blocker; BP: blood pressure; CCB: calcium channel blocker; CHD: coronary heart disease; CV: cardiovascular; HF: heart failure; RCTs: randomised controlled trials; RR: relative risk; SBP: systolic blood pressure; SR: systematic review.

Evidence-based recommendations	Grade
Blood pressure-lowering therapy	
EBR 11: Treatment should begin with any one of the following agents: <ul style="list-style-type: none"> • ACE inhibitor • Angiotensin receptor blocker • Calcium channel blocker • Low-dose thiazide or thiazide-like diuretic 	A ^{192, 199}
EBR 12: If monotherapy does not sufficiently reduce blood pressure add a second agent from a different pharmacological class.	A ¹⁹²

Practice points
Blood pressure-lowering therapy
PP 13: If blood pressure is not responding to pharmacotherapy, reassess for: <ul style="list-style-type: none"> • non-adherence • undiagnosed secondary causes of raised blood pressure • hypertensive effects of other drugs • treatment resistance due to sleep apnoea • undisclosed use of alcohol or recreational drugs • unrecognised high salt intake (particularly in patients taking ACE inhibitors or angiotensin receptor blockers) • 'white coat' raised blood pressure • technical factors affecting measurement • volume overload, especially with CKD
PP 14: If dual therapy at higher doses does not sufficiently reduce blood pressure, add an additional agent.
PP 15: If combination therapy does not sufficiently reduce blood pressure, consider specialist advice.
PP 16: Treatable secondary causes for raised blood pressure should be considered before commencing blood pressure drug therapy.
PP 17: The following combinations should generally be avoided: <ul style="list-style-type: none"> • potassium-sparing diuretic plus either ACE inhibitor or angiotensin receptor blocker • beta-blocker plus verapamil

2.3.2 Lipid-lowering therapy

Lipid-lowering therapy should be determined by individual needs and should aim towards optimal lipid levels

Evidence from several systematic reviews and meta-analyses suggests that more intensive lipid modification produces greater reductions in cardiovascular events.^{209, 213, 216} In a meta-analysis of 26 randomised trials (mixed populations) of statins, each 1.0 mmol/L decrease in LDL-C equated to a 25% reduction in major vascular events in people without previous CVD (RR 0.75, 95% CI 0.69–0.82) and a 0.4% lower risk difference per year.²⁰⁹ However, there are no clinical trials that have evaluated the relative and absolute benefits of cholesterol lowering to different TC and LDL-C targets in relation to clinical events. Establishing a cholesterol target for therapy is therefore an extrapolation from the apparent benefits indicated by major trials of lipid lowering, while maintaining appropriate margins for safety, given that there are still no long-term follow up studies of statin therapy.

The recommendations in these guidelines also refer to levels of non-HDL-C and triglycerides. Non-HDL-C refers to the cholesterol in LDL, intermediate density lipoprotein and very low-density lipoproteins and is calculated by subtracting HDL-C from TC. Unlike LDL-C, the calculation of non-HDL-C does not require triglycerides to be less than 4.5 mmol/L. This makes it particularly useful for people with high triglycerides. Triglyceride levels are also important. Hypertriglyceridaemia is associated with the development of early onset CVD and significantly increases the risk of acute pancreatitis.²⁸⁵

The evidence for fixed-dose or individual titration of statin therapy is limited. One large meta-analysis performed a pre-determined assessment on the effects of statin dose on outcomes based on secondary prevention studies.²⁸⁶ Intuitively, one would expect that as the dose of a drug is increased, a greater amount of benefit is attained. However, with statin therapy, this was not the case above a certain dose. Over the range of doses reported, all statins, with the exception of pravastatin, showed some evidence of a dose response for reduction in TC and/or LDL-C with fixed dosing, but not with dose titration. Overall, there appeared to be no major difference between dose titration regimens or use of a fixed dose in studies of longer duration.

In summary, lipid lowering reduces cardiovascular events irrespective of initial lipid levels. Targets for lipid-lowering therapy have been developed by extrapolation from the apparent benefits indicated by major trials of lipid lowering,

therefore treatment for lipid lowering should aim towards these targets rather than consider them definitive.

Order of lipid-lowering treatment

Lipid-lowering pharmacotherapy includes statins, fibrates, bile acid binding resins, niacin (nicotinic acid) and selective cholesterol absorption inhibitors (e.g. ezetimibe). The effectiveness of each of these agents is covered in section 2.2.2 Lipid-lowering therapy. Of all the methods to modify lipids, the weight of evidence suggests that statins are the most effective and should be the first-line agent.^{216–219}

The lipid-lowering efficacy provided by the different statins appears to be fairly similar.^{211, 217, 236} For the reduction of cardiovascular events, meta-analyses suggest that although the point estimates of their effect sizes vary, the confidence intervals overlap in each case except for non-fatal MI where simvastatin can just be differentiated from pravastatin (RR 0.62, 95% CI 0.56–0.69 and 0.78, 95% CI 0.70–0.87, respectively).²¹¹ Another meta-analysis of 164 short-term primary and secondary trials found rosuvastatin 5 mg/day, atorvastatin 10 mg/day and lovastatin or simvastatin 40 mg/day reduced LDL-C by about 35%, but fluvastatin and pravastatin produced smaller reductions.²¹⁷ Rosuvastatin 10 mg/day, atorvastatin 20 mg/day and lovastatin or simvastatin 80 mg/day reduced LDL-C by about 45% and rosuvastatin 80 mg/day by about 60%. In clinical practice, the choice of statin is more likely to be related to the dosage required for lowering TC and LDL-C. Combination therapies (e.g., statins and ezetimibe) may also be considered when target LDL-C levels are not achievable with statins alone.

Systematic reviews have confirmed that statins, as first-line therapy, are safe and easy to use.^{208, 287, 288} Liver dysfunction is occasional and reversible. Rhabdomyolysis is very rare and severe muscle pain may require immediate cessation of therapy. Because statins are prescribed on a long-term basis, possible interactions with drugs that are metabolised by the cytochrome P450 pathway (e.g. cyclosporin, macrolides, azole antifungals, calcium antagonists, protease inhibitors, sildenafil, warfarin, digoxin, nicotinic acid, fibrates, etc.) also deserves particular attention. In cases where there is potential for interaction via this pathway, pravastatin is an acceptable alternative to atorvastatin or simvastatin. All patients started on a statin should be advised to report unexplained muscle pains or other adverse effects promptly, especially if associated with fever or malaise. If such effects are mild, a different statin may be tried and/or the statin dose reduced after discussing the risks involved with the patient. If severe side effects are experienced, statin therapy should be discontinued.

Due to the weight of evidence in favour of statins, fibrate monotherapy cannot be recommended as first-line treatment for raised lipid levels, but may be considered in those whose triglyceride levels remain elevated despite treatment with the maximally tolerated dose of statins and who have persistently low HDL-C levels. Triglyceride levels greater than 10mmol/L pose a risk of pancreatitis and should be treated with fenofibrate, nicotinic acid or fish oil as first-line therapy.

Nicotinic acids and ezetimibe may be considered in addition to statin therapy where insufficient lipid control has been achieved. Bile acid sequestrants using cholestyramine may be considered as monotherapy where statins are not tolerated or are contraindicated. They may also be considered in addition to statin therapy. Overall, there is limited evidence for various lipid lowering agents either in combination with statins or alone.

People with diabetes

Several systematic reviews have looked exclusively at responses to lipid modification of people with type 2 diabetes. The results from these reviews are consistent and suggest that people with diabetes gain similar benefits from statin therapy as people without.^{206, 208, 209, 211, 289} Perhaps the best evidence for people with diabetes comes from the *Collaborative Atorvastatin Diabetes Study* (CARDS), a large study conducted entirely in people with diabetes who did not have either raised cholesterol levels or a clinical history of CVD, even though many were hypertensive.²⁹⁰ In that study, the AR reduction attributable to statin therapy was 1.70% (95% CI, 0.11–3.29) for all-cause mortality and 1.35% (95% CI 0.30–2.40) for total stroke. The NNT for four years to prevent one death was 59 (95% CI 30.4–88.5).

The evidence for fibrates in people with type 2 diabetes is less clear. One systematic review of 11 trials (78% of population were deemed primary prevention) reported a significant reduction in non-fatal coronary events (RR 0.84, 95% CI 0.74–0.96) but no effect on stroke or mortality outcomes.²²² In the largest study included in the review, the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, fenofibrate therapy did not significantly reduce the risk of coronary events.²⁹¹ However, it did reduce total cardiovascular events, mainly due to fewer non-fatal MIs and revascularisations. Furthermore, in people with dyslipidaemia (defined as low HDL-C with high triglycerides), the benefit of fenofibrate appeared to be more pronounced. In that group, CVD events occurred in 16.3% of people randomised to placebo and 14.0% in people receiving fenofibrate ($p=0.06$).

A more recent trial (ACCORD) found that the combination of fenofibrate and simvastatin did not reduce the rate of fatal

CVD events, non-fatal MI or non-fatal stroke, compared with simvastatin alone.²⁹² Of interest, however, was a possible benefit according to lipid subgroups. People with dyslipidaemia displayed a more pronounced benefit ($p=0.057$ for interaction), similar to the result reported in the FIELD study.²⁹¹ However, in contrast to the FIELD study, a gender difference was observed, with the primary outcome rate increasing by 38% for women and decreasing by 18% for men.²⁹²

Collectively, these findings do not support the routine use of combination therapy with fenofibrate and statins to reduce CVD risk in people with type 2 diabetes, except in those with dyslipidaemia. Clinicians should note that in primary prevention, the treatment threshold is determined by the level of AR while the treatment target for triglycerides is <2.0 mmol/L. In contrast, in secondary prevention of CVD for people with type 2 diabetes, the treatment threshold is a triglyceride level above 2.3 mmol/L in combination with HDL levels below 1.0 mmol/L (refer to the *National Evidence-based Guideline on Secondary Prevention of Vascular Disease in type 2 diabetes currently being drafted*).

People with CKD

The benefits provided by statin therapy for people with CKD are similar to those observed in the general population. Statin therapy decreased all-cause mortality (RR 0.81, 95% CI 0.74–0.89) and cardiovascular mortality (RR 0.80, 95% CI 0.70–0.90) among people with non-dialysis dependent CKD to an extent similar to that found in the general population.^{235, 293} The same authors reported that statins reduced fatal cardiovascular events (RR 0.81, 95% CI 0.73–0.90) and non-fatal cardiovascular events (RR 0.78, 95% CI 0.73–0.84), for all stages of CKD but had no significant effect on all-cause mortality (RR 0.92, 95% CI 0.82–1.03).²⁹³ Importantly there were no significant differences in adverse events reported (including rhabdomyolysis and elevated liver enzymes). However, trials usually included people with pre-existing CVD. Meta-regression analysis found that treatment effects did not vary significantly with stage of CKD. This is consistent with a subgroup analysis in another meta-analysis, which found no difference in the effect of statins with varying levels of GFR.²⁰⁹

The Study of Heart and Renal Protection (SHARP) represents the largest trial of lipid modification in people with CKD performed to date.²⁹⁴ In that study, 9,438 participants with advanced CKD and no known history of CHD were randomised to one of three treatment arms: ezetimibe 10 mg plus simvastatin 20 mg daily, matching placebo or simvastatin 20 mg daily. In the latter arm, participants were re-randomised at one year to either ezetimibe 10 mg plus simvastatin 20 mg daily, or to placebo. The primary

endpoint was a composite of MI, coronary death, ischaemic stroke or any revascularisation procedure. Compared with placebo, randomisation to ezetimibe 10 mg plus simvastatin 20 mg daily yielded average LDL-C differences of 1.10 mmol/L at one year and 0.85 mmol/L at 2.5 years. Recent evidence from the SHARP trial, published during the finalisation of these guidelines, showed similar reductions in LDL-C (0.85 mmol/L) at a median follow up of 4.9 years. This data reported a 17% proportional reduction in major atherosclerotic events compared with placebo (RR 0.83, 95% CI 0.74-0.94) with no evidence of adverse effects.²²⁶ While this evidence did not result in a regrading of recommendation EBR14, the outcome data further support the use of ezetimibe in combination with a statin if LDL-C levels are not sufficiently reduced on a statin alone.

A secondary analysis from the Justification for the Use of Statins in Prevention – an Intervention Trial Evaluating

Rosuvastatin (JUPITER) trial reported positive effects from statin therapy on cardiovascular and mortality outcomes among people with moderate CKD (eGFR <60 ml/min/1.73 m²) at study entry (n=3,267), compared with those with baseline eGFR ≥60 ml/min/1.73 m² (n=14,528).²⁹⁵ Over a median follow-up period of 1.9 years, a higher rate of vascular events was observed in the group with moderate CKD (HR 1.54, 95% CI 1.23–1.92, p=0.0002). In the same group, rosuvastatin was associated with a 45% reduction in risk of the combined primary endpoint – MI, stroke, hospital stay for unstable angina, arterial revascularisation or confirmed cardiovascular death (HR 0.55, 95% CI 0.38–0.82, p=0.002) and a 44% reduction in all-cause mortality (HR 0.56, 95% CI 0.37–0.85, p=0.005). An almost identical effect of rosuvastatin on the primary endpoint was observed among those with more preserved renal function (HR 0.57, 95% CI 0.45–0.72, p<0.001).

Evidence-based recommendations	Grade
Lipid-lowering therapy	
EBR 13: Statins should be used as first-line therapy	A ^{206, 208, 209}
EBR 14: If LDL-C levels are not sufficiently reduced on maximally tolerated doses of statin, one or more of the following may be added: <ul style="list-style-type: none"> ezetimibe bile acid binding resin nicotinic acid. 	C ²²⁴⁻²²⁶ D ^{219,223} D ^{218,227}
EBR 15: Where statins cannot be tolerated at all, one or more of the following can be used: <ul style="list-style-type: none"> ezetimibe bile acid binding resin nicotinic acid. 	D ²²⁵ D ²²³ D ²²⁷⁻²²⁹
EBR 16: If triglyceride levels remain elevated, treatment with one of the following may be considered: <ul style="list-style-type: none"> fenofibrate (especially if HDL is below target) nicotinic acid fish oil. 	C ²²⁰⁻²²² C ^{218, 227} C ²³⁰⁻²³²

Practice point
PP 18: Treatable secondary causes of dyslipidaemia should be considered before commencing lipid lowering pharmacotherapy

2.3.3 Principles of pharmacological therapy

A number of issues should be considered when making treatment decisions for the management of CVD risk.

Balancing the benefits and risks of treatment

For all individuals, a clinical judgment should be made to assess the balance between the benefits and risks of pharmacological treatment. Clear benefits in preventing cardiovascular events and reducing premature mortality have been demonstrated for BP and lipid-lowering therapy in many clinical trials. However not all clinical situations in which their use may be considered have been covered by clinical trials, e.g. in the elderly.

Use of these therapies are associated with risks and other negative effects which should be taken into consideration when deciding the appropriateness of implementing the treatment recommendations contained in these guidelines. These therapies may be contraindicated in some situations and their use may result in troublesome side effects. In addition, polypharmacy may be unaffordable to some, may increase the risk of side effects and may impact on quality of life.

The appropriateness of general treatment targets to the individual should also be considered. CVD risk associated with lipid and BP levels is continuous and specific targets are somewhat arbitrary and should be used as a guide to treatment and not as a requirement, especially if they cannot be easily achieved without causing unwanted effects. The risks associated with the effort required to reach a particular target as opposed to achieving a near-target value may outweigh any small absolute benefit. Any reduction in a risk factor will be associated with some benefit.

Prescribing pharmacological treatment

Benefits and risk should be carefully considered before initiating or changing pharmacological treatment. The primary consideration is clinical need and clinical appropriateness of a particular therapy. The choice of agent should be guided by clinical effectiveness but once the decision on the class of drug has been made, further consideration should be given to the cost to both the individual and government. The use of cheaper alternatives such as generic medications instead of more expensive options achieves similar health gains while increasing consumer and societal affordability.

2.4 Populations requiring special consideration

2.4.1 People with diabetes

CVD is the major cause of death in people with diabetes with nearly 11,900 Australian deaths in 2005 of which CVD was involved in more than 50%: CHD (48%), stroke (16%) and PVD in 6%.³⁰ Diabetes approximately doubles the risk for a range of cardiovascular diseases independently of traditional risk factors.²⁹⁶ While diabetes is a clear risk factor for CVD the role of improved control of blood glucose for preventing CVD morbidity and mortality in people with type 2 diabetes is unclear although it has been found to prevent or reduce microvascular complications (retinopathy, renal disease and neuropathy).³⁰

Lifestyle

Lifestyle modification and support (particularly diet, weight control and physical activity) is critically important in diabetes care.³⁰ The lifestyle recommendations in these guidelines for CVD prevention in the general population apply equally for people with diabetes.

Pharmacotherapy

BP lowering reduces cardiovascular events and all-cause mortality in people with type 2 diabetes in the same manner as for the general population.^{192, 195} While no difference is noted between different classes of BP-lowering therapy for CVD outcomes,¹⁹⁵ there is clear evidence that in people with type 2 diabetes, antihypertensive therapy with an ARB or ACE inhibitor decreases the rate of progression of albuminuria, promotes regression to normoalbuminuria and may reduce the risk of decline in renal function.^{31, 297, 298}

The benefit in terms of renal protection was also found in the recent ROADMAP study which included 4,447 people with type 2 diabetes and normoalbuminuria but additional risk factors (33.4% had pre-existing CVD).²⁹⁷ While overall baseline BP was already low (mean 136/81 mm Hg) treatment to low BP targets (<130/80 mmHg) was achieved by more people in the intervention arm using an ARB vs other agents (80% vs 71%). Treatment with ARB prevented (8.2% vs 9.8%) and delayed the onset of microalbuminuria (23% delay to onset; $p=0.01$). An increase in CVD mortality was noted although numbers are low (15 v 3) and the difference greater in those with CHD (2.0% mortality with ARB v 0.2% mortality with other agents, $p=0.02$). A post hoc analysis found a reduction in combined cardiac morbidity (acute coronary syndrome, silent MI, coronary

revascularization and hospitalization because of congestive heart failure) (1.1% v 2.3%; $p < 0.01$).

Given the importance of preventing and managing renal complications in people with diabetes, these classes of drugs (ACE inhibitor or ARB) should be preferred as first-line therapy. However, more than one agent is often needed to reduce BP. In a pre-specified subgroup analysis from the ACCOMPLISH trial, those with diabetes ($n=6,946$; 15% had previous MI and 8% had previous stroke) significantly reduced the risk of CVD events with a combination of a CCB plus an ACE inhibitor compared with those treated with a combination of a thiazide diuretic plus an ACE inhibitor (HR 0.79, 95% CI 0.68–0.92, $p=0.003$) even though mean blood pressure was similar in both groups (~132/73 mmHg).²⁹⁹ In the pre-specified subgroup analysis of the ASCOT trial for those with diabetes ($n=5,137$, at least 38% had pre-existing CVD), the CCB based combination (mostly with an ACE inhibitor) compared to the Beta Blocker combination (mostly with a thiazide diuretic) reduced the risk of combined CVD events and procedures (HR 0.86, 95% CI 0.76–0.98, $p=0.026$). There was a greater reduction of in-trial BP with the CCB based combinations compared to those using Beta Blocker based combinations (mean difference on CCB combination was 3.0 mmHg SBP and 1.9 mmHg DBP lower), however, there was no difference by the end of the study (~135/75 mmHg in each group).³⁰⁰ In the ADVANCE trial ($n=11,140$, 32% had major macrovascular disease) treatment with a fixed dose ACE inhibitor plus a diuretic reduced the risk of combined macro and micro disease (HR 0.91, 95% CI 0.83–1.00, $p=0.04$) compared to placebo.²⁷³ Evidence for BP targets for those with diabetes has also been recently updated (refer to section 2.3.1 Blood pressure-lowering therapy).

Several systematic reviews have looked exclusively at responses to lipid modification of people with type 2 diabetes. The results from these reviews are consistent and suggest that people with diabetes gain similar benefits from statin therapy as people without.^{206, 209, 211}

In the CARDS study, the AR reduction attributable to statin therapy was 1.70% (95% CI 0.11–3.29) for all-cause mortality and 1.35% (95% CI 0.30–2.40) for total stroke. The NNT for four years to prevent one death was 59 (95% CI 30.4–88.5).^{211, 301}

Evidence for the benefit of lipid lowering with fibrates in people with type 2 diabetes is less clear. In the trials performed to date, fenofibrate therapy alone did not significantly reduce the risk of coronary events or stroke in people with type 2 diabetes,^{222, 291} nor did the combination of fenofibrate and simvastatin.²⁹² However, two of those trials (ACCORD and FIELD studies), demonstrated beneficial effects with fenofibrate therapy on lowering microvascular complications.^{291, 292}

The role of aspirin for the primary prevention of cardiovascular events in people with type 2 diabetes has been assessed in four systematic reviews.^{239, 243, 247, 248} These reviews consistently report that aspirin therapy is associated with a modest non-significant reduction in risk of major cardiovascular events in people with diabetes. Given that these effects are less than those for the general population the recommendations to not routinely treat with aspirin are consistent for people with or without diabetes (refer to section 2.2.3 Antiplatelet therapy).

Readers are referred to other guidelines for information on pharmacotherapy specific to diabetes care (blood glucose management).³⁰ Recommendations for the secondary prevention of CVD in those with diabetes is covered in the *National Evidence-Based Guideline on Secondary Prevention of Vascular Disease in type 2 diabetes* (currently being drafted). While recommendations are consistent in primary and secondary populations some of the grading of individual recommendations differs slightly, due to the underlying evidence for the different populations.

Evidence-based recommendations	Grade
Populations requiring special consideration: people with diabetes	
EBR 17: Blood pressure-lowering therapy in people with diabetes should preferentially include an ACE inhibitor or angiotensin receptor blocker.	A ^{297, 298, 302, 303}
EBR 18: If monotherapy does not sufficiently reduce blood pressure add one of the following: <ul style="list-style-type: none"> • Calcium channel blocker • Low dose thiazide or thiazide-like diuretic. 	B ^{299, 300} C ^{273, 299}

2.4.2 People with CKD

People with CKD are at significantly increased risk of cardiovascular events. In a pooled analysis of four large community-based, longitudinal studies, CKD (eGFR 15–60 ml/min/1.73 m²) was associated with a 20% increased risk of cardiovascular events and death.³⁰⁴ This is consistent with a recent meta-analysis, which found CKD and albuminuria are independent predictors of all-cause mortality and cardiovascular mortality in the general population.³⁰⁵ For this reason, individuals with CKD should be identified early so that appropriate preventative measures can be taken. This section provides a summary of the evidence for CKD, as it pertains to absolute CVD risk reduction. The reader is directed to the main text for more detailed information.

Lifestyle

Limited evidence exists on the effects of lifestyle modification (i.e. smoking, physical activity and alcohol) on CVD outcomes in patients with CKD. Dietary recommendations outlined for the prevention of CVD apply equally to those with CKD. Furthermore, all adults should be encouraged to participate in at least 30 minutes of moderate intensity activity on most or preferably every day of the week and all smokers should be advised to stop.

Pharmacotherapy

High BP is common in CKD and represents a major target for intervention to prevent disease progression. In general, the clinical evidence suggests that people with CKD receive the same or similar benefits from BP-lowering therapy as the general population, irrespective of the level of kidney function. A recent systematic review considered during finalisation of these guidelines, included three trials which compared different BP targets in adults with CKD and showed no difference in outcomes for people treated to lower BP targets (<125/75 to 130/80 mmHg) versus higher targets (<140/90 mmHg).²⁷⁷ More BP-lowering pharmacotherapy was needed to achieve the lower BP targets, and this group had a slightly higher rate of adverse events. Much less evidence is available for people on maintenance dialysis. However, the available evidence suggests that treatment using agents that lower BP reduces cardiovascular morbidity and mortality for this group.¹⁹⁷ While more studies are required, the possible risks and benefits of BP lowering should be considered for all people receiving dialysis.

Two meta-analyses provide evidence that ACE inhibitors and ARBs are the preferred agents for BP lowering in people with CKD because of their renoprotective effects

more than their impact on mortality outcomes. In the first meta-analysis,³⁰² ACE inhibitors compared with placebo significantly reduced the risk of developing microalbuminuria in normoalbuminuric people with diabetes (RR 0.60, 95% CI 0.43–0.84). No subgroup analysis was conducted for those with and without existing CVD. No effect was seen for doubling of creatinine (RR 0.81, 95% CI 0.24–2.71) or all-cause mortality (RR 0.81, 95% CI 0.64–1.03). When compared with CCBs, ACE inhibitors significantly reduced progression to microalbuminuria (RR 0.58, 95% CI 0.40–0.84). The effect of ACE inhibitors was independent of baseline BP, renal function and type of diabetes; however, there was insufficient data to be certain that these factors are not important effect modifiers.

The second meta-analysis³⁰³ compared the survival effects of ACE inhibitors and ARBs in 49 trials with mixed populations of primary and secondary CVD. No significant difference was found in the risk of all-cause mortality for ACE inhibitors compared with placebo (RR 0.91, 95% CI 0.71–1.17) and ARBs compared with placebo (RR 0.99, 95% CI 0.85–1.17). However, ACE inhibitors showed a significant reduction in the risk of all-cause mortality when given at maximally tolerated dose compared with half or less than half the maximally tolerated dose (RR 0.78, 95% CI 0.61–0.98). ACE inhibitors and ARBs had similar beneficial effects on renal outcomes.

The benefits provided by statin therapy are similar in people with CKD to those observed in the general population. In a Cochrane review, statin therapy decreased all-cause mortality and cardiovascular mortality among people with non-dialysis dependent CKD to an extent similar to that found in the general population.²³⁵ The same authors reported in an expanded meta-analysis that statins significantly reduced lipid levels in those with CKD, irrespective of stage of disease, but showed no benefit on all-cause mortality.²⁹³ A secondary analysis from the JUPITER trial in people with moderate CKD (eGFR <60 ml/min/1.73 m²) at study entry (n=3,267), compared with those with baseline eGFR ≥60 ml/min/1.73 m² (n=14,528) and found rosuvastatin was associated with a 45% reduction in risk of the combined primary endpoint – MI, stroke, hospital stay for unstable angina, arterial revascularisation or confirmed cardiovascular death (HR 0.55, 95% CI 0.38–0.82; p=0.002) and a 44% reduction in all-cause mortality (HR 0.56, 95% CI 0.37–0.85, p=0.005).²⁹⁵ Recently, the landmark SHARP trial reported a combination of ezetimibe 10 mg plus simvastatin 20 mg daily reduced LDL-C by an average of 0.85 mmol/L and reduced major CVD events by 17% (RR 0.83, 95% CI 0.74–0.94) compared to statin therapy alone, without evidence of adverse events.²²⁶

In summary, the evidence suggests that, apart from choice of agent for initiation of BP-lowering treatment, people with CKD should be managed for CVD risk in the same way as the general population.

Evidence-based recommendation	Grade
Populations requiring special consideration: people with CKD	
EBR 19: Blood pressure-lowering therapy in people with CKD should begin with an ACE inhibitor or angiotensin receptor blocker.	A ^{302, 303}

Chapter 3:

Monitoring of Pharmacotherapy

The goal for management of absolute CVD risk is to reduce the person's level of AR. This is achieved by treatment of multiple individual risk factors such as blood pressure and lipid levels which have been shown to have a continuous association with the risk of CVD events.

Moderate reductions in several risk factors is considered more effective in reducing overall CVD risk than a major reduction in one factor.⁵ Decisions regarding management of risk are therefore made according to the person's AR level, while response to treatment is monitored by measurement of individual risk factors.

In people with moderate to high CVD risk, having an effective strategy for monitoring treatment response is essential for achieving long-term CVD prevention. There is some evidence to support the use of monitoring, particularly to measure response to treatment of individual risk factors and for adherence. In general, the literature to support medication monitoring and/or adherence is consistent and reports either improvement in individual risk factors or, in some instances, a reduction in overall CVD risk.

3.1 Maximising the benefits of pharmacotherapy

The literature reports several methods for monitoring adherence to pharmacological interventions in terms of effect (e.g. BP or lipid levels). These methods include self-monitoring,³⁰⁶ tele-monitoring,³⁰⁶ case management³⁰⁷ and individualised provision of information.^{308, 309} These studies consistently report that regular monitoring of individual risk factors is associated with improvement in CVD risk factor outcomes. Furthermore, several studies³¹⁰⁻³¹² report that lack of monitoring contributes to poor adherence to statin therapy and therefore worse outcomes.

Although targets for BP and lipid levels have been generally agreed, based on extrapolations of what has been achieved in clinical trials, the relationship between BP levels, lipid levels and CVD risk is known to be continuous. Therefore, targets should be considered indicative and should be used for monitoring treatment effects and adherence to medication while considering the individual person's risk/benefit profile. After commencement of BP lowering therapy and until treatment is stable or targets achieved, BP levels should be reviewed at intervals of six weeks unless there are concerns or indications for more frequent monitoring. Similarly, after commencement of lipid therapy, lipid levels should be reviewed at 12 weekly intervals.

Monitoring of patient response to treatment may lead to reconsideration of appropriate management. In some patients who make significant and sustained lifestyle changes such as smoking cessation or loss of 10–20% of body weight, there will be a consequent significant reduction of individual risk factors. Reduction or withdrawal of pharmacotherapy may be considered in these cases; however, monitoring should continue for at least 12 months to ensure a sustainable impact on the risk factors.

Consensus-based recommendations

Maximising the benefits of pharmacotherapy

CBR 7: Pharmacotherapy for blood pressure-lowering should aim towards the following targets while balancing the risks/benefits:

- $\leq 140/90$ mmHg for adults without CVD (including those with CKD)
- $\leq 130/80$ mmHg for adults with micro or macro albuminuria (UACR >2.5 mg/mmol in males and >3.5 mg/mmol in females)
- $\leq 130/80$ mmHg for all adults with diabetes

CBR 8: Pharmacotherapy for lipid lowering should aim towards the following targets while balancing the risks/benefits:

- TC <4.0 mmol/L
- HDL-C ≥ 1.0 mmol/L
- LDL-C <2.0 mmol/L
- Non HDL-C <2.5 mmol/L
- TG <2.0 mmol/L

Practice point

Maximising the benefits of pharmacotherapy

PP 19: Adults who commence pharmacotherapy should have their medication adjusted as required and response assessed regularly (approximately 6-12 weekly) until sufficient improvement has been achieved or maximum tolerated dose has been reached.

PP 20: Reduction or withdrawal of pharmacotherapy may be considered in adults who make sustained lifestyle changes which significantly reduce their risk. (e.g. smoking cessation, significant weight loss).

3.2 Patient adherence

Failure to take prescribed medication is a major barrier to optimal prevention of CVD, however the literature concerning interventions to improve adherence to medications remains surprisingly weak. One Cochrane review involving 78 trials found only modest effects for interventions to improve adherence to medications across a range of populations and settings. Conflicting evidence for short-term interventions on compliance was found and very few studies reported changes in patient outcomes.³¹³ Almost all of the interventions that were effective for long-term compliance were complex, including combinations of more convenient care, information, reminders, self-monitoring, reinforcement, counselling, family therapy, psychological therapy, crisis intervention, telephone follow-up and supportive care.

One recent Cochrane review (72 trials) assessed different interventions to improve BP control in hypertensive adults in a primary care, outpatient or community setting.³¹⁴ Organisational interventions (nine trials) to enable regular review in tandem with a rigorous stepped-care approach to antihypertensive drug treatment were found to be the

most effective, but this finding was dominated by findings from a single large trial – the Hypertension Detection and Follow-Up study. Self-monitoring (18 trials) was associated with a reduction in SBP (2.5 mmHg) and DBP (1.8 mmHg) and may be a useful adjunct strategy. Other interventions assessed in this systematic review did not produce clear results. Educational interventions directed at physicians (10 trials) did not change BP control, but education for patients (20 trials) may have a modest effect although heterogeneity was noted. Use of health care professionals such as nurses and pharmacists (12 trials) demonstrated generally favourable but heterogeneous results. Lastly, reminders (postal, computer or telephone) improved follow-up and control of patients, but produced heterogeneous results in terms of BP reduction.

Another Cochrane review (38 trials) specific to BP-lowering therapy in an ambulatory setting suggested that simplifying dosing regimens was the most consistently effective intervention (seven out of nine studies). Motivational strategies (e.g. financial incentives or reminder packages/aids) and complex interventions involving

more than one technique were less consistent. Effects were generally modest and patient education alone was largely ineffective.³¹⁵ Further, in a systematic review of 11 trials investigating the effects of home BP monitoring on medication adherence, six of the 11 trials reported a statistically significant improvement in medication adherence; 84% of these were complex interventions using home BP monitoring in combination with other adherence-enhancing strategies such as patient counselling by nurses, pharmacists or telephone-linked systems, patient education and the use of timed medication reminders.³¹⁶ Two moderate quality reviews of simplifying doses by using fixed-dose combinations to improve adherence for raised BP reported improved compliance with combination treatment (24% decrease risk of non-compliance in one review).^{317, 318}

Another systematic review (11 trials) found strategies for patient re-enforcement and reminding (e.g. telephone reminders or pharmacist review) to have the most consistent benefits in improving adherence for lipid-lowering therapy (four of six trials were positive with absolute improvement in adherence of 6–24%).³¹⁹ Other strategies found to increase adherence, included simplification of the drug regimen (11% improvement) and patient information and education (13% improvement), although results were inconsistent and the quality of some studies was low. One high-quality systematic review (21 trials) in people with type 2 diabetes failed to find clear benefits for various strategies including nurse-led interventions, home aids, diabetes education, pharmacy led interventions, adaptation of dosing and frequency of medication taking.³²⁰ The evidence is difficult to interpret due to heterogeneity; however overall there seems to be a modest improvement in adherence from the more complex interventions.

Appendix 1:

Guidelines development groups and terms of reference

The guidelines development process was coordinated by the National Stroke Foundation on behalf of the National Vascular Disease Prevention Alliance (NVDPA) with partner agencies represented on the advisory and/or expert working group committees as appropriate. The guidelines have been developed according to the processes outlined in the document *NHMRC Standards and Procedures for Externally Developed Guidelines (2007)*.

Project Committees

Three groups were established in the development of the guidelines.

Advisory Committee

The Advisory Committee had 17 representatives from a wide range of backgrounds including diabetes, nephrology, stroke, cardiology, Indigenous health, general practice, economics, a consumer and the Pharmaceutical Benefits Advisory Committee (PBAC). The Committee was responsible for:

- overseeing operational aspects of the guidelines development
- determining the topics and questions to be addressed in the guidelines
- advising on a plan for communication, dissemination and implementation
- assisting the EWG as needed (particularly in regard to responding to consultation where significant difference in opinion exists)
- developing recommendations for periodically updating the guidelines
- regular reporting to the full committee of the NVDPA.

Members of the Advisory Committee included:

Dr Erin Lalor (Chair)
Chief Executive Officer,
National Stroke Foundation
Chair of NVDPA

Dr Andrew Boyden (until February 2011)
National Director-Clinical Issues,
National Heart Foundation

Dr Dominique Cadilhac
Head, Public Health Division,
National Stroke Research Institute

Professor Stephen Colagiuri
Diabetologist,
Boden Institute of Obesity, Nutrition, Exercise
and Eating Disorders,
The University of Sydney

Professor Jennifer Doust (PBAC representative until August 2010)
Epidemiology and Public Health,
Bond University

Ms Dianne Fraser
Assistant Director, Chronic Disease Branch,
Department of Health and Ageing

Professor Mark Harris (RACGP representative)
General Practitioner,
Centre for Primary Health Care and Equity,
The University of New South Wales

Dr Nancy Huang (until March 2010)
National Manager Clinical Programs,
National Heart Foundation

Professor David Johnson
Nephrologist,
Princess Alexandra Hospital and
University of Queensland

Professor Greg Johnson (from November 2010)
Chief Executive Officer,
Diabetes Australia – Victoria

Dr Nadia Lusic (NACCHO representative)
Public Health Medical Officer,
Victorian Aboriginal Community Controlled Health
Organisation (VACCHO)

Associate Professor Timothy Mathew
National Medical Director,
Kidney Health Australia

Mr Noel Muller (Consumer Health Forum representative)
Consumer

Dr Rashmi Sharma (PBAC representative from December
2010)
General Practitioner,
Isabella Plains Medical Centre, ACT

Associate Professor Jonathan Shaw (Baker IDI guideline
development group representative)
Associate Director,
Baker IDI Heart and Diabetes Institute

Dr Ian White (until December 2010)
National Policy Manager,
Diabetes Australia

Ms Jinty Wilson (from March 2011)
National Manager Clinical Programs,
National Heart Foundation

Expert Working Group

The EWG had 12 members including endocrinologists, cardiologists, nephrologists, general practitioners, geriatricians, a consumer and a PBAC representative. The EWG was responsible for:

- assisting as required with the appraisal and grading of identified research
- using the evidence base to develop the guidelines recommendations
- assisting with the drafting of the guidelines document
- linking with members of the corresponding group where relevant
- assisting with the consultation process
- assisting with the response to feedback gained during the consultation process.

The NVDPA is grateful to the members of the EWG who provided their time and expertise to develop these guidelines.

Members of the EWG included:

Professor Stephen Colagiuri (Chair)
Diabetologist,
Boden Institute of Obesity, Nutrition, Exercise
and Eating Disorders,
The University of Sydney

Professor Andrew Tonkin
Cardiologist, Cardiovascular Research Unit,
Monash University

Professor Leonard Arnolda
Cardiologist,
Canberra Hospital and
Australian National University

Professor Alex Brown
Indigenous Health,
Executive Director and Margaret Ross Chair of Indigenous
Health,
Baker IDI Central Australia

Professor Terry Campbell, AM
Cardiologist (PBAC representative),
University of New South Wales

Professor Derek Chew
Cardiologist,
Flinders University

Dr David Dunbabin
Stroke Specialist/Geriatrian,
Royal Hobart Hospital and
University of Tasmania

Professor Mark Harris
General Practitioner,
Centre for Primary Health Care and Equity,
University of New South Wales

Professor David Johnson
Nephrologist,
Princess Alexandra Hospital and
University of Queensland

Mr Richard McCluskey
Consumer representative

Professor Mark Nelson
General Practitioner,
Menzies Research Institute of Tasmania,
University of Tasmania

Associate Professor David Sullivan
Clinical Biochemistry,
Royal Prince Alfred Hospital and
University of Sydney

Corresponding Group

The Corresponding Group had 22 members with wide representation across all of the previously identified groups and also broad representation across the lifestyle issues such as smoking, physical activity, nutrition, depression and alcohol. This group was responsible for:

- assisting as required with the appraisal and grading of identified research
- assisting with the drafting of the guidelines document (including recommendations)
- linking with members of the EWG where relevant
- assisting with the consultation process
- assisting with the response to feedback gained during the consultation process.

The NVDPA wishes to thank the members of the Corresponding Group for their input to the development of the guidelines.

Members of the Corresponding Group included:

Professor Philip Barter
Lipid management,
University of Sydney

Professor Adrian Bauman
Behavioural Epidemiology and Health Promotion,
University of Sydney

Dr Dominique Cadilhac
Head, Public Health Division,
National Stroke Research Institute

Professor David Clarke
Psychology,
Beyondblue,
Monash University

Professor Peter Clifton
Nutrition,
Australian Atherosclerosis Society

Dr Emil Djakic
General Practitioner,
Australian General Practice Network

Dr Martin Gallagher
Nephrologist,
Caring for Australians with Renal Impairment

Dr Melina Gattellari
Public Health,
Stroke Society of Australasia

Associate Professor Timothy Gill
Public health nutrition,
National Heart Foundation

Professor Leonard Kritharides
Cardiologist,
Concord Hospital and
The University of Sydney

Dr Alasdair MacDonald
General practitioner,
Internal Medicine Society of Australia and New Zealand

Associate Professor Arduino Mangoni
Cardiologist,
Flinders University

Professor Manny Noakes
Nutrition,
CSIRO

Professor Caryl Nowson
Nutrition,
Deakin University

Associate Professor Anushka Patel
Cardiologist,
The George Institute for Global Health

Ms Adriana Platona
The Australian Government,
Department of Health and Ageing

Professor Vlado Perkovic
Nephrologist,
The George Institute for Global Health

Professor Prasuna Reddy
Psychologist,
Deakin University

Professor Jo Salmon
Nutrition,
Deakin University

Associate Professor Markus Schlaich
Renal Physician,
High Blood Pressure Research Council of Australia

Dr Lynn Weekes
Pharmaceutical,
National Prescribing Service

Associate Professor Margarite Vale
Nutrition,
Cardiac Society of Australia and New Zealand

Editorial Independence

The EWG was responsible for the content of the guidelines with independence from the funding source. A DOHA representative formed part of the Advisory Committee to oversee the process of the guidelines development.

Conflict of Interest

A policy regarding disclosure and management of potential conflicts of interest (COI) was implemented. All Advisory Committee and EWG members completed COI forms and a COI register was maintained and updated regularly.

COI were managed in the following manner:

- Open disclosure of all COI to all members of the committee and public declaration of all COI in guidelines
- If the COI is deemed significant, individuals may be restricted from involvement in discussions and decisions on related topics. This is determined by the chair of the relevant committee and has occurred once
- If the COI is considered exclusionary, the individual will be excluded from membership of the relevant committee or from employment in the guidelines team. This will be determined by the chair of the relevant committee and the CEO of the NSF, the lead agency for this project. This level of COI has been experienced and the relevant member resigned from the committee.

A copy of the Conflict of Interest Policy can be supplied on request.

National Stroke Foundation Guidelines Project Team

Ms Ruth Friedman
Senior Project Manager, CVD Guidelines,
National Stroke Foundation

Mr Kelvin Hill
Manager, Guidelines Program,
National Stroke Foundation

Ms Diana Reddan
Senior Administration Assistant,
National Stroke Foundation

External Consultants

medScript

Mr Brad Dalton
Medical writer

[International Centre for Allied Health Evidence \(iCAHE\)](#)
[University of South Australia](#)
Dr Susan Hillier
Systematic Review Lead

Kylie Johnson
Evidence Review

Janine Dizon, Valentin Dones, Karly Hayman,
Jonathan Ucinck
Data Extraction

Alexandra Young
Database Searching

[Centre for Burden of Disease and Cost Effectiveness](#)
[University of Queensland](#)
Professor Theo Vos
Health Economic Modelling Project Lead

Dr Linda Cobiack
Health Economic Modelling

[Deakin Health Economics](#)
[Strategic Research Centre - Population Health](#)
[Deakin University](#)
Professor Rob Carter
Health Economic Modelling

Ms Anne Magnus
Health Economics Literature Synthesis

Appendix 2:

Guidelines development process report

1. Methodology

These guidelines were developed according the standards outlined in the *NHMRC Standards and Procedures for Externally Developed Guidelines (2007)*.

2. Clinical questions

The clinical questions were initially framed by building on the work undertaken in the development of the *Guidelines for the Assessment of Absolute Cardiovascular Disease Risk*. Further refinement was undertaken after consultation with international guidelines groups in Scotland and New Zealand. Questions were then grouped under topics and circulated to experts for comment. Some experts were consulted individually for further detailed comments. In response to the comments from experts, the questions were modified for further discussion and final approval at a face-to-face meeting of the Advisory Committee held on 26 November 2009.

The clinical questions are outlined below:

Absolute risk assessment

1. Which AR assessment method is most predictive of future CVD events in a mixed adult (aged >18) population not known to have CVD or diabetes?
 2. Which AR assessment method is most predictive of future CVD events in a mixed adult (aged >18) population not known to have CVD and who have diabetes?
 3. Which AR assessment method is most predictive of future CVD events in a mixed adult (aged >18) population not known to have CVD and who are overweight (defined as BMI within the range 25.0–29.9 kg/m²) or obese (BMI ≥30kg/m²)?
 4. Which AR assessment method is most predictive of future CVD events in adult (aged >18) Aboriginal and Torres Strait Islander peoples not known to have CVD?
 5. Which AR assessment method is most predictive of future CVD events in adult (aged >18) people with chronic kidney disease (eGFR <45ml/min1.73 m²) not known to have CVD?
- #### Aims of treatment, monitoring and follow-up
6. Is there evidence that multiple risk intervention is more effective in reducing CVD events and all cause mortality than intervention on single risk factors? NOTE: evidence was systematically identified but used in narrative review (rather than comprehensive critical appraisal and summary process) to form important part of main body of guidelines.
 7. What evidence exists to support the benefit of monitoring treatment effects? Report evidence for secondary outcomes defined as AR levels; individual risk factor levels; side effects; compliance with treatment.
 8. Do strategies to promote concordance with medication reduce the risk of CVD? NOTE: as for Q6 evidence was systematically identified but used in narrative review to form important part of main body of guidelines.
- #### Blood pressure
9. Does pharmacological blood pressure-lowering reduce CVD events and all cause mortality compared to 'control'?

10. What is the evidence for one blood pressure-lowering drug class or any combination of drug classes being more effective than any other blood pressure-lowering drug class or combination for reducing CVD events and all cause mortality? Report evidence for secondary outcome defined as: Reduction of BP.
11. Should blood pressure therapy be initiated with a single drug or with a combination?
12. Should antihypertensive therapy employ drugs at fixed doses or should individuals always be titrated to target blood pressure levels?
13. Does more intensive blood pressure-lowering produce greater reductions in CVD events and all cause mortality?

Lipids

14. Does pharmacological lipid modification compared to control reduce CVD events and all cause mortality?
15. What is the evidence for one lipid modifying drug class or any combination of drug classes being more effective than any other lipid-modifying drug class or combination for the reduction of CVD events and all cause mortality? Report evidence for secondary outcome defined as: Reduction of blood lipids.
16. Should lipid lowering therapy employ drugs at fixed doses or should individuals always be titrated to target lipid levels?
17. Does more intensive lipid modification treatment produce greater reductions in CVD events and all cause mortality?

Antiplatelets

18. Does antiplatelet therapy compared to control reduce CVD events and all cause mortality? Report evidence for secondary outcome: Bleeding complications.
19. What is the evidence for one antiplatelet therapy or dose or any combination of therapy/doses being more effective than any other antiplatelet therapy/dose or combination for the reduction of CVD events and all cause mortality? Report evidence for secondary outcome: Bleeding complications.

Obesity

20. Does reducing weight reduce CVD events and all cause mortality? Report evidence for secondary outcomes: BP; Lipid parameters.

Diet and nutrition

21. Is there evidence that following dietary advice reduces CVD events and all cause mortality? Report evidence for outcomes: BP; Lipid parameters; Diabetes.

Physical activity

22. Is there evidence that physical activity reduces CVD events and all cause mortality?
23. What is the evidence for physical activity type and dose or any combination of type/doses being more effective than any other physical activity type and dose or combination for the reduction of CVD events and all cause mortality? Report evidence for secondary outcomes: BP; Lipid parameters.

Alcohol

24. What is the evidence that the patterns and levels of alcohol consumption alter CVD events and all cause mortality? Report evidence for secondary outcomes: BP; Lipid parameters.

Smoking

25. Does smoking cessation reduce CVD events and all cause mortality?

Depression

26. Does treatment (pharmacological and non pharmacological) of depression reduce CVD events and all cause mortality?

3. Literature review

The systematic literature review was undertaken according to the process outlined in the *NHMRC Standards and Procedures for Externally Developed Guidelines (2007)* by an external group from the Centre for Allied Health Evidence (iCAHE), University of South Australia, led by Dr Susan Hillier and Professor Karen Grimmer-Somers.

Searches were conducted in relevant databases using an agreed search protocol which lists details of search terms, inclusion/exclusion criteria, and data extraction and appraisal methodology. Additional hand searching was conducted by the NSF project team in several key journals to identify any major trials or meta-analyses published after the systematic literature review.

3.1 Criteria for considering studies for the review

Search dates

The search dates were 2006 to June 2010 for the first five questions relating to assessment of CVD risk which updated the search conducted for the *Clinical Guidelines for the Assessment of Absolute Cardiovascular Disease Risk* (which used no limits on the date of publication). The search dates were 2002 to June 2010 for the remaining questions relating to management of absolute CVD risk. Hand searching was conducted between June 2010 and May 2011.

Types of studies

Existing guidelines, systematic reviews (Level 1 evidence, based on the *NHMRC Levels of Evidence and Grades for Recommendations for Developers of Guidelines (2009)*), randomised controlled trials (Level II evidence) were considered for inclusion, crossing intervention and diagnostic domains. Where there was a scarcity of Level I or Level II evidence, it was planned to expand the review to consider lower levels of evidence. Studies were limited to English language only.

Types of participants

The review included research conducted in adults without pre-existing CVD or in those with and without CVD but where those without CVD were reported separately.

Types of outcomes

In principle, the primary outcome for each question was cardiovascular events (definition for CVD as for the *Guidelines for the Assessment of Absolute Cardiovascular Disease Risk*).

The secondary outcome of interest was AR reduction, followed by surrogate outcomes such as individual risk factor reduction as specified in the questions (e.g. BP control).

3.2 Search strategy for identification of studies

A broad search strategy using the following databases and sources was used to identify potential studies:

- Medline
- Embase
- Cinahl
- PsychINFO
- Cochrane Library, including CENTRAL Cochrane Controlled Trial Register (CCTR) and DARE for some topics.

In addition, the following websites were searched including Australian Centre for Clinical Effectiveness, National Institute for Health and Clinical Excellence, National Library for Health, Swedish Council on Technology Assessment in Healthcare, US Agency for Healthcare Research and Quality, and the US National Guidelines Clearing House. The EWG were sent interim search reports and asked to identify any additional studies.

Hand searching undertaken after the online database searching included the following journals: *British Medical Journal*, *New England Journal of Medicine*, *LANCET*, *Circulation*, *Journal of the American Medical Association*, *Archives of Internal Medicine*, *Medical Journal of Australia* and *Diabetes Care*.

The Cochrane library was also reviewed to incorporate new or updated reviews. Hand searching was undertaken to identify major meta-analyses or landmark trials to maximise the currency of the text. In one situation, literature identified after the comprehensive literature review period was deemed by the EWG to be sufficiently important to result in a change to the recommendations (i.e. BP targets for those with CKD). This decision took into consideration the quality of evidence (all high-quality meta-analyses), the need to provide clinicians with the most useful recommendation, alignment to draft international CKD guidelines, and the likely scenario that the current guidelines could be out of date before they were published.

In addition to the initial searches, economic literature was searched via EBSCOhost database (Econlit & CINAHL), Ovid database (EMBASE, Medline), BioMed central and Cochrane library database (Health Technology Assessment, NHS Economic Evaluation). A broad search strategy of Australian and international literature (developed countries including European, North American and Canadian) for the years 2002–2010 was used. The cut-off dates build on the SIGN guidelines used during the systematic review phase.

Search terms

Search terms were used for each group of clinical questions/topics. Search terms were based on those reported in the Supplementary Guidelines Material (SIGN) where the first series of strings are disease/population identifiers and the additional strings relate to the specific question, i.e. intervention (e.g. alcohol and euphemisms). Search strategies used in other databases were adjusted for different databases, but were substantially the same. Searches were combined with guidelines, systematic review, and trial filters as appropriate.

3.3 Study selection

One reviewer assessed the titles and available abstracts of all studies identified by the initial broad searches (based on population and intervention) and excluded any clearly irrelevant studies. Two reviewers then independently assessed papers identified as potentially eligible studies using the inclusion criteria and resolved disagreements on inclusion by consensus, with reference to a third reviewer if necessary. This second phase thus focused on selection of studies based on the outcomes, treatment comparisons and any population subgroups (e.g. diabetes, CKD) which may have different effects of an intervention.

Hand searching identified 44 potential new trials or meta-analyses of which 9 were included in the final guidelines. During finalising of the guidelines two further meta-analyses on BP treatment in those with diabetes were identified and included.

Search terms used in the economic literature review were essentially the same for each database. A broad population identifier (CVD or cardiovascular disease OR coronary disease OR heart attack OR stroke) was used followed by the following terms: Exp “cost and cost analysis”; Costs. ti/ab; Cost effective\$.ti/ab; Cost benefit analys\$.ti/ab; Exp health care costs/; (economic adj2 evaluat\$).ti/ab; and finally primary prevention. Additional snowballing searches were undertaken. The total number of hits was 204 of which 28 were considered in more detail by one member of the project team. Reviewing staff at Deakin University scrutinised the 16 abstracts for omissions and 9 additional appropriate papers were retrieved and reviewed.

The following criteria were used to select economic studies:

- overseas evidence in developed countries of Europe, UK, North America, Canada
- AR of cardiovascular disease criteria
- primary prevention population included has no previous history of CVD
- BP-lowering diuretics, beta blockers, CCBs, ACE inhibitors
- cholesterol-lowering medications statins
- antiplatelets (aspirin)
- adults 35–84
- health outcome measured in Disability Adjusted Life Years (DALYs) or QALYs.

3.4 Search results

Questions 1-5: Absolute risk assessment				
	Dates	Total hits	Retrieval list	Included
Sources: Databases: Medline; Embase; Cinahl; PsychINFO; Cochrane Library, including CENTRAL Cochrane Controlled Trial Register (CCTR) Other sources: See protocol for details of guidelines and internet sites; pearling; EWG.	2006-2010	287	31+3+5	15
Search terms: as per Assessment guidelines then adapted	CVD or cardiovascular disease OR coronary disease OR heart attack OR stroke; AR assessment OR Global risk assessment OR Multivariate risk assessment OR Framingham OR PROCAM			
Outcomes:	Measures of predictive accuracy; odds ratios, relative risk and risk of observed CVD events (including CVD mortality, MI, CHD, stroke, and peripheral vascular disease).			
Questions 6–8: Aims of treatment, monitoring and follow-up				
	Dates	Total hits	Retrieval list	Included
Sources a/a	2002-2010	138	31	(Q6) 18 (Q7) and 8) 13
Search Terms:	Multiple intervention, single intervention/treatment, monitor, cardiovascular, primary prevention, risk factors, compliance, adherence, AR, side effects.			
Outcomes:	Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral vascular disease), all case mortality Secondary (Q7 only): AR levels, Individual risk factor levels, Side effects, Compliance with treatment.			
Questions 9-13:Blood pressure				
	Dates	Total hits	Retrieval list	Included
Sources a/a	2002-2010	3090	42+4	21
Search Terms:	Blood Pressure; Antihypertensive Agents; Adrenergic beta-antagonists; DIURETICS; Angiotensin-Converting Enzyme Inhibitors Receptors, Angiotensin; Angiotensin II Type 1 Receptor Blockers, Calcium Channel Blockers; lower\$ adj2 blood pressure\$; centrally acting agents; alpha blockers.			
Outcomes:	Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral vascular disease), all case mortality Secondary (Q10 only): BP changes, microvascular complications (particularly for those with diabetes and/or CKD)			
Questions 14-17:Lipids				
	Dates	Total hits	Retrieval list	Included
Sources a/a	2002-2010	413 + 64	49	26

Search Terms:	antilipemic agent; hypocholesterolemic agent\$. lipid\$ adj2 (low\$ or depress\$) lipid modifying drugs; Dislipidaemia; Statins; HMGCoA inhibitors; familial hypercholesterolemia Added: HMGCoA Reductase; Inhibitors, Simvastatin, Clofibrate, Procetafen, Bezafibrate, Niacin, Azetidienes, Colesevelam, Fibrate, Fenofibrate, Nicotinic Acid, Ezetimibe, Anticholesterolemic agent, Omega-3 fatty acids, Bioacids			
Outcomes:	Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral vascular disease), all case mortality Secondary (Q15 only): lipid changes			
Q18-19: Antiplatelets				
	Dates	Total hits	Retrieval list	Included
Sources a/a	2002-2010	1761	85	16
Search Terms:	Aspirin; Platelet Aggregation Inhibitors; Clopidogrel; dipyridamole; acetylsalicylic acid; antiplatelet; Warfarin; Antithrombotic agents; Thrombin inhibitors; Thrombin receptor antagonists; Heparinoids			
Outcomes:	Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral vascular disease), all case mortality Secondary: Bleeding complications			
Q20: Obesity				
	Dates	Total hits	Retrieval list	Included
Sources a/a	2002-2010	321	61	4
Search Terms:	Weight loss; weight reduction; reducing weight; Bariatric surgery; antiobesity medications; behavioural therapy			
Outcomes:	Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral vascular disease), all case mortality Secondary: Bleeding complications			
Q21: Diet and Nutrition				
	Dates	Total hits	Retrieval list	Included
Sources a/a	2002-2010	1626	32+16	18
Search Terms:	Diet;Intervention; Advice; Lifestyle; Sodium chloride/salt; Saturated fats; Antioxidants; Omega-3 fatty acids; Soy protein; Glycaemic index or load; Vegetables; Phytosterols, sterols, stanols; Nuts; Low carbohydrate; Low fat; High protein; Weight loss/ energy restriction; Fibre pectin; soluble fibre; Trans fats			
Outcomes:	Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral vascular disease), all case mortality Secondary: Blood pressure, Lipid parameters, Diabetes			
Q22-23: Physical Activity				
	Dates	Total hits	Retrieval list	Included
Sources a/a	2002-2010	1211	103+2	17
Search Terms:	Exercise; sports; physical education and training; exertion; physical\$ adj2 Fit; physical\$ adj2 fitness; physical adj2 train\$; physical adj2 activit\$; train\$ adj2 strength\$; train\$ adj2 aerobic\$; aerobic\$ adj2 exercise\$; exercise\$ adj2 train\$; Added <i>FITNESS</i> adj (<i>Train\$ or program\$</i>); Resistance training.			

Outcomes:	Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral vascular disease), all case mortality Secondary (Q23): Blood pressure, Lipid parameters			
Q24: Alcohol				
	Dates	Total hits	Retrieval list	Included
Sources a/a	2002-2010	139	76	13
Search Terms:	Alcohol Drinking; Alcohol drinking quantity; Alcohol drinking pattern; ALCOHOLIC BEVERAGES; BEER; WINE; alcohol; spirits			
Outcomes:	Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral vascular disease), all case mortality Secondary: Blood pressure, Lipid parameters			
Q25: Smoking				
	Dates	Total hits	Retrieval list	Included
Sources a/a	2002-2010	417	79	1
Search Terms:	Smoking Cessation; "TOBACCO USE DISORDER" ; TOBACCO; NICOTINE;Tobacco, Smokeless; SMOKING; (quit\$ or stop\$ or ceas\$ or giv\$) adj2 smoking;TOBACCO; SMOKE POLLUTION; Second hand smoking; Passive smoking			
Outcomes:	Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral vascular disease), all case mortality			
Q26 – Depression				
	Dates	Total hits	Retrieval list	Included
Sources a/a	2002-2010	1178	22	0
Search Terms:	Depressive disorder; Dysthymic disorder; depression/ depression, involuntal/ depression, postpartum/; Seasonal affective disorder; Major depressive disorder; Treatment pharmacological or other; Screening for depression			
Outcomes:	Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral vascular disease), all case mortality			

4. Evidence tables

Data from included studies was abstracted along with a methodological appraisal (see below). This included information including citation, study type, evidence level (as per *NHMRC Levels of Evidence and Grades for Recommendations for Developers of Guidelines (2009)* patient number and characteristics, intervention/s, comparison, length of follow-up, outcome measure, effect size and funding source (as appropriate).

Methodological quality assessment

Two reviewers independently assessed the methodological quality of each included trial and resolved disagreements by consensus, with reference to a third reviewer if necessary. Methodological quality of existing guidelines was assessed using the Appraisal of Guidelines Research and Evaluation Collaboration (AGREE) *Agree instrument*. Methodological quality of included systematic reviews and controlled trials was assessed using a modified checklist based on the Scottish Intercollegiate Guidelines Network (SIGN) *Methodology checklist for systematic reviews and meta-analyses* and the Guidelines International Network draft

evidence tables. These checklists were developed and used previously by the NSF. Methodological quality of included cohort studies was assessed using the SIGN *Methodology checklist for cohort studies*. For diagnostic studies identified, the SIGN *Methodological checklist for diagnostic studies* was used.

5. Formulation of recommendations

To assist in the formulation of recommendations, where a body of evidence exists for each question, the NHMRC *Grades* process has been applied. This has resulted in an Evidence Statement for each question. The project team including the chair of the EWG, along with input of individual members of the EWG or corresponding group, used these statements and the underlying evidence to draft recommendations. The draft recommendations along with the summary matrices were initially discussed by the EWG at a face-to-face meeting of the working group on 7 September 2010. In addition to the summary matrices, economic modelling on the cost benefit of various drug therapies was commissioned and used to inform the development of the recommendations. Subsequent meetings via teleconferences were undertaken followed by a modified Delphi process (over two rounds) to achieve consensus (defined as >75% of responses from EWG) of the final wording of the recommendations. The recommended grading matrix was used to guide the strength of the recommendation.

5.1 Link between research and recommendations following an absolute risk approach

These guidelines take an AR approach to the management of CVD risk which has posed some challenges in formulation of the recommendations. This is because although there is robust and compelling evidence in the published literature which clearly shows that pharmacotherapy reduces the levels of individual risk factors (blood pressure and lipids) with consequent reduction in CVD mortality or CVD events, this evidence is based on a single risk factor/relative risk approach. Therefore the expert panel carefully considered the literature before making and grading the recommendations in an AR paradigm. When examining the evidence, consideration was given to any heterogeneity found between subgroups and the generalisability of the findings. The final grading of these recommendations was downgraded to account for the uncertainty of applying evidence from a relative risk approach to an AR paradigm.

Reporting of study results

Study results have been reported in the text of these guidelines in the same form as reported in the research i.e. where relative risk reduction has been the measure used in the study, the results are reported using this term and have not been converted to AR reduction.

5.2 NHMRC grade of recommendation matrix: evidence-based recommendations

Grade of recommendation	Description
A	Body of evidence can be trusted to guide practice
B	Body of evidence can be trusted to guide practice in most situations
C	Body of evidence provides some support for recommendation but care should be taken in its application
D	Body of evidence is weak and recommendation must be applied with caution

Matrix reproduced from NHMRC *Levels of Evidence and Grades for Recommendations for Developers of Guidelines* (2009)

Additional guidance

Where no robust evidence was found for the search questions, the EWG followed the consensus process to develop consensus-based recommendations. Practice points were provided to give practical guidance to facilitate the implementation of the guidelines.

5.3 Guidelines text

The body of the text was drafted by a consultant medical writer (medScript) based on an agreed framework. Early drafts were circulated for input from the EWG and finalised by the project team for public consultation.

CBR	Consensus-based recommendations: developed by the guidelines expert working group when a systematic review of the evidence found either an absence of direct evidence which answered the clinical question or poor quality evidence, which was deemed not to be strong enough to formulate an evidence-based recommendation.
PP	Practice points: developed by the guidelines expert working group where a systematic review had not been conducted but there was a need to provide practical guidance to support the implementation of the evidence-based and/or consensus-based recommendations.

6. Consultation

6.1 Correlation with the draft *National Evidence-Based Guideline on Secondary Prevention of Vascular Disease in type 2 diabetes*

These guidelines were developed at the same time as the National Evidence-Based Guideline on Secondary Prevention of Vascular Disease in type 2 diabetes (currently being drafted). The two groups consulted extensively to ensure that the two guidelines provided a consistent continuum of care for patients (including cross representation on each advisory committee). As far as possible, given the evidence available for the different populations, the guidelines are consistent. Where there are differences in the grading of recommendations, this is due to the difference in evidence for the two populations.

6.2 Public Consultation

In line with the requirement under Section 14A of the National Health and Medical Research Council Act 1992, the public consultation process invited feedback during a month-long period in April 2011 and included an advertisement in the press inviting public comment. In addition, a notice of the opportunity for comment was posted on the websites of NVDPA member organisations and copies of the guidelines were distributed to a broad group of identified stakeholders and networks. Consumer organisations were also contacted for comment. Finally, the draft document was circulated via the networks of the various experts supporting the project. Five prompted questions, modified from key questions included in the Guidelines Implementability Tool, were also included in the consultation feedback form to provide general feedback.

Overall there were 388 individual comments received from 24 individuals and 19 organisations (including key organisations such as the Royal Australian College of General Practitioners, Stroke Society of Australasia, state health departments, Australian General Practice Network and the Cardiac Society of Australia and New Zealand). Public consultation resulted in many detailed responses, including many positive comments.

The major contentious issues and changes made in response to the public consultation are outlined below:

6.3 Contentious issues and responses

Issue	Response
BP treatment thresholds Concerns were raised by a number of individuals and organisations regarding the lack of a BP treatment for the low AR group. Suggestions were made to use the 160/100 mmHg threshold as had been recommended for the moderate-risk group.	The EWG agreed that pharmacotherapy for low risk adults is generally not appropriate taking an AR approach. However, it was agreed that a BP $\geq 160/100$ mmHg should be treated with pharmacotherapy, both for the CVD risk and to prevent non-CVD complications such as heart failure and renal failure, therefore, a recommendation has been included to treat adults at low CVD risk who have persistent BP $\geq 160/100$ mmHg with BP-lowering pharmacotherapy in addition to lifestyle intervention.
Assessment for under 45s and over 75s Concerns were raised about imputing age 30 and using FRE as this will overestimate risk. Similarly concern that imputing 74 will underestimate risk in the over 74 age group.	The EWG balanced the lack of strong evidence supporting CVD risk assessment for people aged under 45 with the need to provide some guidance for General Practitioners. The EWG therefore agreed that recommendations would not be made for CVD risk assessment of the under 45 year old age group (35 for A&TSI peoples). The text has been modified to remove the recommendations for risk assessment of younger people and to include some broad guidance on ensuring that people in this age group who have a strong family history of CVD or single, isolated, elevated risk factors are appropriately managed. The text was modified for the older age group to clarify that FRE is used to ensure that age is not the only consideration when assessing risk in this age group.
Moderate risk treatment Lack of clarity about this recommendation.	Recommendation has been divided into two recommendations to clarify the meaning.
Lipids Queries arose regarding interpretation of the evidence especially for low-risk populations.	References have been reviewed and text modified to ensure that primary and secondary prevention evidence is appropriately identified. Evidence was also updated with recent meta-analyses.
Monitoring Lack of clarity about whether AR is used to monitor progress of treatment or whether treatment is monitored by individual risk factors.	Text inserted to explain that AR is the entry point for treatment and treatment decisions are made on the basis of risk level, but treatment response is monitored by measurement of multiple individual risk factors.

7. Strategy for updating the guidelines

The guidelines will need to be updated no later than five years after being published (i.e. by 2016/7). However, given the current national reform activity around guidelines and standards no decision has been made regarding the strategy to review the currency of the guidelines and any method of updating the guidelines. These decisions will be made by the NVDPA in consultation with the NHMRC and other bodies (e.g. The Australian Commission on Safety and Quality in Health Care).

8. Implementation considerations

8.1 Background

The NVDPA’s new *Guidelines for the Management of Absolute Cardiovascular Disease Risk* is an important step along the path to improved prevention of CVD in Australia. Of greater importance is the dissemination and application in practice. Like the guidelines themselves, implementation strategies should use an evidence-based approach based on an underlying framework for CVD prevention. In addition to the various NVDPA guideline development groups, establishment of this plan was enhanced by obtaining structured feedback at a meeting of key stakeholders (46 government, non-government, consumer and professional organisation representatives) on 3 March 2011. This meeting was called to specifically address implementation considerations from a broad range of perspectives.

8.2 Strategic framework

These guidelines are one important part of a coordinated strategic framework for improving CVD prevention in Australia. This framework includes activities at an individual


and population level to raise awareness of CVD risk, assess risk and manage risk to prevent CVD as outlined in diagram 8.2. These guidelines focus only on comprehensive risk assessment and management aimed at primary prevention of CVD. Therefore, the guidelines and implementation strategies should not be considered as a standalone process but need to be linked to other important strategies both at an individual and population level to maximise their impact.

8.3 Levels to consider when implementing guidelines

Local factors operate over several different levels; all need to be considered to maximise the effect of guidelines. These levels are broadly described into four main categories: professional, organisational, consumers and regulatory/ financial. Strategies to address barriers identified at each of these levels need to be developed. Strategies that enhance enabling factors should also be created. These are briefly described below:

- 1. Professional level: strategies supporting health professionals to adopt recommendations in the guidelines. Strategies include:

Diagram 8.2 Strategic framework of CVD prevention



Adapted from “Putting prevention first,” Department of Health (England) 2008

- a. dissemination/distribution of the guidelines
 - b. education and training
 - c. audit and feedback, reminders or decision support tools
 - d. use of local consensus processes.
2. Organisational level: strategies supporting organisational change to facilitate adoption of the guidelines. Such strategies may include quality improvement systems, accreditation processes, adoption of policies and protocols.
 3. Consumer level: strategies supporting behaviour change among consumers in relation to the guidelines.
 4. Regulatory or financial level: strategies targeting regulatory systems to support change at all levels. This may include change in reimbursement items for GPs, incentives, approval and cost of medicines.

8.4 Evidence-based implementation of clinical guidelines

Several systematic reviews of evidence for guidelines implementation have been undertaken.³²¹⁻³²⁹ While most strategies have been found to lead to small to moderate improvement (e.g. 5–10%) there is no simple or single strategy that will apply in all settings.³²⁶ However methodological weaknesses and poor reporting of the study setting and uncertainty about the generalisability of the results limit the strength of the conclusions.³²⁶

It is suggested that strategies to implement the guidelines will be most effective where a concrete plan is developed that tailors specific strategies based on an analysis of local factors necessary for clinical behaviour change.³²¹ Such factors include assessment of both the barriers and enablers to achieving the recommendations in the clinical guidelines.³²¹ More than one approach is often needed to overcome barriers because these occur at different operational levels within the health system. These levels are discussed above.

Evidence (generally focused on changes at the professional level) from recent systematic reviews indicates:

- audit and feedback produce small to modest improvements in adherence to evidence-based care from a large number of wide ranging studies.³²⁷ However, quality-improvement activities often use a multifaceted strategy such as educational meetings, reminders, printed material or opinion leaders with or without audit and feedback^{326,}

³²⁷

- educational meetings alone are not likely to be effective for changing complex behaviours but can be effective if used with other interventions³²⁴
- inter-professional collaboration (collaboration between professionals within and across locations) may have a positive effect in patient outcomes³²⁹
- interventions tailored to identified barriers (for example, through interactive group work) are more likely to improve professional practice than no intervention or dissemination of guidelines alone³²¹
- printed education materials may have some benefits compared with no material but the effect is unclear compared with other interventions³²³
- local opinion leaders can successfully reduce non-compliance with evidence-based practice³²²
- quality improvement collaboratives may have some benefit, but the evidence for this, although positive, was limited.³²⁸ However, this approach has been successfully utilised by the Australian Primary Care Collaboratives (APCC) to improve best-practice care for diabetes and chronic heart disease in general practice.³³⁰

8.5 Recommended implementation activities

Considering the evidence for guideline implementation, strategies to implement the *Guidelines for the Management of Absolute Cardiovascular Disease Risk* will need to be chosen based on the target audience and level of focus (e.g. professional, organisational, consumer or regulatory/financial level). Each strategy will need to consider potential barriers (or enablers) and be tailored to address identified factors. Some initial examples are provided below.

Consultation with stakeholders and a review of the evidence has led to potential examples of barriers, enablers and possible solutions for each level to be considered when implementing the guidelines.

Professional level

Potential barriers

- Recommendations between different guidelines may be inconsistent, as well as guidelines presented as discrete publications
- Guidelines need to be adopted by multiple stakeholders, all of whom may have different roles to play in their implementation
- Change in clinical practice requires adopting new principles and beliefs about risk assessment and management (e.g. not treating individuals at low AR, moving away from treatment based on single risk factor targets, use of the Framingham Risk Equation, etc.)
- Education on a relative risk approach may continue for some time through other agencies
- Different descriptions/definitions of risk
- Evidence base for interventions taking an AR approach
- Health professionals (particularly GPs) have little time and heavy workloads
- Workforce shortage of allied health professionals may create issues for appropriate referral
- Training (at post graduate and undergraduate level): different curricula for different health professionals, messages from curriculum and supervisors may be inconsistent
- Relevant CVD risk data not currently integrated into medical software used in primary care
- Concept of lifestyle prescription still vague amongst health professionals and consumers
- Limited evaluation of 'Lifescrpts' program

Potential enablers

- APCC network and systems
- IT platforms used in most primary care settings
- Health reform including Medicare Locals, performance reporting and role of the Australian Commission on Safety and Quality in Health Care in implementation of guidelines and setting national clinical standards
- Pressure of colleagues and system
- Local champions, e.g. proposed lead clinicians groups
- Clinical and professional association networks
- Proposed expansion of practice nurse/allied health professionals roles in management of patients

Potential activities at professional level

Dissemination: Ensure broad access to information regarding new guidelines

Target audience

GPs
Practice nurses
Health care professionals
Medical specialists
Clinical networks Primary health care organisations (PHCOs)
Medicare Locals
Aboriginal Health Workers and similar Health Professional Associations
Emergency departments (especially rural)

- Publication in a variety of sources/formats:
 - o summaries in medical journals
 - o summaries drawing various, related guidelines together
 - o use websites and NHMRC Clinical Practice Guidelines Portal
 - o develop and distribute concise and/or integrated summaries
 - o distribute via endorsing organisations, clinical networks and other existing networks
 - o promote heavily on launch via media and PR
 - o electronic dissemination and inclusion in medical software (see below)
- Presentations and educational activities (see below)
- Ensure alignment and inclusion in other guidelines, e.g. Red Book, CARPA Manual
- Use of existing industry representatives where appropriate

Education: individuals, groups: Move practice from relative risk to AR approach

Target audience

GPs
Practice Nurses
Health care professionals
Specialists
Emergency departments
Undergraduate and post graduate course coordinators for all health professionals

- Education resources developed and promoted e.g. algorithms (important to develop separate resources and education for indigenous population)
- Professional development. Use of key opinion leaders in educational activities:
 - o workshops (face to face)
 - o online educational activities
 - o conference presentations
 - o education outreach to individual practices
- Use existing programs, e.g. National Prescribing Service (NPS) education program, RACGP
- Link to CPD points for all relevant activities and disciplines
- Pathways (e.g. Practice protocols for GP clinics/Indigenous health providers/emergency departments to develop roles for each health professional, i.e. practice nurses, allied health in addition to GP)
- Up-skill other people, e.g. practice nurses
- Regular reminders about available programs to referring practitioners for management
- Work with undergraduate and post-graduate education providers (all relevant disciplines) to include in curriculum and communicate out to supervisors
- Use of existing industry representatives where appropriate

Reminders or clinical decision support tools (CDST): Support practice of AR

Target audience

Primary

Medical software industry (e.g. PEN), RACGP

Secondary

GPs, Practice nurses, specialists

- Integrate recommendations into current systems (including automatic calculation of risk)
- Integrate guidelines with other guidelines in CDST and with clinical history
- Link with audit and feedback tools
- Ensure inclusion of mechanisms to prompt management action and recall so practice IT systems can be used to send reminder letters to patients for assessment
- Resources developed and promoted, e.g. algorithms
- Consolidation of referral databases to lifestyle management programmes

Audit and feedback: Highlight current practice and actions for improvement

Target audience

GPs

Practice Nurses

Practice Managers

Health care professionals

Specialists

- Build on current work to establish systems to audit clinical data to determine adherence to recommendations (including benchmarking)
- Build capacity for easily developed reports on performance at practice and individual level.
- Involvement in primary care collaborative and QI activities
- Link feedback with other strategies for education such as key opinion leaders
- Publications, conference presentations.

Local consensus processes: Inclusion of participating providers in discussion to ensure that they agree that the chosen clinical problem is important and the approach to managing the problem is appropriate

Target audience

GPs

Practice nurses

Specialists

Primary health care organisations (PHCOs)

Health care professionals

- Involvement in primary care collaborative and QI activities
- Supported discussions at local level to develop consensus
- Solutions to improve systems for QI (see organisational level solutions)
- Use existing programs and clinical and association networks.

Consumer level

Potential barriers

- Concept of risk (particularly AR) is complex and difficult to explain
- Behaviour change recommended in guidelines often difficult to maintain (particularly lifestyle and maintaining medications over time)
- Consumers often at GP for reasons other than a risk assessment
- Consumers may receive too much information and material that is too complex
- Concept of lifestyle prescription still vague amongst health professionals and consumers
- Social, geographical and cultural barriers to access to services (particularly A&TSI communities and those in remote settings)

Potential enablers

- Health reform establishing new agencies that may support implementation (e.g. National Prevention Agency and its social marketing activities)
- Other agencies developing information for consumers that may send common messages (e.g. RACGP Red Book, CARPA Manual, NPS fact sheets)
- Community networks e.g. NACCHO and its state organisations

Potential activities at consumer level

Education or systems to involve consumers: Improves awareness, engagement and adherence to management

Target audience

General population >45 years old (> 35 years if A&TSI population)

Consumer Health Forum, relevant peak and professional bodies who are involved in producing information for consumers

- Develop online and printed educational materials for consumers including simple explanations of risk
- Support inclusion of common consumer messages in communication channels of other agencies and websites (e.g. Consumers Health Forum, NACCHO, Better Health channel, RACGP Red Book, NPS, etc.)
- Campaigns educating people of CVD risk, and need for risk assessments
- Include consumers in development of material and develop in line with standard health literacy levels and also consider Indigenous and Culturally and Linguistically Diverse (CALD) backgrounds
- Develop online consumer tools aimed at prompting discussion with GP
- Develop evidence-based tools health professionals can use to demonstrate risk and how it will change over time and through modification of risk factors.

Organisational level

Potential barriers

- Data for quality improvement, and to support decision making is not integrated into clinical software
- Uncertainty around data integrity and validity
- Time required to record and analyse data and plan quality improvement activities
- Geographical barriers in rural and remote services (limited access to adequate staffing and equipment)
- Other agencies may promote data based on relative risk approach

Potential enablers

- Practices already undertaking QI activities
- RACGP developing primary care audit activities
- Health reform including Medicare Locals, performance reporting and role of the Australian Commission on Safety and Quality in Health Care in implementation of guidelines and setting national clinical standards
- Existing 'Lifescrpts' program and diabetes lifestyle programs
- Electronic health records activity

Potential activities at organisational level

Systems to focus on quality improvement: Improves access to quality improvement systems

Partners

RACGP

Australian College of Rural and Remote Medicine (ACRRM)

APCC

- Develop nationally agreed performance indicators related to CVD risk reduction
- Improve data collection systems and develop mechanisms to interrogate data and feedback areas for improvement to practices (and other areas such as CVD and related disease admissions)
- Integrate tools and data into medical software
- Continue to promote practice support programs focusing on IT and data collection
- Consider more intense QI programs which offer practice visits to analyse data broadly, provide feedback and identify gaps that can drive quality improvement
- Information targeted especially to users: GP vs. practice nurse vs. Aboriginal health workers
- Link other strategies at professional level (e.g. feedback and education)
- Advertise/encourage practices to become involved in APCC around CVD prevention
- Reallocate roles or add workforce to focus on implementing guidelines
- Introduction of technology, e.g. electronic transmission of ECG and echocardiography from regional to metropolitan centres
- Change organisational structure and processes designed to improve implementation (e.g. new GP super clinic, or Medicare Locals)
- Make sure strong input from key opinion leaders (including proposed Lead Clinicians Groups and other existing clinical governance bodies)

Regulatory/ financial level

Potential barriers

- Concerns about the potential costs of guideline recommendations
- Potential disconnect between current reimbursement for PBS items and new recommendations
- Current Medicare Benefits Schedule (MBS) policy does not support practice recommended in guidelines
- Limitations of other government policies e.g. Enhanced Primary Care limit of five annual visits prevents people from receiving a range of specialist care

Potential enablers

- Home medicines review program
- New preventative health agenda
- Current additional supports in MBS and Pharmaceutical Benefits Scheme (PBS) for Indigenous and Torres Strait Islander peoples
- Current MBS review
- Electronic health records activity
- Development of Medicare Locals
- Accreditation activities

Potential activities at regulatory/financial level

Policy change: System change to support practice of AR

Partners

Australian Government Department of Health and Ageing (MBS, PBS, Preventive Health Agency)

APCC

NHMRC, Commission on Safety and Quality

NPS

- Undertake economic modelling around guideline implementation to provide evidence for policy decision making
- Explore the Practice Incentives Program to identify opportunities to support system and practice change
- Review of PBS criteria for medications recommended in the guidelines to ensure consistency
- Policy change to support programs identifying people in the community who may require risk assessment and management
- Review Enhanced Primary Care program to broaden scope and provide incentives for private allied health practices
- Link and integrate policy and programs for related diseases (e.g. vascular, diabetes and kidney)

Appendix 3:

Economic Considerations

This report was prepared by: Anne Magnus, Deakin Health Economics, Strategic Research Centre- Population Health.

Economic evaluation of NVDPA Guidelines for the Management of Absolute Cardiovascular Disease Risk¹⁰

1.0 Introduction

Cardiovascular disease is the most expensive disease group in Australia in terms of annual direct health care costs which have been recently estimated to be more than \$5.2 billion in 2004–05.⁸ Therefore, providing cost-effective cardiovascular disease prevention, management and treatment is important to avoid unnecessary costs to society. This report presents a review of the cost-effectiveness literature on evidence-based CVD prevention with pharmacotherapy. A systematic review was conducted as part of the guidelines process (see Appendix 2, Guidelines development process report for search strategy). As the breadth of pharmaceuticals under study was wide (incorporating BP-lowering, cholesterol-lowering agents, aspirin and combinations of the same) and the methods used quite disparate, a narrative review was deemed the most appropriate way to summarise the cost-effectiveness evidence. The literature was firstly assessed for internal validity of each paper and secondly assessed for its generalisability to the Australian context.

The need to review the cost-effectiveness literature occurs because, although a newly proposed strategy may be more clinically effective than the comparator, it may also cost more to achieve additional health benefits. Or the reverse situation can occur, where the proposed strategy is less clinically effective but costs less to achieve its benefits. In an ideal setting, the proposed strategy would yield both more benefits and cost less than the current strategy, i.e. it would dominate current practice by saving more health and saving dollars. The most efficient strategy is the one with the lowest incremental cost-effectiveness ratio (ICER). The strategy with the lowest ICER is not necessarily the one with the most total health benefits or the one with the least total

expenditure. What constitutes a cost-effective intervention is a value judgment and is not the only policy objective used in the evaluation of proposed changes in the health sector, as more expensive treatments may be considered necessary on the basis of value judgements. In previous Australian policy decisions, \$30,000–50,000 per QALY saved has been considered to represent value-for-money from the perspective of the health sector.³³¹

2.0 Aim of the guidelines

The aim of the *Guidelines for Management of Absolute CVD Risk* project is to develop high-quality clinical guidelines and resources for management of CVD risk using an absolute risk approach in adults aged over 45 years (35 for Aboriginal and Torres Strait Islander peoples) with no previous history of CVD.

The Guidelines for Management of Absolute CVD Risk make recommendations that relate to the use of medications listed on the PBS. The development process has included an economic assessment of the cost-effectiveness of initiation and on-going use of CVD preventive drug therapy (including BP-lowering medications, cholesterol-lowering medications and potentially antiplatelets) by AR criteria and a comparison of this approach with the impact and costs currently incurred by the health system around the use of these medications. Current practice in Australia is not easy to describe in detail, but is informed by the previously existing individual risk factor management guidelines, such as those for management of hypertension and lipid levels. Limited survey data of current prescribing patterns in Australia reflect departures from the perfect adoption of the existing individual risk factor management guidelines.

2.1 Economic question within the proposed guidelines

Is the AR approach to prevention of CVD in adults aged over 45 years (35 for Aboriginal and Torres Strait Islander peoples) with no history of CVD, more cost-effective than current practice from a health sector perspective, considering lifetime costs and benefits of pharmacotherapy which includes BP-lowering medications, cholesterol lowering statins and antiplatelets?

2.2 The economic framework of the literature review

The objective of this review was to answer the economic research question by reference to the available literature. This required estimating the additional direct health sector cost per additional unit of effect gained, measured in life years adjusted for quality, using a robust, consistent and standard method.

3.0 Steps in the economic evaluation

The internal validity of the studies for each class of drug was undertaken for each drug separately and in combinations, since this more closely approximated the recommendations of the guidelines. Studies which examined the drugs in comparison to placebo were excluded as the objective was not to assess the cost-effectiveness of these drugs compared to doing nothing, but rather to compare to current practice or some other consideration of patient risk profile.

3.1 Evaluation of internal validity

Using a well-respected strategy proposed by Drummond,³³² the following items were used to critically appraise the economic literature for internal validity:

- Was the study question well defined?
- Were appropriate health care options chosen and clearly described?
- Was the effectiveness of the health care options established?
- Were all the relevant costs and consequences identified for each health care option?
- Were costs and consequences measured accurately?
- Were costs and consequences valued credibly?
- Was differential timing considered?
- Was incremental analysis performed?

- Was a sensitivity analysis performed?
- Were all issues of concern presented with results?

3.2 Evaluation of external validity and generalisability to the Australian situation

Once the evidence from the literature was gathered, each of the major components of an economic evaluation (i.e. clinical, economic, epidemiological, health care patterns, treatment comparators) was verified versus Australian conditions before a study's results were deemed potentially transferable. To this end the patient group, the health system, the prevention strategy options, the incremental costs and benefits, and other factors relating to these particular guidelines were considered.

4 Internal Validity

4.1 Single use of drugs

a) Aspirin

Selection of studies

Five studies examined the cost-effectiveness of aspirin for single use in the prevention of CVD.³³³⁻³³⁷ Since it is an inexpensive drug, even the small health benefits reported in various meta-analyses noted within these guidelines would yield a favourable cost-effectiveness ratio. However, the absolute benefit of aspirin in addition to other effective pharmacotherapy (to lower BP or lipids) is unclear, while underpowered recent evidence³³⁸ raises questions of the health benefits at the risk of important side effects, therefore its use for primary prevention has not been recommended in these guidelines. For this reason no further evaluation of the cost effectiveness of aspirin has been included.

b) Lipid-lowering pharmacotherapy

Selection of studies

Five studies examined the cost-effectiveness of statins for single use in the prevention of CVD.^{211, 225, 339-341} Gumbs *et al*³⁴² was a systematic review of older cost-effectiveness literature and Pilote *et al*³³⁹ a cost outcome study with subgroup analysis, so was of limited relevance to this review. The remaining four studies were all evaluations using Markov models (two set in the US and two in the UK), comparing single use of a statin with either current practice or no statin use (an ambiguous comparator situation that may include the use of other drugs). The schARR models^{211, 225} relating to the UK health system were the best examples of model

design and economic evaluation, giving consideration to all important elements of model design, validation and cost-effectiveness assessment that others have excluded, e.g. much sensitivity analysis and consideration of comparators, discount rates and compliance issues therefore were included in the analysis.

Statins

Ward *et al*²¹¹ estimated the discounted cost per QALY estimates for primary prevention using statins (as a drug class) at the age of 45 ranged between £9,500 and £30,500 for men and women as annual CHD risk levels ranged from 3% to 0.5%. By the age of 85 years the corresponding values were £36,800 and £110,600. In the UK setting the value for money threshold is usually considered to be between £20,000 to £30,000 per QALY, making these drugs cost effective for the younger age groups. Ward *et al*²¹¹ particularly highlight greater uncertainty in the results for young persons, which arose in the modelling due to the requirement to extrapolate benefits well beyond the timeframes of the trials, and particularly so in the case of young people.

The US studies extrapolated trial based efficacy data over a timeframe of 5 –25 years rather than lifetime. Ramsay *et al*³⁴¹ reported a drug company-funded study and concluded that when prescribing atorvastatin compared to no statins, there was a need to give the expensive drug for a long time before it became cost effective. At five years the ICER for atorvastatin was US\$137,000/QALY (i.e. not cost effective) whereas after 25 years the intervention was dominant (i.e. both cost and health saving). While Ramsey *et al* was one of the more relevant studies it used a shorter timeframe for analysis and was silent concerning the impact of compliance with therapy. Pletcher *et al*³⁴⁰ assessed the cost-utility of ATPIII guidelines compared to current practice and concluded that the guidelines would be cost-effective when statin prices were moderate. However Pletcher *et al* included the costs of unrelated future health care events within their analysis, excluded consideration of strokes, and used a shorter time horizon for evaluation of benefits and costs.

Ezetimibe

The other schARR model developed by Ara *et al*²²⁵ evaluated the use of ezetimibe as monotherapy and concluded there was enormous uncertainty around its cost-effectiveness credentials due to the short-term trial periods for establishment of efficacy. There was a wide range of results depending on the treatment strategies compared.

When comparing ezetimibe monotherapy with no treatment in individuals with baseline LDL-C values of 3.0–4.0 mmol/L, the results ranged from £21,000 to £50,000 per QALY (i.e. some treatments were cost effective). Results for individuals with baseline LDL-C values over 5.0 mmol/L were below £30,000 per QALY (i.e. all treatments were cost effective).

c) Blood pressure-lowering pharmacotherapy

Selection of studies

Four studies³⁴³⁻³⁴⁶ were found and examined. Lundkvist *et al*³⁴³ was eliminated because it evaluated placebo as the comparator to BP-lowering treatment. One study related to the US, one to the UK and the remaining study presented ICERs for four European countries. A number of weaknesses appeared in the European study comparison³⁴⁶ including reliance on efficacy results from a small trial (n=59), adoption of the Framingham risk prediction equations developed in the US without calibration to local population events, adoption of the same utility weights for vastly different clinical conditions (MI and angina: stroke and TIA), and non translation of local country costs to a comparable unit. The results of this study, while relevant, were considered of limited use here.

ACE Inhibitors

The US study³⁴⁵ examined the cost effectiveness of ACE inhibitor therapy as first-line BP-lowering therapy compared to conventional BP-lowering therapy with beta blockers or diuretics and presented the ICERs over a lifetime in 40-year-old males only, concluding that the ICERs were unattractively high.

d) Combination pharmacotherapy

Selection of studies

Eleven studies were identified that evaluated various combinations of the drugs of interest to this review. Studies were selected that included aspirin as an element of the intervention or comparator even though it was not evaluated as monotherapy. These combination therapy evaluations were expected to provide more insight into the potential cost-effectiveness of the proposed guidelines, however, issues of internal validity were found, that limited their usefulness. Two were eliminated as they pertained to developing countries³⁴⁷ and Argentina,³⁴⁸ and were outside the scope of this evaluation. Three were eliminated as they were cost-effectiveness studies which measured cost per reduction in BP³⁴⁹ or cardiac event prevented³⁵⁰ or coronary event free life years.³⁵¹ It was necessary to have a common

unit of benefit measurement, which made these studies of limited value without translation into QALYs. No cost offsets were incorporated for cardiac events prevented by the intervention in two studies.^{350, 352} This meant that the costs of all the relevant alternatives had not been included in the analysis. The comparator was either not clearly stated or referred to as 'no intervention' in four studies.³⁵⁰⁻³⁵⁴ As no drug regime was stipulated clearly as comparator, the cost-effectiveness ratios presented in these studies was of limited value. The remaining two studies (Newman *et al* and Ara *et al*) were stronger economic evaluations having none of these aforementioned limitations but they were somewhat limited in scope to either males only³⁵⁵ or the drug ezetimibe,²²⁵ prescribed in addition to statins in patients not achieving adequate lipid control on statins. Newman *et al* did not clearly state the perspective of the analysis, or the timeframe for measurement of costs and benefits which limited interpretation of the results. Ara *et al* considered all the relevant issues for a sound cost-effectiveness study but were limited in their modelling by the paucity of clinical information. Ara *et al* concluded that comparing the costs and benefits of adding ezetimibe to ongoing statin treatment with maintaining statin treatment at the current dose, the lifetime ICERs range from £25,000 to £66,000 per QALY for the primary cohorts.

Another issue of concern was the use of US-based Framingham risk equations to predict CVD events in UK or Europe without calibration to relevant country CVD risk profiles and events. It was also uncommon to find Markov models that have been validated against other source data. There was little discussion of adherence/compliance assumptions stated in the modelling when this can have an impact on both costs and consequences.³⁵⁶ Negative side effects of therapy were not always included in analyses and therefore the impact of these remains unclear.

5.0 External validity

5.1 Patient group

Cardiovascular risk factor profile

In assessing the role of any strategy for primary CVD prevention in Australia it is important to know the number of CVD events that would be prevented in actual practice as that is the number that generates the economic impact. The baseline population risk of an event is determined by the presence of CVD risk factors which include age, elevated BP, cholesterol, BMI, smoking, family history of CHD and diabetes. It is this baseline risk that will be reduced by the relative risk reduction reported in trials conducted either in Australia or elsewhere. In order to produce meaningful comparisons, the Australian population CVD risk factor profile should be the same as the population profile in cost-effectiveness studies and modelling conducted in other countries. This analysis examined age, BP, cholesterol and BMI as CVD risk factors to assess the usefulness of the international cost-effectiveness findings.

Increasing age is a CVD risk factor. There is a higher proportion in the over 65 years category (16.6% and 18.3%) in both the European and UK 2010 populations respectively, than in Australia and the US (13.6% and 14.0% respectively). On this CVD risk factor Australia has a similar risk profile to the US, without giving consideration to gender distribution.

Population age structure, International comparison(a) – at 30 June

	2010				2015(b)			2010-2015		
	Aged 0–14 years	Aged 15–64 years	Aged 65 years and over	Median Age	Aged 0–14 years	Aged 15–64 years	Aged 65 years and over	Median Age	Total fertility rate(c)	Life expectancy(d)
Selected countries	%	%	%	Years	%	%	%	years	rate	years
Australia	18.9	67.5	13.6	36.9	17.6	66.0	16.4	39.9	1.9	82.0
Canada	16.3	69.6	14.1	39.9	15.8	68.2	16.0	40.9	1.6	81.4
China (excl. SARs and Taiwan)	19.9	71.9	8.2	34.2	19.0	71.5	9.4	35.6	1.8	74.0
Hong Kong (SARs of China)	11.5	75.6	12.9	41.9	10.6	74.4	14.9	43.8	1.0	82.8
France	18.4	64.6	17.0	40.1	18.1	62.8	19.1	41.3	1.9	81.9
Greece	14.2	67.5	18.3	41.6	14.1	66.4	19.5	43.3	1.4	80.1
India	30.8	64.3	4.9	25.0	28.7	65.9	5.4	26.5	2.5	65.2
Indonesia	26.7	67.2	6.1	28.2	24.9	68.5	6.6	30.1	2.0	72.2
Italy	14.2	65.4	20.4	43.3	14.0	64.1	21.9	45.1	1.4	81.6
Japan	13.2	64.2	22.6	44.7	12.4	61.3	26.3	46.6	1.3	83.7
Republic of Korea	16.2	72.8	11.0	37.9	14.1	73.0	13.0	40.7	1.3	80.0
Malaysia	29.1	66.1	4.8	26.3	27.2	67.0	5.8	28.0	2.4	75.2
New Zealand	20.2	66.8	13.0	36.6	19.6	65.9	14.5	37.4	2.0	81.0
Papua New Guinea	39.5	58.1	2.5	20.0	37.4	59.8	2.8	20.9	3.8	62.3
Philippines	33.5	62.2	4.3	23.2	31.6	63.6	4.8	24.5	2.9	72.9
Singapore	15.6	74.2	10.2	40.6	12.9	73.6	13.6	43.4	1.3	81.0
South Africa	30.3	65.1	4.6	24.9	29.6	65.1	5.3	25.7	2.4	52.9
Sweden	16.5	65.2	18.3	40.9	17.0	63.0	20.1	41.6	1.9	81.6
United Kingdom	17.4	66.0	16.6	39.9	17.2	64.9	17.9	40.3	1.9	80.1
United States of America	20.2	66.8	13.0	36.6	19.8	65.9	14.3	37.2	2.0	79.9
Vietnam	25.1	68.6	6.3	28.5	23.1	70.3	6.6	30.2	2.0	75.4
World	26.9	65.5	7.6	29.1	26.0	65.8	8.2	30.2	2.5	68.9

(a) Selected countries included major OECD countries, the world's most populous countries, Australia's closest neighbours and trading partners.

(b) International data are United Nations medium variant projections. Australian data are ABS medium series (Series B) projections.

(c) Births per woman. United Nations are medium variant projections for the period 2010–2015.

(d) Life expectancy at birth. United Nations are medium variant projections for the period 2010–2015, for males and females combined.

Source: All international data and Australian total fertility rate and life expectancy figures have been sourced from World Population Prospects, 2008 Revision. Australian 2010 estimates from this publication are from ABS, **Australian Demographic Statistics** (cat. no. 3101.0) and Australian 2015 population projections are from ABS, **Population Projections, Australia 2006 to 2101** (cat. no. 3222.0).

Risk factors of BMI, BP and cholesterol between 1980 and 2008 have been the topic of study in recent Lancet publications.³⁵⁷⁻³⁵⁹ While there are issues concerning availability of nationally representative, measured data, the consistent techniques adopted in these papers were robust and they demonstrated clearly the degree of uncertainty surrounding their estimates.

Differences in BMI are linked to gender, dietary composition, caloric intake, physical activity levels and socioeconomic status. Australia and US³⁵⁹ have higher BMI profiles than parts of Europe so the CVD risk factor profile of Americans is closer to Australians than Europeans, making US evidence more readily generalisable to the Australian population than evidence from the UK or Europe.

Differences in BP across populations are linked to dietary salt, fruit and vegetable intake, lifestyle and use of medications for BP lowering. BP differences within populations are also linked to age and gender. Australasia and the US had the lowest BP in women and BP was lower than European males in 2008. Falling BP trends have been estimated for most regions of the world with the highest falls occurring in Australia and North America³⁵⁷. This would again suggest greater generalisability of US evidence to the Australian population as the CVD risk profile is similar on this risk factor.

Differences in cholesterol across populations are linked to variations in diet, especially consumption of animal-based fat compared to plant-based fats, adiposity and use of cholesterol-lowering medications. No differences between the countries were reported making up the high-income region of North America, Australasia and Western Europe,³⁵⁸ so no conclusion can be drawn concerning the relative generalisability of population CVD risk profiles in international studies to the Australian population. Rather it would appear that cholesterol levels in Australian, US, UK and Europe are sufficiently similar to not be a problem when attempting to generalise conclusions of cost-effectiveness studies conducted in these countries.

Thus the populations of the US and Australia have greater similarity in these major components of CVD risk factor profiles than Europe and UK. Comparisons of clinical impact in cost-effectiveness studies can then be more readily generalised from US studies to Australia.

5.2 Framingham prediction equations

Any application of Framingham CVD prediction equations (developed in the US population), in international studies should be first validated or recalibrated to local population data. This is rarely done and makes the health benefits reported in UK and European studies subject to bias (overestimation or underestimation depending on the risk factor prevalence). When Framingham based predictions are applied in models to US data, the length of time elapsed since the estimation of the equations is also important to consider, since CVD rates have fallen in the US beyond what could be attributed to shifts in risk factors alone.

5.3 Gender-based data

There is limited data from clinical studies in women so greater uncertainty surrounds estimates of cost-effectiveness of any drug therapy in this group.

5.4 Health system setting

Exactly what constitutes service delivery in UK, US Europe and Australia requires consideration of access to services and service offerings. There will be variability in the rates of conducting procedures, the types of staff working/treating in and out of hospital settings. What is considered a health sector cost or health funder cost within these different country settings differs due to system funding structures (i.e. the relative mix of public/private/out of pocket costs). What constitutes 'usual care' or current conventional care will differ between countries and has not necessarily been enumerated in the studies covered in this review. Results taken from any other country require consideration of all these factors before further consideration of translation of local currency into a common currency and year for comparison purposes.

5.5 Health care option

For effective comparison, the comparators should be relevant to the policy question within the proposed guidelines. Thus this review has not considered placebo as a valid comparator, but rather current practice since the aim was to evaluate alternative mixes of existing drugs rather than the addition of a new adjunctive therapy. In considering the proposed health care options, caution was taken since the reviewed modelling over the lifetime of the population far exceeded the timeframe of trials that contributed benefits of drug therapy. Trial-based assessments of costs can be quite different from routine practice in that additional monitoring may have been required, thus the trial based costings were not readily generalisable without adjustment to a routine setting.

5.6 Resource costs

Prices of drugs vary over time as patents expire and prescribing patterns may or may not shift to more generic drugs. This can contribute to different results in cross-country comparisons and drug price has often been identified in sensitivity analysis as the most important factor influencing the cost-effectiveness outcomes. This was particularly relevant to the evaluation of expensive statin therapy and should be factored in to any future modelling in the Australian setting. US costs are higher than other countries and have been quite often valued on the basis of cost-to-charge ratios since data was more readily available on charges in administrative databases. This made the resulting estimates further questionable in comparison with Australia.

Compliance with therapy has been previously highlighted as an issue that has an effect on the generalisability of a cost-effectiveness study.³⁵⁶ Compliance affects costs in an unknown direction since scripts can be filled but not taken (keeping costs high but without benefit) or scripts may not be filled (reducing overall costs and benefits). Irregular drug use, affecting costs and unknown impact on benefits has not been accounted for in any of the models considered here. Compliance can be measured in trials in several ways, but it is not well studied in the long term past 3–5 years. The real impact of compliance is unknown and assumptions need to be made in each study and the impact on the results compared in sensitivity analysis.

5.7 Marginal versus average cost

Studies that presented average costs of preventive therapy were not considered. Studies estimating the incremental cost effectiveness of therapy were included, since this evidence informs the research question.

5.8 Other specific issues relating to the guidelines

For resource allocation policy impact, consideration of final health outcomes such as mortality and morbidity should be made in preference to intermediate health outcomes such as reduction in cholesterol or BP. To this end all studies not presenting results in the desired format have been excluded.

6.0 Conclusion

It is difficult to extrapolate cost-effectiveness results from international studies to the Australian context given differences in health services provision and funding, pharmaceutical pricing policies and practices, and the potential variations in CVD risk in target populations. Overall the evidence from overseas studies was particularly limited, not only by the number of suitable studies found which were relevant to the issues addressed in the *Guidelines for Management of Absolute CVD Risk*, but also by several questions relating to internal validity and by some considerable issues with external validity which prevented the direct application of overseas cost-effectiveness conclusions to the Australian situation. However, despite the limitations, one consistent conclusion recurring in most analyses wherever conducted was the sensitivity of cost-effectiveness results to statin prices.

7.0 Further work

As the review of international cost-effectiveness literature did not yield useful evidence with which to compare the new guidelines, specific cost modelling of the recommendations using Australian data has also been undertaken by external consultants as part of the guidelines development process. This process included cost effectiveness modelling for various drugs, which was used to inform the development of the recommendations. Further modelling was done after completion of the recommendations, to determine the total costs and the cost effectiveness of the finalised recommendations.

Table 1. Analysis of studies

Target Population												
Author	Publication year	Intervention	Comparator	Study setting	Type of evaluation	Gender	Age	Risk factor/ co-morbidity	Analytic horizon	Discounting	Perspective	Compliance
Annemans <i>et al</i>	2006	Low-dose aspirin	Placebo	UK Germany Spain and Italy	Cost utility	Both	50, 55, 60	Patient groups at 2%, 3%, 4%, 5% risk of a fatal coronary heart disease event in 10 years using SCORE algorithm	10 yrs	Country-specific rates for both costs and benefits applied. The rates vary from 3% to 5%	Health care payer	No statement
Ara <i>et al</i>	2008	Ezetimibe in combination with statins	Statin monotherapy	UK	Cost utility	Both	40	Individuals who have not achieved cholesterol control with statins	Lifetime	3.5%	National Health Service	Discussed
Earnshaw <i>et al</i>	2011	Low dose aspirin with omeprazole 20 mg/d	Low dose aspirin alone.	US	Cost utility	Men	45, 55, 65	A range of underlying 10 year CHD risk (2.5%, 5%, 7.5%, 10%, 15%, 25%)	Lifetime	3%	Third-party payer	100% assumed
Franco <i>et al</i>	2007	Smoking cessation to smokers, aspirin given to all, BP-lowering drugs given to people with SBP>140 mmHg and statins given to all	No intervention	Netherlands	Cost effectiveness	Men	45-55 & 55-65	Framingham study participants meeting age and risk thresholds (low moderate and high)	10 years	4%	Third-party payer	No statement
Gaziano <i>et al</i>	2006	Aspirin, CCB, ace inhibitor and statins for primary prevention	No treatment	Developing country regions (WHO)	Cost utility	Both	35-74	Multiple levels of 10-year risk for CHD	Lifetime	3%	Societal	Sensitivity analysis
Greving <i>et al</i>	2008	Low-dose aspirin no quantity listed	No aspirin	Netherlands	Cost utility	Both	45, 55, 65, 75	At various levels of 10 year cardiovascular disease risk based on number of risk factors	10 yrs	4% for costs & 1.5% for benefits	Health care payer	No statement
Grover <i>et al</i>	2008	Lipid treatment or hypertension management	Not stated	Canada	Cost effectiveness (averages)	Both	40-74	2,121 participants surveyed from the Canadian heart health survey without CVD who qualify for lipid treatment or hypertension management	Not stated	3%	Health care system	No statement
Jonsson <i>et al</i>	2003	Anti hypertensive treatment with felodipine	The lowest change in BP	26 countries	Cost effectiveness	Both	50-80	18,790 trial patients with hypertension	Trial length of 3.8 yrs	None	Societal	No statement
Lamotte <i>et al</i>	2006	Low-dose aspirin	No aspirin	Europe, 4 countries	Cost utility	Both	Not specified	1.5% 10-year risk of a coronary heart disease event	10 yrs	Country specific	Public healthcare payer	No statement
Lungkvist <i>et al</i>	2005	Candesartan anti hypertensive treatment	Placebo	Europe	Cost utility	Both	70-89	Elderly patients with mild to moderate hypertension	Lifetime	3%	Societal	No statement
Marshall	2006	Treatment with aspirin or up to 4 BP-lowering drugs and statins	Do nothing	UK	Cost effectiveness	Both	Not specified	Taken from the Health Survey for England of 1998 using eligibility criteria for treatments with joint British recommendations	10 yrs	3%	Health services	100% assumed
Montgomery <i>et al</i>	2003	Hypertensive medication not specified clearly	No treatment not further specified	UK	Cost utility	Both	30-70	Low- and high-risk groups defined with smoking, BP, diabetes, etc	Lifetime	6% for costs and 1.5% for benefits	Health services	Discussed

Target Population

Author	Publication year	Intervention	Comparator	Study setting	Type of evaluation	Gender	Age	Risk factor/ co-morbidity	Analytic horizon	Discounting	Perspective	Compliance
Murray <i>et al</i>	2003	Statin, diuretic, BP-lowering drug and aspirin	No intervention	3 World regions	Cost utility	Both	30-100	People with an estimated combined risk of cardiac event over the next decade above a given threshold. Thresholds reported as 35%, 25%, 15%, 5%	100 yrs	3%	Decision makers not further specified	Discussed
Newman <i>et al</i>	2008	Polypill combination therapy of simvastatin, captopril, hydrochlorothiazide and atenolol	Current standard care	US	Cost utility	Men	>55 yrs	Regardless of baseline risk factors	Not stated	3%	Not stated	100%
Neyt <i>et al</i>	2009	Low dose pravastatin	Smoking cessation, or aspirin interventions	Belgium	Cost effectiveness	Men	50 & 60yrs	Moderate and high risk of coronary heart disease	10 yrs	3% for costs & 1.5% for benefits	Belgian decision makers	Discussed
Nordman <i>et al</i>	2003	ACE inhibitors to all	Conventional therapy	US	Cost utility	Men	40yrs	Requiring antihypertensives but no other comorbidity	Lifetime	5%	Third-party payer	Sensitivity analysis
Pignone <i>et al</i>	2006	Low-dose aspirin, a statin, both drugs as a combination	No therapy	US	Cost utility	Men	45 yrs old	Various levels of 10-year risk for CHD	Lifetime	3%	Third-party payer	100% assumed
Pignone <i>et al</i>	2007	Aspirin	No therapy	US	Cost utility	Women	65 yrs	7.5% 10-year risk of a coronary heart disease event	Lifetime	3%	Third-party payer	100% assumed
Pilote <i>et al</i>	2005	Lipids to people w/o CVD	Lipids to people with CVD	Canada	Cost outcome with sub group analysis	Both	30-74	Population surveyed with Canadian Heart Health Survey	Lifetime	5%	Societal	No statement
Pletcher <i>et al</i>	2009	ATP III guidelines and a number of risk based and age-based strategies	Current practice	US	Cost utility	Both	35-85	10-year CHD risk varying from > 0 to >15%	30 years	3%	Healthcare system	100% assumed
Ramsay <i>et al</i>	2008	10mg/day atorvastatin	No HMG-CoA reductase inhibitor (statin) therapy	US	Cost utility	Both	>20yrs	People with type 2 diabetes, and one additional risk factor (retinopathy, albuminuria, current smoking or hypertension), but no CVD history	5,10,25 years	3%	US payer	No statement
Schwander <i>et al</i>	2009	eprosartan	enalapril	6 countries within Europe	Cost utility	Both	Adult	Populations of 6 European countries	Lifetime	Country-specific rates for both costs and benefits applied. The rates vary from 3% to 5%	European health care-payer perspective	Compliance is entered to the model
Ward <i>et al</i>	2007	Statins for primary and secondary prevention of CHD or CVD	Non use of statins	UK	Cost utility	Both	45-85	Multiple levels of risk for CHD in next 10 years	Lifetime	6% for costs and 1.5% for benefits	National Health Service	Accounts for increasing non-compliance for 5 years and holds constant from then on

Table 2. An overview of economic evaluation study results

Study	Base year/ currency	Cost-effectiveness results	Relevance/quality/ comments
Annemans <i>et al</i> 2006	2003 Euros	Low-dose aspirin is dominant in all countries at all levels of risk except for Italy due to the higher cost of a gastrointestinal bleed there.	Not relevant Aspirin not relevant to the guidelines Compared to placebo Sponsorship from Bayer
Ara <i>et al</i> 2008	2006 British pounds	The lifetime results for treatment Scenario 1 (ezetimibe 10 mg plus current weighted statin versus current weighted statin titrated by one dose) range from £24,000 per QALY for males aged 45 years with a baseline LDL-C of 3.5mmol/L and no history of CVD to £62,000 per QALY for females aged 75 years with a baseline LDL-C of 2.5 mmol/L and no history of CVD.	Relevant study Well-designed cost-utility study that acknowledges limitations in the source data National Institute for Health Research HTA Programme sponsored
Earnshaw <i>et al</i> 2011	2009 US\$	Treatment with aspirin for CHD prevention is less costly and more effective than no treatment in men > 45 years with > 10-year, 10% CHD risks.	Not relevant Aspirin not relevant to the guidelines Sponsorship from Bayer
Franco <i>et al</i> 2007	2003 Euros	The most cost-effective treatment is smoking cessation therapy, representing savings in all situations. Statin therapy is the least cost-effective treatment (ranging from €73,971 to €19,027 per YLS). Aspirin was the second most cost-effective intervention (ranging from €2,263 to €16,949 per YLS) followed by antihypertensive treatment (ranging from Euros 28,187 to Euros 79,843 per YLS). These rankings were maintained for all age group/risk group categories analysed. A cut-off value for the ICER of Euros 20,000 per YLS was chosen	Limited relevance Some quality considerations including: Not a cost-utility study, limited to males, initial comparator is no intervention, 10-year time horizon, adverse events not included Sponsorship from the Netherlands Heart Foundation
Gaziano <i>et al</i> 2006	2001 US\$	Across six developing World Bank regions, primary prevention yielded ICERs of US\$746–890/QALY gained for patients with a 10-year AR of CVD greater than 25%, and US\$1039–1221/QALY gained for those with an AR greater than 5%.	Not relevant Conducted for developing countries Sponsorship from Fogarty International Centre, National Institutes of Health
Greving <i>et al</i> 2008	2005 Euros	Aspirin treatment for primary prevention is cost-effective for men with a 10-year CVD risk of >10% and for women with a risk of >15%. This occurs much later in life for women than men.	Not relevant Aspirin not relevant to the guidelines Sponsorship from Netherlands Organization for Health Research and Development
Grover <i>et al</i> 2008	2002 Canadian \$	The average cost-effectiveness of lipid therapy would be approximately CA\$16,700 per YOLS while hypertension therapy would be approximately CA\$37,100 per YOLS	Limited relevance Not a cost-utility study Incremental results not presented Sponsorship from Astra Zeneca


Study	Base year/ currency	Cost-effectiveness results	Relevance/quality/comments
Gumbs <i>et al</i> 2007	Review	<p>Policymakers who want to use economic evaluations should use those that employed appropriate methodology and produced valid results. In that regard it seems that policymakers are better informed using recent publications, as the quality of considered studies appears to have increased over time. However policymakers should remain critical regarding the methodology employed as the overall quality of the policy context economic evaluations is disappointing. This review focused on the methodology employed by the studies but policymakers should also consider whether the results are applicable to their own setting.</p>	<p>Focussed on quality of the economic evaluations</p> <p>Not included in Table 1</p> <p>Sponsorship not stated</p>
Jonsson <i>et al</i> 2003	1995 Swedish Krona	<p>The CV-related health care cost per patient during 3.8 years of follow-up was SEK32, 000 and SEK35,000 for the target groups 90 and 80 DBP, respectively.</p>	<p>Not relevant.</p> <p>Cost-effectiveness study of cost per reductions in BP</p> <p>Some quality considerations including:- no discussion of compliance issues</p> <p>Sponsorship from Astra Zeneca</p>
Lamotte <i>et al</i> 2006	2003 Euros	<p>In patients at low risk of CHD and low risk of gastrointestinal bleed, low-dose aspirin is cost-effective.</p> <p>For patients with an annual risk of CHD of 1.5%, the model resulted in 10-year savings with low-dose aspirin of on average €201, 281, 797, and 427 per patient in UK, Germany, Spain and Italy respectively.</p>	<p>Not relevant</p> <p>Aspirin not relevant to the guidelines</p> <p>Compared to placebo</p> <p>Sponsorship from Bayer</p>
Lundkuist <i>et al</i> 2005	2001 Euros	<p>Candesavtan-based antihypertensive treatment was associated with 0.0289 additional QALY per patient and an incremental cost per QALY gained of approximately €13,000.</p>	<p>Not relevant</p> <p>Compared to placebo</p> <p>Sponsorship not stated</p>
Marshall 2006	1996 British Pounds	<p>Cost per cardiovascular event prevented is strongly determined by cardiovascular risk. For any treatment it is over £45 000 in an individual at <10%, 10-year CVD risk and under £30 000 for any treatment in a patient at over 45%, 10-year CVD risk.</p>	<p>Not relevant</p> <p>Cost-effectiveness evaluation per change in risk category.</p> <p>Some quality considerations including:-the costs of coronary events is not included in the comparisons of health states, age not specified, short 10-year time horizon, comparator is do nothing.</p> <p>Sponsorship not stated</p>
Montgomery <i>et al</i> 2003	2002 British Pounds	<p>In terms of cost-effectiveness, treatment was more effective, but also cost more than non-treatment for all age, sex, and risk strata except the oldest high-risk men and women. Incremental cost per QALY among low-risk groups ranged from £1030 to £3304. Cost-effectiveness results for low-risk individuals were sensitive to the utility of receiving antihypertensive treatment. Treatment of high-risk individuals was highly cost effective, such that it was the dominant strategy in the oldest age group, and resulted in incremental costs per QALY ranging from £34 to £265 in younger age groups.</p>	<p>Relevant study</p> <p>Some quality considerations including: differential discount rates applied to costs and benefits, no adverse events were included, the treatment intervention was not described in detail, only strokes and myocardial infarctions considered, Framingham equations applied without calibration to the population under study</p> <p>Sponsored by UK Medical Research Council Training fellowship and UK NHS Primary Career Scientist Award</p>

Study	Base year/ currency	Cost-effectiveness results	Relevance/quality/comments
Murray <i>et al</i> 2003	2000 International dollars using purchasing power parity exchange rates	<p>Combination treatment for people whose risk of a cardiovascular event over the next 10 years is above 35% is cost effective leading to substantial additional health benefits by averting an additional 63 million DALYs per year worldwide.</p> <p>The absolute-risk approach at a threshold of 35% is always more cost effective than treatment based on either the measured systolic BP or the measured cholesterol concentration.</p> <p>From the perspective of how best to achieve the best population health for the available resources, the optimum overall strategy is a combination of the population-wide and individual-based interventions.</p>	<p>Relevant study</p> <p>Some quality considerations including: Comparator was no intervention, no cost offsets were included for cardiac events prevented</p> <p>Sponsorship not stated</p>
Newman <i>et al</i> 2008	2003/04 US\$	Under baseline assumptions, combination polypharmacy was less expensive and more effective than the current standard, namely, no treatment. Thus, the use of combination polypharmacy was a dominant strategy	<p>Relevant study</p> <p>Some quality considerations including: limited to males ≥ 55 years, the analytic time horizon and perspective not stated</p> <p>Sponsorship not stated</p>
Neyt <i>et al</i> 2009	2007 Euros	The results showed that smoking cessation is an intervention that should be encouraged. Low-dose aspirin was more cost-effective ranging from €3.854/LYG to €29.509/LYG compared to smoking cessation for smokers and ranging from €401/LYG to €13.451/LYG compared to no-treatment for non-smokers. The results for statin treatment are less cost effective. Only for the high risk group aged 60, the cost-effectiveness was about €30,000/LYG under the assumption that the cheapest alternative statin would be prescribed. For other subgroups the ICER for statin treatment was about €50,000/LYG	<p>Limited relevance</p> <p>Some quality considerations including: limited to males, aged 50 and 60, the analytic time horizon was only 10 years, differential discounting applied to costs and benefits, the comparator interventions are less relevant than current practice</p> <p>Sponsorship stated as 'no external funding'</p>
Nordmann <i>et al</i> 2003	1999 US\$	The cost-effectiveness ratios are unattractively high: US\$200,000 per QALY gained for the echocardiography strategy (compared with ECG), and US\$700,000 for the 'ACE inhibitor for all' strategy (compared with ECG). The incremental cost effectiveness of prescribing ACE inhibitor therapy to everybody was never less than US\$100,000/QALY in the sensitivity analysis.	<p>Relevant study</p> <p>Some quality considerations including: 40-year-old males only.</p> <p>Sponsorship not stated</p>
Pignone <i>et al</i> 2006	2003 US\$	For 45-year-old men who do not smoke, are not hypertensive and have a 10-year risk for CHD of 7.5%, aspirin was more effective and less costly than no treatment. The addition of a statin to aspirin therapy produced an incremental cost-utility ratio of US\$56,200 per quality-adjusted life-year gained compared with aspirin alone. The addition of a statin is more cost-effective as risk increases.	<p>Relevant study</p> <p>Some quality considerations including: limited analysis of 45 year old males, the comparator is aspirin and no therapy</p> <p>Sponsorship from Bayer</p>
Pignone <i>et al</i> 2007	2005 US\$	Aspirin use cost US\$13,300 per additional QALY gained in the base case. Results were sensitive to age, CVD risk, relative risk reductions with aspirin for ischaemic strokes and MI, excess risk of haemorrhagic stroke and gastrointestinal bleeding, and the disutility of taking medication. Probabilistic sensitivity analysis for 65-year-old women at moderate CVD risk found a 27% chance that aspirin produces fewer QALYs than no treatment, a 35% chance that the cost-utility ratio was less than US\$50,000 per QALY gained, and a 37% probability that it was greater than US\$50,000 per QALY gained.	<p>Not relevant</p> <p>Aspirin not relevant to the guidelines</p> <p>Sponsorship from Bayer</p>

Study	Base year/ currency	Cost-effectiveness results	Relevance/quality/comments
Pilote <i>et al</i> 2005	1996 Canadian\$	Among the surveyed individuals with a TC level higher than 6.2mmol/L the proportions of individuals for which lipid-lowering therapy was cost-effective (at a threshold level of CA\$50,000/year of life saved) were 85.6% of men and 28.7% of women for primary prevention.	Limited relevance. Average cost effectiveness only. Not a cost-utility study. Sponsorship provided by a grant from the Fonds de la Recherche en Santé de Quebec.
Pletcher <i>et al</i> 2009	2006 US\$	Full adherence to ATP III primary prevention guidelines would require starting (9.7 million) or intensifying (1.4 million) statin therapy for 11.1 million adults and would prevent 20 000 myocardial infarctions and 10 000 CHD deaths per year at an annual net cost of US\$3.6 billion (US\$42 000/QALY) if low-intensity statins cost US\$2.11 per pill. The ATP III guidelines would be preferred over alternative strategies if society is willing to pay US\$50,000/QALY and statins cost US\$1.54 to US\$2.21 per pill. At higher statin costs, ATP III is not cost-effective; at lower costs, more liberal statin-prescribing strategies would be preferred; and at costs less than US\$0.10 per pill, treating all persons with low-density lipoprotein cholesterol levels greater than 3.4 mmol/L (130 mg/dL) would yield net cost savings.	Relevant study Some quality considerations including: Study included unrelated health care costs. Shorter than lifetime horizon analysed Sponsorship from Flight Attendants Medical Research Institute and Swanson Family Fund
Ramsey <i>et al</i> 2008	2005 US\$	Within the time horizon of the trial (5 years), the cost effectiveness of atorvastatin was US\$137,276 per QALY. At 10 years, the incremental cost per QALY improved to US\$ 3,640 per QALY. At 25 years, the overall costs were lower and QALYs higher in the atorvastatin arm. Costs of managing CV events were lower after five years for patients treated with atorvastatin. For patients with type 2 diabetes and one additional risk factor for CV disease, normal LDL-cholesterol and no history of a CV event, primary prevention with atorvastatin appears to be cost saving and improve outcomes over 25 years although it is costly from a short-term US-payer perspective.	Relevant study Some quality considerations including: Cost of adverse events not included No statement on compliance Sponsored by Pfizer
Schwander <i>et al</i> 2009	2007 Euros	Comparing eprosartan to enalapril in a primary prevention setting the mean costs per quality adjusted life year (QALY) gained were highest in Germany (€24,036) followed by Belgium (€17,863), the UK (€16,364), Norway (€ 13,834), Sweden (€ 11,691) and Spain (€ 7,918).	Relevant study Some quality considerations including: no adverse events included, utility weights applied may not be appropriate, Framingham equations applied without calibration to the population under study, effectiveness data taken from one small trial (n=59) Sponsored by Solvay Pharmaceuticals
Ward <i>et al</i> 2007	2004 British Pounds	The cost-effectiveness of statins depends on the CHD risk in the population treated and the age and gender of the population under consideration. In primary prevention the discounted cost per QALY estimates for primary prevention at the age of 45 range between £9,500 and £30,500 for men and women as annual CHD risk levels fall from 3% to 0.5%. By the age of 85 years the corresponding values are £36,800 and £110,600	Relevant study High-quality study except for differential discount rates applied to costs and benefits National Institute for Health Research HTA Programme sponsored


Appendix 4: Assessment and Management summary

Risk Assessment and Management Algorithm: Adults aged 45 years and over without known history of CVD



Risk Assessment and Management Algorithm:

Aboriginal and Torres Strait Islander adults aged 35 and over without known history of CVD



EBR: Evidence-based recommendation (Graded A-D), CBR: Consensus-based recommendation, PP: Practice Point

Risk Management Summary - High Risk

CVD risk	Lifestyle	Pharmacotherapy			Targets	Monitoring
		BP lowering	Lipid lowering	Antiplatelet		
High risk Clinically determined Diabetes and age >60 years Diabetes with microalbuminuria (>20 mcg/min or UACR >2.5 mg/mmol for males, >3.5 mg/mmol for females) Moderate or severe CKD (persistent proteinuria or eGFR <45 mL/min/1.73 m ²) A previous diagnosis of FH SBP ≥180 mmHg or DPB ≥110 mmHg Serum TC >7.5 mmol/L A&TSI adults aged >74 years or calculated using FRE as >15% AR of CVD events over 5 years	Frequent and sustained specific advice and support regarding diet and physical activity. Appropriate advice, support and pharmacotherapy for smoking cessation. Advice given simultaneously with blood pressure and lipid lowering pharmacotherapy	Treat simultaneously with lipid lowering unless contraindicated or clinically inappropriate. Consider other treatable causes for raised BP before starting therapy. Commence with ACE inhibitor OR angiotensin receptor blocker OR CCB OR Low dose thiazide or thiazide-like diuretic. For diabetes or CKD commence with ACE inhibitor or angiotensin receptor blocker. Add second or third agent from different class as needed towards target. Consider withdrawal of therapy for people who make profound lifestyle changes.	Treat simultaneously with BP lowering unless contraindicated or clinically inappropriate. Consider other treatable causes for dyslipidaemia before starting therapy. Commence with a statin. Add ezetimibe, bile acid binding resin or nicotinic acid if LDL-C levels not sufficiently reduced or required dose of statin not tolerated. Use these agents as monotherapy if statins not tolerated at all. Add fenofibrate, nicotinic acid or fish oil to statin if TG levels not sufficiently reduced. Consider withdrawal of therapy for people who make profound lifestyle changes.	Not routinely recommended	BP: ≤140/90 mmHg in general or people with CKD; ≤130/80 mmHg in all people with diabetes; ≤130/80 mmHg if micro or macro albuminuria (UACR > 2.5 mg/mmol in men and >3.5 mg/mmol in women) Lipids: TC <4.0 mmol/L; HDL-C ≥ 1.0 mmol/L; LDL-C <2.0 mmol/L; Non HDL-C <2.5 mmol/L; TG < 2.0 mmol/L Lifestyle: Smoking cessation (if smoker); consume diet rich in vegetables and fruit, low in salt and saturated and trans fats; at least 30 mins moderate intensity physical activity on most or preferably every day of the week; limit alcohol intake.	BP and lipids monitored at approx 6 weekly intervals until sufficient improvement achieved or maximum tolerated dose reached. Adjust medication as required. Review of AR according to clinical context.

Risk Management Summary - Moderate Risk

CVD risk	Lifestyle	Pharmacotherapy			Targets	Monitoring
		BP lowering	Lipid lowering	Antiplatelet		
Moderate risk Calculated using FRE as 10–15% AR of CVD events over 5 years	<p>Appropriate, specific advice and support regarding diet and physical activity.</p> <p>Appropriate advice, support and pharmacotherapy for smoking cessation.</p> <p>Lifestyle advice given in preference to pharmacotherapy.</p>	<p>Not routinely recommended Consider BP lowering if 3–6 months of lifestyle does not reduce risk.</p> <p>Consider BP-lowering therapy in addition to lifestyle advice if:</p> <ul style="list-style-type: none"> • BP persistently $\geq 160/100$ mmHg • Family history of premature CVD • Specific population where the FRE underestimates risk e.g. A&TSI peoples, South Asian, Maori and Pacific Islander, Middle Eastern. <p>Consider other treatable causes for raised BP before starting therapy.</p> <p>Commence any agent as for high risk. Add second or third agent from different class as needed to reach target.</p> <p>Consider withdrawal of therapy for people who make profound lifestyle changes.</p>	<p>Not routinely recommended Consider lipid lowering if 3–6 months of lifestyle does not reduce risk.</p> <p>Consider lipid-lowering therapy in addition to lifestyle advice if:</p> <ul style="list-style-type: none"> • Family history of premature CVD • Specific population where the FRE underestimates risk e.g. A&TSI peoples, South Asian, Maori and Pacific Islander, Middle Eastern. <p>Consider other treatable causes for dyslipidaemia before starting therapy.</p> <p>Commence statin as for high risk.</p> <p>Consider additional treatment as for high risk if indicated.</p> <p>Consider withdrawal of therapy for people who make profound lifestyle changes.</p>	<p>Not routinely recommended</p>	<p>BP: $\leq 140/90$ mmHg in general or people with CKD;</p> <p>$\leq 130/80$ mmHg in all people with diabetes;</p> <p>$\leq 130/80$ mmHg if micro or macro albuminuria (UACR > 2.5 mg/mmol in men and > 3.5 mg/mmol in women)</p> <p>Lipids: TC < 4.0 mmol/L; HDL-C ≥ 1.0 mmol/L; LDL-C < 2.0 mmol/L; Non HDL-C < 2.5 mmol/L; TG < 2.0 mmol/L</p> <p>Lifestyle: Smoking cessation (if smoker); consume diet rich in vegetables and fruit, low in salt and saturated and trans fats; at least 30 mins moderate intensity physical activity on most or preferably every day of the week; limit alcohol intake.</p>	<p>BP and lipids monitored at approx 6 weekly intervals until sufficient improvement achieved or maximum tolerated dose reached.</p> <p>Adjust medication as required.</p> <p>Review of AR every 6–12 months</p>

Risk Management Summary - Low Risk

CVD risk	Lifestyle	Pharmacotherapy			Targets	Monitoring
		BP lowering	Lipid lowering	Antiplatelet		
Low risk Calculated using FRE as <10% AR of CVD events over 5 years	<p>Brief, general lifestyle advice regarding diet and physical activity.</p> <p>Appropriate advice, support and pharmacotherapy for smoking cessation</p>	<p>Not routinely recommended.</p> <p>Consider BP-lowering therapy in addition to specific lifestyle advice if BP persistently $\geq 160/100$ mmHg.</p> <p>Consider other treatable causes for raised BP before starting therapy.</p> <p>Commence any agent as for high risk. Add second or third agent from different class as needed to reach target.</p> <p>Consider withdrawal of therapy for people who make profound lifestyle changes.</p>	Not routinely recommended	Not routinely recommended	<p>BP: $\leq 140/90$ mmHg in general or people with CKD;</p> <p>$\leq 130/80$ mmHg in all people with diabetes;</p> <p>$\leq 130/80$ mmHg if micro or macro albuminuria (UACR >2.5 mg/mmol in men and >3.5 mg/mmol in women)</p> <p>Lipids: TC <4.0 mmol/L; HDL-C ≥ 1.0 mmol/L; LDL-C <2.0 mmol/L; Non HDL-C <2.5 mmol/L; TG <2.0 mmol/L</p> <p>Lifestyle: Smoking cessation (if smoker); consume diet rich in vegetables and fruit, low in salt and saturated and trans fats; at least 30 mins moderate intensity physical activity on most or preferably every day of the week; limit alcohol intake.</p>	<p>BP monitored at approx 6 weekly intervals until sufficient improvement achieved or maximum tolerated dose reached.</p> <p>Adjust medication as required.</p> <p>Review AR every 2 years.</p> <p>Blood test results within 5 years can be used.</p>

A&TSI: Aboriginal and Torres Strait Islander peoples; BP: Blood Pressure; CKD: Chronic Kidney Disease; DBP: Diastolic Blood Pressure; FH: Familial Hypercholesterolaemia; FRE: Framingham Risk Equation; HDL-C: High Density Lipoprotein Cholesterol; LDL-C: Low Density Lipoprotein Cholesterol; SBP: Systolic Blood Pressure; TC: Total Cholesterol; TG: Triglycerides.

Appendix 5:

Recommendations for future research

The recommendations in these guidelines have been developed from the current evidence base, using methodology from **NHMRC Levels of Evidence and Grades for Recommendations for Developers of Guidelines (2009)** to appraise and evaluate the quality of the evidence. However, these guidelines are based on an AR approach rather than assessing individual risk factors. Almost all of the research reviewed during the development process selected study participants based on one or more factors (but not on a formal comprehensive risk assessment considering a number of factors together). This has meant a larger number of practice points are provided compared with previous guidelines which have used a single risk factor approach. This difference in single verses AR highlights major gaps in evidence for this approach. Hence a list of future research priorities has been included here. Research priorities should be based on consideration of the burden of disease, the potential to conduct high quality research in the area and the potential impact on health outcomes.

Assessment tools

- Validation of the FRE or other tools in populations including the aged and adults aged 18- 30 years and determination of the optimum age for risk assessment.
- Investigation of the extra predictive value of significant risk factors that are not currently included in the FRE such as obesity, physical inactivity, family history of CVD, socioeconomic status and psychosocial factors.
- Comparison of the predictive value of emerging biomarkers with current risk assessment tools.
- Development of a risk assessment equation for people already on pharmacotherapy for blood pressure or lipid lowering.

Absolute risk prediction in specific subpopulations

- Investigation of new or modified tools for absolute CVD risk assessment based on risk equations specific to the Australian population, especially the indigenous population.
- Determination of the best predictive tool for people with diabetes and/or CKD.

Treatment

- Clinical trials for pharmacotherapy to lower blood pressure or lipids to be conducted and analysed using AR selection criteria.
- Clinical trials of the value of including aspirin for management of CVD risk using an AR approach in combination with blood pressure and/or lipid lowering therapy.
- New combination therapies such as various versions of the Polypill to be investigated for effect on population AR reduction.

- Studies of lifestyle measures to be conducted with more methodological rigour, such as statistically significant sample sizes, exclusion of people with CVD at baseline, and appropriate time for follow-up.

Cost effectiveness of absolute risk

- Detailed local study of the cost effectiveness of various AR assessment tools compared to current practice to determine whether AR improves outcomes and reduces health care costs;
- Study of the cost effectiveness of various health system models for identification and management of chronic diseases.

Patient adherence

- High quality study comparing different interventions for improvement of patient adherence to medication.
- Communication of risk information to consumers
- Development of an effective method for communication to consumers of AR status and the potential impact of management strategies.

Glossary and abbreviations

Glossary of terms

Abdominal obesity

Excess body fat predominantly around the waist.

Absolute risk (global risk, total risk)

The numerical probability of an event occurring within a specified period, usually expressed as a percentage. (e.g. 5-year AR of 15% means there is a 15% probability that the individual will experience a cardiovascular event within five years).

Absolute risk reduction

The arithmetic difference between event rates in two groups (e.g. the rates of CVD in a lipid-lowering treatment group subtracted from the rate in the untreated group). For any given relative risk reduction, the AR reduction decreases when event rates are low in the given population.

Albuminuria

The presence of excessive amounts of a protein called albumin in the urine.

Anti-platelet agents

Medicines that reduce the risk of abnormal blood clotting (e.g. aspirin, clopidogrel).

Atrial fibrillation (AF)

Rapid, irregular beating of the heart which can mean that the heart is not pumping efficiently.

Blood pressure (BP)

The pressure of the blood against the inner walls of the arteries as it is pumped around the body by the heart. Blood pressure varies from moment to moment and is affected by factors such as body position, breathing, emotional state, physical activity and sleep.

Body mass index (BMI)

A calculated number used to identify and measure underweight, overweight or obesity, calculated from a person's height and weight. $BMI = \text{weight (in kg)} \div \text{height (in m)}^2$.

Cardiovascular disease (CVD)

Group term for all medical conditions affecting the heart or blood vessels (e.g. coronary heart disease, stroke, peripheral arterial disease, some types of kidney disease).

Cardiovascular events

Group of outcomes which may vary between trials but normally includes myocardial infarction, stroke, death from a vascular cause (including coronary, pulmonary embolism, haemorrhage) or any arterial revascularisation procedure.

Cholesterol

See lipids.

Chronic heart failure (CHF)

A condition in which the heart does not pump blood effectively, typically resulting in breathlessness and fatigue.

Chronic kidney disease (CKD)

Long-term inability of the kidney/s to function normally, most commonly caused by diabetes, inflammation of the kidneys or high blood pressure.

Cochrane review

A comprehensive systematic review and meta-analysis (where possible).

Cohort studies

A type of medical research in which a selected group of people is studied over time, often over a period of several years.

Coronary heart disease (CHD)

A disease in which arteries that surround the heart and supply blood to the heart muscle become partly blocked.

Diabetes mellitus (diabetes)

A long-term disease that affects the way body cells take up and use glucose (sugar) from the blood, resulting in abnormally high levels of glucose in the blood.

Dyslipidaemia

An abnormal amount of lipids (e.g. cholesterol or triglycerides) in the blood, usually abnormally high levels.

Family history of CVD

A family history of premature cardiovascular disease refers to an event that occurs in relatives including parents, grandparents, uncles and/or aunts before the age of 55 years.

Familial hypercholesterolaemia

An inherited condition in which removal of cholesterol from the blood is reduced, causing high blood cholesterol levels and early heart disease in some families.

Framingham Risk Equation

A statistical method of predicting an individual's likelihood of developing CVD within the next five or 10 years, based on risk factors such as age, sex and blood pressure.

Hypertension

Raised blood pressure.

Lipids

Fatty substances naturally occurring in the blood (cholesterol and triglycerides).

Macroalbuminuria

A raised level of albumin in the urine (more than 300mg of albumin in the urine per day).

Microalbuminuria

A slightly raised level of albumin in the urine (between 30 mg and 300 mg per day).

Myocardial infarction (heart attack)

Temporary loss of blood supply to the heart muscle, typically caused by a blood clot that suddenly blocks a narrowed artery. This can result in heart muscle damage.

Non HDL-C

The cholesterol in low density lipoprotein, intermediate density lipoprotein and very low density lipoprotein.

Numbers needed to treat (NNT)

Average number of patients who need to be treated to prevent one additional bad outcome. The number is the inverse of the absolute risk reduction.

Peripheral arterial disease (PAD)

Disease affecting the arteries other than those of the heart or brain.

Proteinuria

The presence of excessive amounts of protein (>150 mg per day) in the urine. These proteins are typically albumin, but also consist of low molecular weight immunoglobulin, lysozyme, insulin and beta-2 microglobulin.

Relative risk (RR)

The ratio of the rate of events (e.g. CVD) in the population exposed to a risk factor to the rate among the unexposed population (e.g. the risk of someone developing a CVD event who has a given set of risk factors, compared with the risk in someone of the same age and sex who does not have those risk factors).

Relative risk reduction (RRR)

The difference in event rates between two groups (e.g. treatment group versus control group), expressed as a proportion of the event rate in the untreated group. Often remains constant whether event rates are high or low within the population.

Renovascular disease

Cardiovascular disease affecting the blood vessels supplying the kidney.

Risk factor

A characteristic of a person (or people) that is positively associated with a particular disease or condition.

Stroke

Sudden loss of blood supply to the brain (e.g. due to blockage of an artery by a blood clot, or because the artery breaks or bursts).

TC: HDL ratio

Total cholesterol divided by high density lipoprotein. Used in the Framingham Risk Equation.

Transient ischaemic attack (TIA)

Transient episode of neurologic dysfunction caused by loss of blood flow. TIAs share the same underlying cause as stroke and the same symptoms but symptoms resolve within a few minutes or less than 24 hours.

Triglycerides

See Lipids.

Abbreviations

ACE: Angiotensin-converting enzyme

AF: Atrial fibrillation

APCC: Australian Primary Care Collaboratives

AR: Absolute risk

ARB: Angiotensin receptor blocker

A&TSI: Aboriginal and Torres Strait Islander Peoples

AUC: Area Under the ROC curve

BP: Blood pressure

BMI: Body mass index

CAD: Coronary artery disease

CCB: Calcium channel blocker

CHD: Coronary heart disease

CKD: Chronic kidney disease

CI: Confidence interval

CVD: Cardiovascular disease

DALY: Disability adjusted life years

DBP: Diastolic blood pressure

DoHA: Department of Health and Ageing

ECG: Electrocardiography

EGFR: Estimated glomerular filtration rate

EWG: Expert working group

FRE: Framingham Risk Equation

GFR: Glomerular filtration rate

GP: General practitioner

HDL: High-density lipoprotein cholesterol (also HDL-C)

HMG-CoA: 3-hydroxy-3-methylglutaryl-coenzyme A (statin)

ICER: Incremental cost-effectiveness ratio

LDL: Low-density lipoprotein cholesterol (also LDL-C)

LVH: Left ventricular hypertrophy

MBS: Medicare Benefits Schedule

MI: Myocardial infarction

NHMRC: National Health and Medical Research Council

NNT: Numbers needed to treat

NVDPA: National Vascular Disease Prevention Alliance

OGTT: Oral Glucose Tolerance Test

OR: Odds ratio

PBAC: Pharmaceutical Benefits Advisory Committee

PBS: Pharmaceutical Benefits Scheme

QALY: Quality adjusted life year

RACGP: Royal Australian College of General Practitioners

RCT: Randomised controlled trial

RR: Relative risk

RRR: Relative risk reduction

SBP: Systolic blood pressure

SCORE: Systematic Coronary Risk Evaluation project

SR: Systematic review

TC: Total cholesterol

TG: Triglyceride

TIA: Transient ischaemic attack

UACR: Urinary albumin:creatinine ratio

UKPDS: United Kingdom Prospective Diabetes Study

Bibliography

1. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. *Am Heart J*. 1991 Jan;121(1 Pt 2):293-8.
2. Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. *Lancet*. 2005 Jan 29-Feb 4;365(9457):434-41.
3. Kannel WB. Some lessons in cardiovascular epidemiology from Framingham. *Am J Cardiol*. 1976 Feb;37(2):269-82.
4. Australian Institute of Health and Welfare 2011. Health determinants, the key to preventing chronic disease. Cat No. PHE 157. Canberra: AIHW.
5. Tonkin A, Barter P, Best J, Boyden A, Furler J, Hossack K, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005. *Heart Lung Circ*. 2005 Dec;14(4):275-91.
6. Hillier S, Grimmer-Somers K, Merlin T, Middleton P, Salisbury J, Tooher R, et al. FORM: an Australian method for formulating and grading recommendations in evidence-based clinical guidelines. *BMC Med Res Methodol*. 2011 Feb 28;11:23.
7. Begg SJ, Vos T, Barker B, Stanley L, Lopez AD. Burden of disease and injury in Australia in the new millennium: measuring health loss from diseases, injuries and risk factors. *Med J Aust*. 2008 Jan 7;188(1):36-40.
8. Australian Institute of Health and Welfare 2011. Cardiovascular disease: Australian facts 2011. Cardiovascular disease series. Cat.no. CVD 53. Canberra: AIHW.
9. Australian Institute of Health and Welfare 2008. Australia's health 2008. Cat. no. AUS 99. Canberra: AIHW.
10. National Vascular Disease Prevention Alliance. Guidelines for the assessment of absolute cardiovascular disease risk. 2009.
11. National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to the management of hypertension for doctors 2008.
12. Colagiuri S, Davies D, Girgis S, Colagiuri R. National Evidence-based Guideline for Case Detection and Diagnosis of Type 2 Diabetes. Diabetes Australia and the NHMRC, Canberra 2009.
13. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004 Sep 11-17;364(9438):937-52.
14. Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease. A national clinical guideline, 2007. Available at: www.sign.ac.uk
15. National Vascular Disease Prevention Alliance (Diabetes Australia, Kidney Health Australia and National Stroke Foundation of Australia). Consensus statement for the prevention of vascular disease. *Aust Family Physician* 2004; 33: 234-239.
16. Harris M, Bailey L, Bridges-Webb C, et al. Guidelines for prevention activities in general practice (6th edition). Melbourne; The Royal Australian College of General Practitioners, 2005.
17. National Aboriginal Community Controlled Health Organisation. National guide to a preventative health assessment in Aboriginal and Torres Strait Islander peoples. South Melbourne; Royal Australian College of General Practitioners, 2005.
18. Grundy SM, Pasternak R, Greenland P, Smith S, Jr., Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation*. 1999 Sep 28;100(13):1481-92.
19. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. *Arch Intern Med*. 1992 Jan;152(1):56-64.
20. Hall LM, Jung RT, Leese GP. Controlled trial of effect of documented cardiovascular risk scores on prescribing. *BMJ*. 2003 Feb 1;326(7383):251-2.
21. Lowensteyn I, Joseph L, Levinton C, Abrahamowicz M, Steinert Y, Grover S. Can computerized risk profiles help patients improve their coronary risk? The results of the Coronary Health Assessment Study (CHAS). *Prev Med*. 1998 Sep-Oct;27(5 Pt 1):730-7.
22. Manuel DG, Lim J, Tanuseputro P, Anderson GM, Alter DA, Laupacis A, et al. Revisiting Rose: strategies for reducing coronary heart disease. *BMJ*. 2006 Mar 18;332(7542):659-62.
23. Manuel DG, Kwong K, Tanuseputro P, Lim J, Mustard CA, Anderson GM, et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. *BMJ*. 2006 Jun 17;332(7555):1419.
24. Marshall T. Evaluating national guidelines for prevention of cardiovascular disease in primary care. *J Eval Clin Pract*. 2005 Oct;11(5):452-61.
25. National Institute of Clinical Studies. Rate or rhythm control for recurrent atrial fibrillation. Canberra: National Health and Medical Research Council; 2008.
26. National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians. 2006.
27. New Zealand Guidelines Group; 2005. Available from: www.nzgg.org.nz
28. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2011 Jan;42(1):227-76.

29. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). *J Am Coll Cardiol*. 2006 Sep 5;48(5):e247-346.
30. Colagiuri S, Dickinson S, Girgis S, Colagiuri R. National Evidence-based Guideline for Blood Glucose Control in Type 2 Diabetes. Diabetes Australia and the NHMRC, Canberra 2009.
31. Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Alan C, et al. National Evidence-based Guideline for Diagnosis, Prevention and Management of Chronic Kidney Disease in Type 2 Diabetes. Diabetes Australia and the NHMRC, Canberra 2009.
32. The Cardiac Society of Australia and New Zealand 2010. Guidelines for the diagnosis and management of Familial Hypercholesterolaemia. Available at: <http://www.csanz.edu.au/LinkClick.aspx?fileticket=EOvAvk2jApc%3D&tabid=148> (accessed March 2011).
33. Abbott RD, Behrens GR, Sharp DS, Rodriguez BL, Burchfiel CM, Ross GW, et al. Body mass index and thromboembolic stroke in nonsmoking men in older middle age. The Honolulu Heart Program. *Stroke*. 1994 Dec;25(12):2370-6.
34. Hamm P, Shekelle RB, Stamler J. Large fluctuations in body weight during young adulthood and twenty-five-year risk of coronary death in men. *Am J Epidemiol*. 1989 Feb;129(2):312-8.
35. Poulriot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. *Am J Cardiol*. 1994 Mar 1;73(7):460-8.
36. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. *Arteriosclerosis*. 1990 Jul-Aug;10(4):497-511.
37. World Health Organisation. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO Tech Rep Ser 2000;894(3):i-xii.
38. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. *Arch Intern Med*. 1997 Jul 14;157(13):1413-8.
39. Gimeno-Orna JA, Molinero-Herguedas E, Sanchez-Vano R, Lou-Arnal LM, Boned-Juliani B, Castro-Alonso FJ. Microalbuminuria presents the same vascular risk as overt CVD in type 2 diabetes. *Diabetes Res Clin Pract*. 2006 Oct;74(1):103-9.
40. Khosla N, Sarafidis PA, Bakris GL. Microalbuminuria. *Clin Lab Med*. 2006 Sep;26(3):635-53, vi-vii.
41. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. *Arch Intern Med*. 2000 Apr 24;160(8):1093-100.
42. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004 Sep 23;351(13):1296-305.
43. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: the Framingham study. *Am Heart J*. 1984 Nov;108(5):1347-52.
44. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis*. 2002 Feb;39(2 Suppl 1):S1-266.
45. New Zealand Guidelines Group. The assessment and management of cardiovascular risk. Wellington; NZGG, 2003.
46. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. *Heart*. 2005 Dec;91 Suppl 5:v1-52.
47. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*. 2007 Jun;25(6):1105-87.
48. World Health Organization. Prevention of cardiovascular disease. Guidelines for assessment and management of cardiovascular risk. Geneva; WHO, 2007.
49. Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. *Circ J*. 2006 Oct;70(10):1249-55.
50. Aspelund T, Thorgeirsson G, Sigurdsson G, Gudnason V. Estimation of 10-year risk of fatal cardiovascular disease and coronary heart disease in Iceland with results comparable with those of the Systematic Coronary Risk Evaluation project. *Eur J Cardiovasc Prev Rehabil*. 2007 Dec;14(6):761-8.
51. Bineau S, Dufouil C, Helmer C, Ritchie K, Empana JP, Ducimetiere P, et al. Framingham stroke risk function in a large population-based cohort of elderly people: the 3C study. *Stroke*. 2009 May;40(5):1564-70.
52. Chow CK, Joshi R, Celermajer DS, Patel A, Neal BC. Recalibration of a Framingham risk equation for a rural population in India. *J Epidemiol Community Health*. 2009 May;63(5):379-85.
53. D'Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. 2008 Feb 12;117(6):743-53.
54. De Bacquer D, De Backer G. Predictive ability of the SCORE Belgium risk chart for cardiovascular mortality. *Int J Cardiol*. 2009 Sep 3;143(3):385-90.
55. Dhaliwal SS, Welborn TA. Central obesity and cigarette smoking are key determinants of cardiovascular disease deaths in Australia: a public health perspective. *Prev Med*. 2009 Aug-Sep;49(2-3):153-7.
56. Grover SA, Hemmelgarn B, Joseph L, Milot A, Tremblay G. The role of global risk assessment in hypertension therapy. *Can J Cardiol*. 2006 May 15;22(7):606-13.
57. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Brindle P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. *Heart*. 2008 Jan;94(1):34-9.
58. Loucks EB, Lynch JW, Pilote L, Fuhrer R, Almeida ND, Richard H, et al. Life-course socioeconomic position and incidence of coronary heart disease: the Framingham Offspring Study. *Am J Epidemiol*. 2009 Apr 1;169(7):829-36.
59. Marques-Vidal P, Rodondi N, Bochud M, Pecoud A, Hayoz D, Paccaud F, et al. Predictive accuracy and usefulness of calibration of the ESC SCORE in Switzerland. *Eur J Cardiovasc Prev Rehabil*. 2008 Aug;15(4):402-8.
60. May M, Lawlor DA, Brindle P, Patel R, Ebrahim S. Cardiovascular disease risk assessment in older women: can we improve on Framingham? British Women's Heart and Health prospective cohort study. *Heart*. 2006 Oct;92(10):1396-401.
61. Pencina MJ, D'Agostino RB, Sr., Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart Study. *Circulation*. 2009 Jun 23;119(24):3078-84.
62. Van der Heijden AA, Ortegon MM, Niessen LW, Nijpels G, Dekker JM. Prediction of coronary heart disease risk in a general, pre-diabetic, and diabetic population during 10 years of follow-up: accuracy of the Framingham, SCORE, and UKPDS risk functions: The Hoorn Study. *Diabetes Care*. 2009 Nov;32(11):2094-8.

63. Australian Institute of Health and Welfare 2006. Chronic diseases and associated risk factors in Australia, 2006. Cat. no. PHE 81. Canberra: AIHW.
64. Royal Australian College of General Practice. Guidelines for preventive activities in general practice (The Red Book) 7th Edition 2009. Available at: <http://www.racgp.org.au/guidelines/redbook> (accessed Feb 2011).
65. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998 May 12;97(18):1837-47.
66. Wang Z, Hoy WE. Is the Framingham coronary heart disease absolute risk function applicable to Aboriginal people? *Med J Aust*. 2005 Jan 17;182(2):66-9.
67. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. *Diabet Med*. 2005 May;22(5):554-62.
68. Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS. Prediction of coronary heart disease in middle-aged adults with diabetes. *Diabetes Care*. 2003 Oct;26(10):2777-84.
69. Coleman RL, Stevens RJ, Retnakaran R, Holman RR. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. *Diabetes Care*. 2007 May;30(5):1292-3.
70. Stephens JW, Ambler G, Vallance P, Betteridge DJ, Humphries SE, Hurel SJ. Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? *Eur J Cardiovasc Prev Rehabil*. 2004 Dec;11(6):521-8.
71. Asia Pacific Cohort Studies Collaboration. Coronary risk prediction for those with and without diabetes. *Eur J Cardiovasc Prev Rehabil*. 2006 Feb;13(1):30-6.
72. Chamnan P, Simmons RK, Sharp SJ, Griffin SJ, Wareham NJ. Cardiovascular risk assessment scores for people with diabetes: a systematic review. *Diabetologia*. 2009 Oct;52(10):2001-14.
73. Ruppert K, Roberts MS, Orchard TJ, Zgibor JC. Cardiovascular disease risk prediction in type 1 diabetes: accounting for the differences. *Diabetes Res Clin Pract*. 2007 Nov;78(2):234-7.
74. Game FL, Bartlett WA, Bayly GR, Jones AF. Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus. *Diabetes Obes Metab*. 2001 Aug;3(4):279-86.
75. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, et al. Body-mass index and mortality among 1.46 million white adults. *N Engl J Med*. 2010 Dec 2;363(23):2211-9.
76. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet*. 2009 Mar 28;373(9669):1083-96.
77. Welborn TA, Dhaliwal SS, Bennett SA. Waist-hip ratio is the dominant risk factor predicting cardiovascular death in Australia. *Med J Aust*. 2003 Dec 1-15;179(11-12):580-5.
78. Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. *Lancet*. 2011 Mar 26;377(9771):1085-95.
79. Schneider HJ, Glaesmer H, Klotsche J, Bohler S, Lehnert H, Zeiher AM, et al. Accuracy of anthropometric indicators of obesity to predict cardiovascular risk. *J Clin Endocrinol Metab*. 2007 Feb;92(2):589-94.
80. Snijder MB, van Dam RM, Visser M, Seidell JC. What aspects of body fat are particularly hazardous and how do we measure them? *Int J Epidemiol*. 2006 Feb;35(1):83-92.
81. National Health and Medical Research Council. Clinical practice guidelines for the management of overweight and obesity in adults. Canberra: NHMRC, 2003.
82. Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. *Psychosom Med*. 2004 Nov-Dec;66(6):802-13.
83. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. *Med J Aust*. 2009 Apr 6;190(7 Suppl):S54-60.
84. Bunker SJ, Colquhoun DM, Esler MD, Hickie IB, Hunt D, Jelinek VM, et al. "Stress" and coronary heart disease: psychosocial risk factors. *Med J Aust*. 2003 Mar 17;178(6):272-6.
85. Rugulies R. Depression as a predictor for coronary heart disease. a review and meta-analysis. *Am J Prev Med*. 2002 Jul;23(1):51-61.
86. Van Melle JP, de Jonge P, Spijkerman TA, Tijssen JG, Ormel J, van Veldhuisen DJ, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. *Psychosom Med*. 2004 Nov-Dec;66(6):814-22.
87. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. *Psychosom Med*. 2003 Mar-Apr;65(2):201-10.
88. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. *Lancet*. 2004 Sep 11-17;364(9438):953-62.
89. Gallagher D. Depression and cardiovascular disease: Does antidepressant treatment improve cardiac outcome? *Irish Journal of Psychological Medicine*. 2007;24(4):156-8.
90. Summers KM, Martin KE, Watson K. Impact and clinical management of depression in patients with coronary artery disease. *Pharmacotherapy*. 2010;30(3):304-22.
91. Brindle PM, McConnachie A, Upton MN, Hart CL, Davey Smith G, Watt GC. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. *Br J Gen Pract*. 2005 Nov;55(520):838-45.
92. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). *Heart*. 2007 Feb;93(2):172-6.
93. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. *BMJ*. 2007 Jul 21;335(7611):136.
94. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. *Circulation*. 1998 Sep 8;98(10):946-52.
95. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med*. 2002 Oct 1;113(5):359-64.
96. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke*. 1991 Aug;22(8):983-8.
97. Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A. Monitoring cholesterol levels: measurement error or true change? *Ann Intern Med*. 2008 May 6;148(9):656-61.
98. Russell LB. Preventing chronic disease: an important investment, but don't count on cost savings. *Health Aff (Millwood)*. 2009 Jan-Feb;28(1):42-5.

99. Brunner EJ, Rees K, Ward K, Burke M, Thorogood M. Dietary advice for reducing cardiovascular risk. *Cochrane Database Syst Rev*. 2007(4):CD002128.
100. National Health and Medical Research Council. Dietary guidelines for Australian adults. Canberra: NHMRC, 2003.
101. Hooper L, Summerbell CD, Higgins JP, Thompson RL, Clements G, Capps N, et al. Reduced or modified dietary fat for preventing cardiovascular disease. *Cochrane Database Syst Rev*. 2001(3):CD002137.
102. Bouzan C, Cohen JT, Connor WE, Kris-Etherton PM, Gray GM, Konig A, et al. A quantitative analysis of fish consumption and stroke risk. *Am J Prev Med*. 2005 Nov;29(4):347-52.
103. He K, Song Y, Daviglius ML, Liu K, Van Horn L, Dyer AR, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. *Circulation*. 2004 Jun 8;109(22):2705-11.
104. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. *Am J Clin Nutr*. 2006 Jul;84(1):5-17.
105. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. *BMJ*. 2006 Apr 1;332(7544):752-60.
106. He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. *J Hum Hypertens*. 2002 Nov;16(11):761-70.
107. Hooper L, Bartlett C, Davey SG, Ebrahim S. Advice to reduce dietary salt for prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2004(1):CD003656.
108. Dauchet L, Amouyel P, Dallongeville J. Fruit and vegetable consumption and risk of stroke: a meta-analysis of cohort studies. *Neurology*. 2005 Oct 25;65(8):1193-7.
109. Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. *J Nutr*. 2006 Oct;136(10):2588-93.
110. He FJ, Nowson CA, Lucas M, MacGregor GA. Increased consumption of fruit and vegetables is related to a reduced risk of coronary heart disease: meta-analysis of cohort studies. *J Hum Hypertens*. 2007 Sep;21(9):717-28.
111. He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. *Lancet*. 2006 Jan 28;367(9507):320-6.
112. Elwood PC, Givens DJ, Beswick AD, Fehily AM, Pickering JE, Gallacher J. The survival advantage of milk and dairy consumption: an overview of evidence from cohort studies of vascular diseases, diabetes and cancer. *J Am Coll Nutr*. 2008 Dec;27(6):723S-34S.
113. Anderson JW, Hanna TJ, Peng X, Kryscio RJ. Whole grain foods and heart disease risk. *J Am Coll Nutr*. 2000 Jun;19(3 Suppl):291S-9S.
114. Bazzano LA, He J, Ogden LG, Loria CM, Whelton PK. Dietary fiber intake and reduced risk of coronary heart disease in US men and women: the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. *Arch Intern Med*. 2003 Sep 8;163(16):1897-904.
115. Jacobs DR, Jr., Meyer HE, Solvoll K. Reduced mortality among whole grain bread eaters in men and women in the Norwegian County Study. *Eur J Clin Nutr*. 2001 Feb;55(2):137-43.
116. Liu S, Manson JE, Stampfer MJ, Rexrode KM, Hu FB, Rimm EB, et al. Whole grain consumption and risk of ischemic stroke in women: A prospective study. *JAMA*. 2000 Sep 27;284(12):1534-40.
117. Mozaffarian D, Kumanyika SK, Lemaitre RN, Olson JL, Burke GL, Siscovick DS. Cereal, fruit, and vegetable fiber intake and the risk of cardiovascular disease in elderly individuals. *JAMA*. 2003 Apr 2;289(13):1659-66.
118. Steffen LM, Jacobs DR, Jr., Stevens J, Shahar E, Carithers T, Folsom AR. Associations of whole-grain, refined-grain, and fruit and vegetable consumption with risks of all-cause mortality and incident coronary artery disease and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. *Am J Clin Nutr*. 2003 Sep;78(3):383-90.
119. Kelly SA, Summerbell CD, Brynes A, Whittaker V, Frost G. Wholegrain cereals for coronary heart disease. *Cochrane Database Syst Rev*. 2007(2):CD005051.
120. Kelly S, Frost G, Whittaker V, Summerbell C. Low glycaemic index diets for coronary heart disease. *Cochrane Database Syst Rev*. 2004(4):CD004467.
121. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A. Adherence to Mediterranean diet and health status: meta-analysis. *BMJ*. 2008;337:a1344.
122. Harland JL, Haffner TA. Systematic review, meta-analysis and regression of randomised controlled trials reporting an association between an intake of circa 25 g soya protein per day and blood cholesterol. *Atherosclerosis*. 2008 Sep;200(1):13-27.
123. Castro IA, Barroso LP, Sinnecker P. Functional foods for coronary heart disease risk reduction: a meta-analysis using a multivariate approach. *Am J Clin Nutr*. 2005 Jul;82(1):32-40.
124. Flores-Mateo G, Navas-Acien A, Pastor-Barriuso R, Guallar E. Selenium and coronary heart disease: a meta-analysis. *Am J Clin Nutr*. 2006 Oct;84(4):762-73.
125. Dickinson HO, Mason JM, Nicolson DJ, Campbell F, Beyer FR, Cook JV, et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials. *J Hypertens*. 2006 Feb;24(2):215-33.
126. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. *Health Technol Assess*. 2004 May;8(21):iii-iv, 1-182.
127. Hession M, Rolland C, Kulkarni U, Wise A, Broom J. Systematic review of randomized controlled trials of low-carbohydrate vs. low-fat/low-calorie diets in the management of obesity and its comorbidities. *Obes Rev*. 2009 Jan;10(1):36-50.
128. Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. *Cochrane Database Syst Rev*. 2006(4):CD003817.
129. Witham MD, Avenell A. Interventions to achieve long-term weight loss in obese older people: a systematic review and meta-analysis. *Age Ageing*. 2010 Mar;39(2):176-84.
130. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH, Jr., Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. *JAMA*. 1998 Mar 18;279(11):839-46.
131. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension*. 2003 Nov;42(5):878-84.
132. Mulrow CD, Chiquette E, Angel L, Cornell J, Summerbell C, Anagnostis B et al. Dieting to reduce body weight for controlling hypertension in adults. *The Cochrane Library*, Issue 2, 2004. Chichester; JohnWiley.
133. Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. *Public Health Rep*. 1985 Mar-Apr;100(2):126-31.
134. Dunstan DW, Barr EL, Healy GN, Salmon J, Shaw JE, Balkau B, et al. Television viewing time and mortality: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab). *Circulation*. 2010 Jan 26;121(3):384-91.
135. Katzmarzyk PT, Church TS, Craig CL, Bouchard C. Sitting time and mortality from all causes, cardiovascular disease, and cancer. *Med Sci Sports Exerc*. 2009 May;41(5):998-1005.
136. Hamer M, Chida Y. Walking and primary prevention: a meta-analysis of prospective cohort studies. *Br J Sports Med*. 2008 Apr;42(4):238-43.

137. Lollgen H, Bockenhoff A, Knapp G. Physical activity and all-cause mortality: an updated meta-analysis with different intensity categories. *Int J Sports Med.* 2009 Mar;30(3):213-24.
138. Nocon M, Hiemann T, Muller-Riemenschneider F, Thalau F, Roll S, Willich SN. Association of physical activity with all-cause and cardiovascular mortality: a systematic review and meta-analysis. *Eur J Cardiovasc Prev Rehabil.* 2008 Jun;15(3):239-46.
139. Shiroma EJ, Lee IM. Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. *Circulation.* 2010 Aug 17;122(7):743-52.
140. Woodcock J, Franco OH, Orsini N, Roberts I. Non-vigorous physical activity and all-cause mortality: systematic review and meta-analysis of cohort studies. *Int J Epidemiol.* 2010 Jul 14.
141. Hu G, Tuomilehto J, Silventoinen K, Barengo N, Jousilahti P. Joint effects of physical activity, body mass index, waist circumference and waist-to-hip ratio with the risk of cardiovascular disease among middle-aged Finnish men and women. *Eur Heart J.* 2004 Dec;25(24):2212-9.
142. Pal S, Cheng C, Egger G, Binns C, Donovan R. Using pedometers to increase physical activity in overweight and obese women: a pilot study. *BMC Public Health.* 2009;9:309.
143. Pazoki R, Nabipour I, Seyednezami N, Imami SR. Effects of a community-based healthy heart program on increasing healthy women's physical activity: a randomized controlled trial guided by Community-based Participatory Research (CBPR). *BMC Public Health.* 2007;7:216.
144. Pedersen MT, Blangsted AK, Andersen LL, Jorgensen MB, Hansen EA, Sjogaard G. The effect of worksite physical activity intervention on physical capacity, health, and productivity: a 1-year randomized controlled trial. *J Occup Environ Med.* 2009 Jul;51(7):759-70.
145. Racette SB, Deusinger SS, Inman CL, Burlis TL, Highstein GR, Buskirk TD, et al. Worksite Opportunities for Wellness (WOW): effects on cardiovascular disease risk factors after 1 year. *Prev Med.* 2009 Aug-Sep;49(2-3):108-14.
146. Carroll S, Dudfield M. What is the relationship between exercise and metabolic abnormalities? A review of the metabolic syndrome. *Sports Med.* 2004;34(6):371-418.
147. Orozco LJ, Buchleitner AM, Gimenez-Perez G, Roque IFM, Richter B, Mauricio D. Exercise or exercise and diet for preventing type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2008(3):CD003054.
148. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. *Cochrane Database Syst Rev.* 2006;3:CD002968.
149. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. *Ann Intern Med.* 2005 Feb 15;142(4):233-9.
150. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ.* 2004 Jun 26;328(7455):1519.
151. Ellingsen I, Hjermann I, Abdelnoor M, Hjerkin EM, Tonstad S. Dietary and antismoking advice and ischemic heart disease mortality in men with normal or high fasting triacylglycerol concentrations: a 23-y follow-up study. *Am J Clin Nutr.* 2003 Nov;78(5):935-40.
152. Huhtasaari F, Lundberg V, Eliasson M, Janlert U, Asplund K. Smokeless tobacco as a possible risk factor for myocardial infarction: a population-based study in middle-aged men. *J Am Coll Cardiol.* 1999 Nov 15;34(6):1784-90.
153. Jacobs EJ, Thun MJ, Apicella LF. Cigar smoking and death from coronary heart disease in a prospective study of US men. *Arch Intern Med.* 1999 Nov 8;159(20):2413-8.
154. Kawachi I, Colditz GA, Stampfer MJ, Willett WC, Manson JE, Rosner B, et al. Smoking cessation in relation to total mortality rates in women. A prospective cohort study. *Ann Intern Med.* 1993 Nov 15;119(10):992-1000.
155. Prescott E, Scharling H, Osler M, Schnohr P. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in The Copenhagen City Heart Study. *J Epidemiol Community Health.* 2002 Sep;56(9):702-6.
156. Sauer WH, Berlin JA, Strom BL, Miles C, Carson JL, Kimmel SE. Cigarette yield and the risk of myocardial infarction in smokers. *Arch Intern Med.* 2002 Feb 11;162(3):300-6.
157. Wannamethee SG, Shaper AG, Whincup PH, Walker M. Smoking cessation and the risk of stroke in middle-aged men. *JAMA.* 1995 Jul 12;274(2):155-60.
158. Oberg M, Jaakkola MS, Woodward A, Peruga A, Pruss-Ustun A. Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries. *Lancet.* 2011 Jan 8;377(9760):139-46.
159. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: a statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. *Circulation.* 1997 Nov 4;96(9):3243-7.
160. Unal B, Critchley J, Capewell S. Impact of smoking reduction on coronary heart disease mortality trends during 1981-2000 in England and Wales. *Tob Induc Dis.* 2003;1(3):185.
161. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. *Cochrane Database of Systematic Reviews.* 2008;Issue 1:Art. No.: CD000146. DOI: 10.1002/14651858.CD000146.pub3.
162. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. *Cochrane database of systematic reviews.* 2007;Issue 1:CD000031.
163. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. *Cochrane database of systematic reviews.* 2011;Issue 2:Art. No.: CD006103. DOI: 10.1002/14651858.CD006103.pub5.
164. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. *Cochrane Database of Systematic Reviews.* 2005;Issue 2:Art. No.: CD001292. DOI: 10.1002/14651858.CD001292.
165. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. *Cochrane Database of Systematic Reviews.* 2005;Issue 2:Art No: CD001007 DOI: 10.1002/14651858CD001007pub2.
166. Rice VH, Stead LF. Nursing interventions for smoking cessation. *Cochrane Database of Systematic Reviews.* 2008;Issue 1:Art. No.: CD001188.pub2. DOI: 10.1002/14651858.CD001188.pub2.
167. Sinclair HK, Bond CM, Stead LF. Community pharmacy personnel interventions for smoking cessation. *Cochrane database of systematic reviews* 2004;Issue 1:CD003698.
168. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. *Cochrane Database of Systematic Reviews.* 2008;Issue 2:Art. No.: CD000165. DOI: 10.1002/14651858.CD000165.pub3.
169. Stead LF, Perera R, Lancaster T. Telephone counselling for smoking cessation. *Cochrane Database of Systematic Reviews.* 2006;Issue 3:Art. No.: CD002850. DOI: 10.1002/14651858.CD002850.pub2.
170. Civljak M, Sheikh A, Stead LF, Car J. Internet-based interventions for smoking cessation. *Cochrane Database of Systematic Reviews.* 2010;Issue 9:Art. No.: CD007078. DOI: 10.1002/14651858.CD007078.pub3.
171. National Health and Medical Research Council. Australian guidelines to reduce the health risks from drinking alcohol 2009. Available at: <http://www.nhmrc.gov.au/publications/synopses/ds10syn.htm> (accessed Feb 2011).
172. Foppa M, Fuchs FD, Preissler L, Andrighetto A, Rosito GA, Duncan BB. Red wine with the noon meal lowers post-meal blood pressure: a randomized trial in centrally obese, hypertensive patients. *J Stud Alcohol.* 2002 Mar;63(2):247-51.
173. AIHW (2008) 2007 National Drug Strategy Household Survey – First Results. AIHW cat. no. PHE 98 (Drug Statistics Series No. 20) Australian Institute of Health and Welfare, Canberra.

174. Burger M, Bronstrup A, Pietrzik K. Derivation of tolerable upper alcohol intake levels in Germany: a systematic review of risks and benefits of moderate alcohol consumption. *Prev Med.* 2004 Jul;39(1):111-27.
175. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. *BMJ.* 2011;342:d636.
176. Di Castelnuovo A, Costanzo S, Bagnardi V, Donati MB, Iacoviello L, de Gaetano G. Alcohol dosing and total mortality in men and women: an updated meta-analysis of 34 prospective studies. *Arch Intern Med.* 2006 Dec 11-25;166(22):2437-45.
177. Bagnardi V, Zatonski W, Scotti L, La Vecchia C, Corrao G. Does drinking pattern modify the effect of alcohol on the risk of coronary heart disease? Evidence from a meta-analysis. *J Epidemiol Community Health.* 2008 Jul;62(7):615-9.
178. Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. *Prev Med.* 2004 May;38(5):613-9.
179. Patra J, Taylor B, Irving H, Roerecke M, Baliunas D, Mohapatra S, et al. Alcohol consumption and the risk of morbidity and mortality for different stroke types--a systematic review and meta-analysis. *BMC Public Health.* 2010;10:258.
180. Conen D, Tedrow UB, Cook NR, Moorthy MV, Buring JE, Albert CM. Alcohol consumption and risk of incident atrial fibrillation in women. *JAMA.* 2008 Dec 3;300(21):2489-96.
181. Malinski MK, Sesso HD, Lopez-Jimenez F, Buring JE, Gaziano JM. Alcohol consumption and cardiovascular disease mortality in hypertensive men. *Arch Intern Med.* 2004 Mar 22;164(6):623-8.
182. Koppes LL, Dekker JM, Hendriks HF, Bouter LM, Heine RJ. Meta-analysis of the relationship between alcohol consumption and coronary heart disease and mortality in type 2 diabetic patients. *Diabetologia.* 2006 Apr;49(4):648-52.
183. Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. *Ann Intern Med.* 2004 Feb 3;140(3):211-9.
184. Ebrahim S, Taylor F, Ward K, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. *Cochrane Database Syst Rev.* 2011(1):CD001561.
185. Eriksson MK, Franks PW, Eliasson M. A 3-year randomized trial of lifestyle intervention for cardiovascular risk reduction in the primary care setting: the Swedish Bjorknas study. *PLoS One.* 2009;4(4):e5195.
186. Foltz SC, Lichtenstein AH, Seguin RA, Goldberg JP, Kuder JF, Nelson ME. The StrongWomen-Healthy Hearts program: reducing cardiovascular disease risk factors in rural sedentary, overweight, and obese midlife and older women. *Am J Public Health.* 2009 Jul;99(7):1271-7.
187. Wister A, Loewen N, Kennedy-Symonds H, McGowan B, McCoy B, Singer J. One-year follow-up of a therapeutic lifestyle intervention targeting cardiovascular disease risk. *CMAJ.* 2007 Oct 9;177(8):859-65.
188. Ebrahim S, Beswick A, Burke M, Davey Smith G. Multiple risk factor interventions for primary prevention of coronary heart disease. *Cochrane Database Syst Rev.* 2006(4):CD001561.
189. Aldana SG, Greenlaw RL, Diehl HA, Salberg A, Merrill RM, Ohmine S. The effects of a worksite chronic disease prevention program. *J Occup Environ Med.* 2005 Jun;47(6):558-64.
190. Hayashi T, Farrell MA, Chaput LA, Rocha DA, Hernandez M. Lifestyle intervention, behavioral changes, and improvement in cardiovascular risk profiles in the California WISEWOMAN project. *J Womens Health (Larchmt).* 2010 Jun;19(6):1129-38.
191. Makrides L, Dagenais GR, Chockalingam A, LeLorier J, Kishchuk N, Richard J, et al. Evaluation of a workplace health program to reduce coronary risk factors *Clinical Governance: An International Journal* 2008;13(2):95-105.
192. Law MR, Morris JK, Wald NJ. Use of blood pressure-lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ.* 2009;338:b1665.
193. Wang JG, Staessen JA, Franklin SS, Fagard R, Gueyffier F. Systolic and diastolic blood pressure-lowering as determinants of cardiovascular outcome. *Hypertension.* 2005 May;45(5):907-13.
194. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. *N Engl J Med.* 2008 May 1;358(18):1887-98.
195. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. *Arch Intern Med.* 2005 Jun 27;165(12):1410-9.
196. Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. *Hypertension.* 2009 May;53(5):860-6.
197. Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. *Lancet.* 2009 Mar 21;373(9668):1009-15.
198. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. *BMJ.* 2008 May 17;336(7653):1121-3.
199. Wright JM, Musini VM. First-line drugs for hypertension. *Cochrane Database Syst Rev.* 2009(3):CD001841.
200. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? *BMJ.* 1994 Feb 5;308(6925):367-72.
201. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. *Arch Intern Med.* 1992 Jul;152(7):1490-500.
202. GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. The Whitehall Study. *JAMA.* 1992 Jan 1;267(1):70-6.
203. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). *JAMA.* 1986 Nov 28;256(20):2823-8.
204. United States. National Heart, Lung, and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): final report. Washington; National Institutes of Health: 2002. [cited Feb 2011] Available from url: <http://www.nhlbi.nih.gov/guidelines/cholesterol/>.
205. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *Eur J Cardiovasc Prev Rehabil.* 2007 Sep;14 Suppl 2:E1-40.
206. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. *BMJ.* 2009;338:b2376.
207. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. *Arch Intern Med.* 2010 Jun 28;170(12):1024-31.
208. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev.* 2011(1):CD004816.


209. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhalra N, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010 Nov 13;376(9753):1670-81.
210. Thavandiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. *Arch Intern Med*. 2006 Nov 27;166(21):2307-13.
211. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. *Health Technol Assess*. 2007 Apr;11(14):1-160, iii-iv.
212. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. *Clin Ther*. 2009 Feb;31(2):236-44.
213. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. *Lancet Neurol*. 2009 May;8(5):453-63.
214. Henyan NN, Riche DM, East HE, Gann PN. Impact of statins on risk of stroke: a meta-analysis. *Ann Pharmacother*. 2007 Dec;41(12):1937-45.
215. O'Regan C, Wu P, Arora P, Perri D, Mills EJ. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. *Am J Med*. 2008 Jan;121(1):24-33.
216. Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. *Arch Intern Med*. 2003 Mar 24;163(6):669-76.
217. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *BMJ*. 2003 Jun 28;326(7404):1423.
218. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. *J Am Coll Cardiol*. 2009 Jan 27;53(4):316-22.
219. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systematic review. *Arch Intern Med*. 2005 Apr 11;165(7):725-30.
220. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. *Am Heart J*. 2007 Nov;154(5):943-53.
221. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. *Lancet*. 2010 May 29;375(9729):1875-84.
222. Allemann S, Diem P, Egger M, Christ ER, Stettler C. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. *Curr Med Res Opin*. 2006 Mar;22(3):617-23.
223. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. *JAMA*. 1984 Jan 20;251(3):351-64.
224. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. *Curr Med Res Opin*. 2007 Aug;23(8):2009-26.
225. Ara R, Tumor I, Pandor A, Duenas A, Williams R, Wilkinson A, et al. Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation. *Health Technol Assess*. 2008;12(21):1-212.
226. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*. 2011 Jun 25;377(9784):2181-92.
227. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. *J Am Coll Cardiol*. 2005 Jan 18;45(2):185-97.
228. Clofibrate and niacin in coronary heart disease. *JAMA*. 1975 Jan 27;231(4):360-81.
229. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. *J Am Coll Cardiol*. 1986 Dec;8(6):1245-55.
230. Hartweg J, Perera R, Montori V, Dinneen S, Neil HA, Farmer A. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2008(1):CD003205.
231. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. *Cochrane Database Syst Rev*. 2004(4):CD003177.
232. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet*. 2007 Mar 31;369(9567):1090-8.
233. Levy PJ, Jackson SA, McCoy TP, Ferrario CM. Clinical characteristics of patients with premature lower extremity atherosclerosis associated with familial early cardiovascular disease and/or cancer. *Int Angiol*. 2006 Sep;25(3):304-9.
234. van Dis I, Kromhout D, Geleijnse JM, Boer JM, Verschuren WM. Body mass index and waist circumference predict both 10-year nonfatal and fatal cardiovascular disease risk: study conducted in 20,000 Dutch men and women aged 20-65 years. *Eur J Cardiovasc Prev Rehabil*. 2009 Dec;16(6):729-34.
235. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. *Cochrane Database Syst Rev*. 2009(2):CD007784.
236. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. *Am Heart J*. 2006 Feb;151(2):273-81.
237. Antiplatelet-Trialists'-Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *Antiplatelet Trialists' Collaboration*. *BMJ*. 1994 Jan 8;308(6921):81-106.
238. Antiplatelet-Trialists'-Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002 Jan 12;324(7329):71-86.
239. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *Lancet*. 2009 May 30;373(9678):1849-60.
240. Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. *Arch Intern Med*. 2002 Oct 28;162(19):2197-202.
241. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet*. 2011 Jan 1;377(9759):31-41.
242. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. *JAMA*. 2006 Jan 18;295(3):306-13.
243. Calvin AD, Aggarwal NR, Murad MH, Shi Q, Elamin MB, Geske JB, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. *Diabetes Care*. 2009 Dec;32(12):2300-6.

244. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. *JAMA*. 2010 Mar 3;303(9):841-8.
245. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. *Heart*. 2001 Mar;85(3):265-71.
246. Selak V, Elley CR, Wells S, Rodgers A, Sharpe N. Aspirin for primary prevention: yes or no? *J Prim Health Care*. 2010 Jun;2(2):92-9.
247. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. *BMJ*. 2009;339:b4531.
248. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. *Diabetes Res Clin Pract*. 2010 Feb;87(2):211-8.
249. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. *Diabetes Care*. 2010 Jun;33(6):1395-402.
250. Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. *Cochrane Database Syst Rev*. 2005(4):CD001925.
251. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. *Cochrane Database Syst Rev*. 2005(3):CD001927.
252. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. *Cochrane Database Syst Rev*. 2007(3):CD006186.
253. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009 Sep 17;361(12):1139-51.
254. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. *N Engl J Med*. 2009 May 14;360(20):2066-78.
255. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. *Lancet*. 2007 Aug 11;370(9586):493-503.
256. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. *N Engl J Med*. 2011 Mar 3;364(9):806-17.
257. Messerli FH, Bakris GL, Ferrera D, Houston MC, Petrella RJ, Flack JM, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. *J Clin Hypertens (Greenwich)*. 2006 Aug;8(8):571-81; quiz 82-3.
258. Preston RA, Harvey P, Herfert O, Dykstra G, Jukema JW, Sun F, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. *J Clin Pharmacol*. 2007 Dec;47(12):1555-69.
259. Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M, et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. *Eur Heart J*. 2006 Dec;27(24):2982-8.
260. Blank R, LaSalle J, Reeves R, Maroni J, Tarasenko L, Sun F. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin Gemini Study). *J Clin Hypertens (Greenwich)*. 2005 May;7(5):264-73.
261. Erdine S, Ro YM, Tse HF, Howes LG, Aguilar-Salinas CA, Chaves H, et al. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). *J Hum Hypertens*. 2009 Mar;23(3):196-210.
262. Flack JM, Victor R, Watson K, Ferdinand KC, Saunders E, Tarasenko L, et al. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. *Mayo Clin Proc*. 2008 Jan;83(1):35-45.
263. Hobbs FD, Gensini G, Mancini GB, Manolis AJ, Bauer B, Bohler S, et al. Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorvastatin) to attain recommended target levels for blood pressure and lipids (The JEWEL Program). *Int J Cardiol*. 2006 Jun 16;110(2):242-50.
264. Heart Foundation. Guide to management of hypertension 2008. Available at: http://www.heartfoundation.org.au/Professional_Information/Clinical_Practice/Hypertension/Pages/default.aspx (accessed June 2010).
265. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*. 2003 Dec;42(6):1206-52.
266. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Jr., et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. *Circulation*. 2007 May 29;115(21):2761-88.
267. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
268. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. *BMJ*. 2004 Mar 13;328(7440):634-40.
269. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. *Hypertens Res*. 2005 May;28(5):385-407.
270. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. *Cochrane Database Syst Rev*. 2009(3):CD004349.
271. Zanchetti A. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? *J Hypertens*. 2009 Aug;27(8):1509-20.
272. Turnbull F, Blood Pressure-lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. *Lancet*. 2003 Nov 8;362(9395):1527-35.
273. Patel A; ADVANCE Collaborative Group MS, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*. 2007 Sep 8;370(9590):829-40.
274. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med*. 2010 Apr 29;362(17):1575-85.
275. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. *Circulation*. 2011 Jun 21;123(24):2799-810.
276. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients. *J Hypertens*. 2011 Jul;29(7):1253-69.

277. Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. *Ann Intern Med.* 2011 Apr 19;154(8):541-8.
278. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review. *Cardiovasc Diabetol.* 2009;8:18.
279. Chalmers J. Comparison of various blood pressure-lowering treatments on the primary prevention of cardiovascular outcomes in recent randomised clinical trials. *Clin Exp Hypertens.* 2004 Oct-Nov;26(7-8):709-19.
280. Musini VM, Wright JM, Bassett K, Jauca CD. Blood pressure-lowering efficacy of loop diuretics for primary hypertension. *Cochrane Database Syst Rev.* 2009(4):CD003825.
281. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. *Lancet.* 2010 Mar 13;375(9718):906-15.
282. Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis: impact of drug class on adherence to antihypertensives. *Circulation.* 2011 Apr 19;123(15):1611-21.
283. Chen N, Zhou M, Yang M, Guo J, Zhu C, Yang J, et al. Calcium channel blockers versus other classes of drugs for hypertension. *Cochrane Database Syst Rev.* 2010(8):CD003654.
284. Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. *Arch Intern Med.* 2011 Mar 14;171(5):384-94.
285. Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. *Am J Gastroenterol.* 2009 Apr;104(4):984-91.
286. Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. *BMC Fam Pract.* 2003 Dec 1;4:18.
287. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet.* 2005 Oct 8;366(9493):1267-78.
288. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. *Am J Cardiol.* 2006 Apr 17;97(8A):89C-94C.
289. Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. *BMJ.* 2006 May 13;332(7550):1115-24.
290. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet.* 2004 Aug 21-27;364(9435):685-96.
291. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet.* 2005 Nov 26;366(9500): 1849-61.
292. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med.* 2010 Apr 29;362(17):1563-74.
293. Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. *BMJ.* 2008 Mar 22;336(7645):645-51.
294. Sharp Collaborative G. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. *Am Heart J.* 2010 Nov;160(5):785-94 e10.
295. Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. *J Am Coll Cardiol.* 2010 Mar 23;55(12):1266-73.
296. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet.* 2010 Jun 26;375(9733):2215-22.
297. Haller H, Ito S, Izzo JL, Jr., Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. *N Engl J Med.* 2011 Mar 10;364(10):907-17.
298. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, Heller S, et al. Combined effects of routine blood pressure-lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. *Diabetes Care.* 2009 Nov;32(11):2068-74.
299. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. *J Am Coll Cardiol.* 2010 Jun 29;56(1):77-85.
300. Ostergren J, Poulter NR, Sever PS, Dahlof B, Wedel H, Beevers G, et al. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. *J Hypertens.* 2008 Nov;26(11):2103-11.
301. Colhoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durrington PN, et al. Design of the Collaborative Atorvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. *Diabet Med.* 2002 Mar;19(3):201-11.
302. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. *Cochrane Database Syst Rev.* 2005(4):CD004136.
303. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. *Cochrane Database Syst Rev.* 2006(4):CD006257.
304. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol.* 2004 May;15(5):1307-15.
305. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet.* 2010 Jun 12;375(9731):2073-81.
306. McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. *Lancet.* 2010 Jul 17;376(9736):163-72.
307. Berra K, Ma J, Klieman L, Hyde S, Monti V, Guardado A, et al. Implementing cardiac risk-factor case management: lessons learned in a county health system. *Crit Pathw Cardiol.* 2007 Dec;6(4):173-9.
308. Leal Hernandez M, Abellan Aleman J, Rios Cano EJ, Martinez Crespo J, Sebastian Vicente B, Vicente Martinez R. [Information on cardiovascular risk in hypertense patients monitored in primary care. Does it improve our efficacy?]. *Aten Primaria.* 2006 Jun 30;38(2):102-6.
309. Rabinowitz I, Tamir A. The SaM (Screening and Monitoring) approach to cardiovascular risk-reduction in primary care--cyclic monitoring and individual treatment of patients at cardiovascular risk using the electronic medical record. *Eur J Cardiovasc Prev Rehabil.* 2005 Feb;12(1):56-62.
310. Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. *Expert Opin Pharmacother.* 2009 Dec;10(18):2973-85.

311. Gumbs PD, Verschuren WM, Mantel-Teeuwisse AK, de Wit AG, Hofman A, Trienekens PH, et al. Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study. *Drugs Aging*. 2006;23(9):733-41.
312. Van Ganse E, Souchet T, Laforest L, Moulin P, Bertrand M, Le Jeunne P, et al. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study. *Atherosclerosis*. 2006 Mar;185(1):58-64.
313. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev*. 2008(2):CD000011.
314. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T. Interventions used to improve control of blood pressure in patients with hypertension. *Cochrane Database Syst Rev*. 2010(3):CD005182.
315. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. *Cochrane Database Syst Rev*. 2004(2):CD004804.
316. Ogedegbe G, Schoenthaler A. A systematic review of the effects of home blood pressure monitoring on medication adherence. *J Clin Hypertens (Greenwich)*. 2006 Mar;8(3):174-80.
317. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med*. 2007 Aug;120(8):713-9.
318. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. *Hypertension*. 2010 Feb;55(2):399-407.
319. Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. *Cochrane Database Syst Rev*. 2010;3:CD004371.
320. Vermeire E, Wens J, Van Royen P, Biot Y, Hearnshaw H, Lindenmeyer A. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. *Cochrane Database Syst Rev*. 2005(2):CD003638.
321. Baker R, Camosso-Stepinovic J, Gillies C, Shaw EJ, Cheater F, Flottorp S, et al. Tailored interventions to overcome identified barriers to change: effects on professional practice and health care outcomes. *Cochrane Database Syst Rev*. 2010;Mar 17;3:CD005470.
322. Doumit G, Gattellari M, Grimshaw J, O'Brien MA. Local opinion leaders: effects on professional practice and health care outcomes. *Cochrane Database Syst Rev*. 2007 Jan 24;(1) CD000125.
323. Farmer AP, Légaré F, Turcot L, Grimshaw J, Harvey E, McGowan JL, et al. Printed educational materials: effects on professional practice and health care outcomes. *Cochrane Database Syst Rev*. 2008 Jul 16;(3):CD004398.
324. Forsetlund L, Bjørndal A, Rashidian A, Jamtvedt G, O'Brien MA, Wolf F, et al. Continuing education meetings and workshops: effects on professional practice and health care outcomes. *Cochrane Database Syst Rev*. 2009 Apr 15;(2):CD003030.
325. Francke AL, Smit MC, de Veer AJ, Mistiaen P. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. *BMC Med Inform Decis Mak*. 2008 Sep 12;8:38.
326. Grimshaw G, Eccles M, Thomas R, MacLennan G, Ramsay C, Fraser C, et al. Toward Evidence-Based Quality Improvement Evidence (and its Limitations) of the Effectiveness of Guideline Dissemination and Implementation Strategies 1966–1998. *J Gen Intern Med*. 2006;21:S14-20.
327. Jamtvedt G, Young JM, Kristoffersen DT, O'Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. *Cochrane database of systematic reviews*. 2006;Issue 2:CD000259.
328. Schouten LM, Hulscher ME, van Everdingen JJ, Huijsman R, Grol RP. Evidence for the impact of quality improvement collaboratives: systematic review. *BMJ*. 2008 Jun 28;336(7659):1491-4.
329. Zwarenstein M, Goldman J, Reeves S. Interprofessional collaboration: effects of practice-based interventions on professional practice and healthcare outcomes. *Cochrane Database Syst Rev* 2009 Jul 8;(3):CD000072. 2010.
330. Ford DR, Knight AW. The Australian Primary Care Collaboratives: an Australian general practice success story. *Med J Aust*. 2010 Jul 19;193(2):90-1.
331. Vos T, Corry J, Haby MM, Carter R, Andrews G. Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression. *Australian and New Zealand Journal of Psychiatry*. 2005;39(8):683-92.
332. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, GL. S. Methods for the economic evaluation of health care programmes. Third ed. Oxford: Oxford University Press 2005.
333. Annemans L, Lamotte M, Kubin M, Evers T, FWA. V. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation. *International Journal of Clinical Practice* 2006;60(9):1129-37.
334. Earnshaw SR, Scheiman J, Fendrick AM, McDade C, M. P. Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention. *Arch Intern Med* 2011;171(3):218-25.
335. Greving JP, Buskens E, Koffijberg H, A. A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. *Circulation* 2008;117(22):2875-83.
336. Lamotte M, Annemans L, Evers T, M. K. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. *PharmacoEconomics*. 2006;24(2):155-69.
337. Pignone M, Earnshaw S, Pletcher MJ, JA. T. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. *Arch Intern Med* 2007;167(3):290-5.
338. Fowkes FGR, Price JF, Stewart MCF, Butcher I, Leng GC, Pell ACH, et al. Aspirin for Prevention of Cardiovascular Events in a General Population Screened for a Low Ankle Brachial Index. *JAMA*. 2010;303(9):841-8.
339. Pilote L, Ho V, Lavoie F, Coupal L, Zowall H, S.A. G. Cost-effectiveness of lipid-lowering treatment according to lipid level. *Canadian Journal of Cardiology* 2005;21(8):681-7.
340. Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, et al. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering. *Ann Intern Med* 2009;150(4):243-54.
341. Ramsey S.D, Clarke L.D, Roberts C.S, Sullivan S.D, Johnson S.J, L.Z. L. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. *PharmacoEconomics*. 2008;26(4):329-39.
342. Gumbs P.D, Verschuren M.W.M, Mantel-Teeuwisse A.K, De Wit A.G, De Boer A, O.H. K. Economic evaluations of cholesterol-lowering drugs: A critical and systematic review. *PharmacoEconomics* 2007;25(3):187-99.
343. Lundkvist J, Ekman M, Kartman B, Carlsson J, Jonsson L, H. L. The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: Results from the Study on COgnition and Prognosis in the Elderly. *Journal of Human Hypertension*. 2005;19(7):569-76.
344. Montgomery AA, Fahey T, Ben-Schlomo Y, J. H. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. *Journal of Hypertension*. 2003;21:1753-9.
345. Nordmann AJ, Krahn M, Logan AG, Naglie G, DetskyAS. The cost-effectiveness of ACE Inhibitors as first-line antihypertensive therapy. *PharmacoEconomics*. 2003;21(8):573-85.
346. Schwander B, Gradl B, Zollner Y, Lindgren P, Diener HC, Luders S, et al. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model. *Value in Health*. 2009;12(6):857-71.

347. Gaziano TA, Opie LH, MC. W. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. *Lancet*. 2006;368:679-86.
348. Rubinstein A, Colantonio L, Bardach A, Caporale J, Marti SG, Kopitowski K, et al. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina. *BMC Public Health*. 2010(10):627.
349. Jonsson B, Hansson L, Stalhammar NO. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension. *J Intern Med*. 2003 Apr;253(4):472-80.
350. Marshall T. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study. *European Journal of Cardiovascular Prevention and Rehabilitation*. 2006;13:523-8.
351. Franco OH, der Kinderen AJ, De Laet C, Peeters A, L. B. Primary prevention of cardiovascular disease: Cost-effectiveness comparison. *International Journal of Technology Assessment in Health Care*. 2007;23(1):71-9.
352. Murray CJL, Lauer JA, Hutubessy RCW, Niessen L, Tomijima N, Rodgers A, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. *Lancet* 2003;361: 717-25.
353. Neyt M, De Laet C, Van Brabandt H, Franco O, D. R. Cost-effectiveness of statins in the primary prevention of cardiovascular disease: A systematic review and economic analysis for Belgium. *Acta Cardiologica* 64(1)(pp 1-10), 2009 Date of Publication: February 2009. 2009;64(1):1-10.
354. Pignone M, Earnshaw S, Tice JA, MJ. P. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. *Ann Intern Med*. 2006;144(5):326-36.
355. Newman J, Grobman WA, P. G. Combination Polypharmacy for Cardiovascular Disease Prevention in Men: A Decision Analysis and Cost-Effectiveness Model. *Prev Cardiol*. 2008;11:36-41.
356. DA, Bagust A, Haycox A, T. W. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. *Economic Evaluation*. 2001;10:601-15.
357. Danaei G, Finucane MM, Lin JK, Singh GM, Paciorek CJ, Cowan MJ, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. *Lancet* 2011;377:568-77.
358. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. *Lancet*. 2011;377:578-86.
359. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. *Lancet*. 2011;377:557-67.



An initiative of the National Vascular Disease Prevention Alliance

